Cover Page
Cover Page - shares | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Mar. 28, 2024 | |
Document Information [Line Items] | |||
Document Type | 20-F | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2023 | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY | ||
Entity Registrant Name | Apollomics Inc. | ||
Entity Central Index Key | 0001944885 | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Interactive Data Current | Yes | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Well-known Seasoned Issuer | No | ||
ICFR Auditor Attestation Flag | true | ||
Document Financial Statement Error Correction [Flag] | false | ||
Entity Common Stock, Shares Outstanding | 89,495,790 | ||
Entity Shell Company | false | ||
Entity Emerging Growth Company | true | ||
Entity Ex Transition Period | false | ||
Title of 12(b) Security | Class A Ordinary Shares, par value $0.0001 per share | ||
Trading Symbol | APLM | ||
Security Exchange Name | NASDAQ | ||
Entity File Number | 001-41670 | ||
Entity Incorporation, State or Country Code | E9 | ||
Entity Address, Address Line One | 989 E. Hillsdale Blvd., Suite 220 | ||
Entity Address, City or Town | Foster City | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 94404 | ||
Entity Address, Country | US | ||
Document Registration Statement | false | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Document Shell Company Report | false | ||
Document Accounting Standard | International Financial Reporting Standards | ||
Auditor Name | Grant Thornton LLP | Deloitte Touche Tohmatsu Certified Public Accountants LLP | |
Auditor Firm ID | 248 | 1113 | |
Auditor Location | San Francisco, California | Shenzhen, the People's Republic of China | |
Business Contact [Member] | |||
Document Information [Line Items] | |||
Contact Personnel Name | Sanjeev Redkar | ||
Entity Address, Address Line One | 989 E. Hillsdale Blvd., Suite 220 | ||
Entity Address, City or Town | Foster City | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 94404 | ||
City Area Code | 650 | ||
Local Phone Number | 209-4055 | ||
Warrants [Member] | |||
Document Information [Line Items] | |||
Title of 12(b) Security | Warrants, each exercisable to purchase one Class A Ordinary Share at an exercise price of $11.50 per share | ||
Trading Symbol | APLMW | ||
Security Exchange Name | NASDAQ |
Consolidated Statements of Prof
Consolidated Statements of Profit or Loss and Other Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |||
Mar. 28, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Profit (loss) [abstract] | ||||
Other income | $ 1,217 | $ 1,447 | $ 1,054 | |
Other gains (losses) | 1,191 | (829) | 36 | |
Fair value change of financial assets at fair value through profit and loss ("FVTPL") | 821 | 323 | 2 | |
Fair value change of financial liabilities at FVTPL | 1,597 | |||
Fair value change of convertible preferred shares | (76,430) | (189,646) | (37,424) | |
Research and development expenses | (34,193) | (35,457) | (35,568) | |
Administrative expenses | (20,641) | (9,947) | (15,291) | |
Impairment loss of an intangible asset | 0 | 0 | (3,000) | |
Finance costs | (150) | (93) | (83) | |
Other expense | (46,003) | (6,608) | (4,522) | |
Loss before taxation | (172,591) | (240,810) | (94,796) | |
Income tax expenses | (10) | (1) | (1) | |
Loss and total comprehensive loss for the period, net of taxation, attributable to owners of the Company | $ (172,601) | $ (240,811) | $ (94,797) | |
Loss per share | ||||
Basic loss per common share (US$) | $ (0.23) | $ (2.32) | $ (8.44) | $ (3.37) |
Diluted loss per common share (US$) | $ (0.62) | $ (2.32) | $ (8.44) | $ (3.37) |
Consolidated Statements of Fina
Consolidated Statements of Financial Position - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Non-current assets | ||
Plant and equipment, net | $ 161 | $ 485 |
Right-of-use assets | 425 | 991 |
Intangible assets | 14,757 | 14,778 |
Rental deposits | 119 | 124 |
Time deposits with maturity greater than twelve months | 4,307 | |
Total non-current assets | 15,462 | 20,685 |
Current assets | ||
Deposits, prepayments and deferred expenses | 2,108 | 1,176 |
Financial assets at FVTPL | 5,761 | 19,067 |
Time deposits with maturity less than twelve months | 2,872 | |
Cash and cash equivalents | 32,056 | 32,675 |
Total current assets | 39,925 | 55,790 |
Total assets | 55,387 | 76,475 |
Current liabilities | ||
Other payables and accruals | 9,162 | 11,675 |
Short term bank loans | 4,236 | |
Financial liabilities arising from unvested restricted shares | 68 | |
Lease liabilities, current portion | 158 | 614 |
Total current liabilities | 13,556 | 12,357 |
Net current assets | 26,369 | 43,433 |
Total assets less current liabilities | 41,831 | 64,118 |
Non-current liabilities | ||
Lease liabilities, noncurrent portion | 267 | 377 |
Warrant liabilities at FVTPL | 330 | |
Convertible preferred shares | 511,861 | |
Total non-current liabilities | 597 | 512,238 |
Net assets (liabilities) | 41,234 | (448,120) |
Equity | ||
Treasury shares | (68) | |
Reserves | 26,716 | 14,228 |
Accumulated losses | (646,965) | (474,600) |
Total equity (deficit) | 41,234 | (448,120) |
Issued capital [member] | ||
Equity | ||
Share capital | 9 | 41 |
Total equity (deficit) | 9 | 3 |
Share premium [member] | ||
Equity | ||
Share premium | 661,474 | 12,279 |
Total equity (deficit) | $ 661,474 | $ 12,317 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Shareholders' Equity Deficit - USD ($) | Total | Share capital [Member] | Treasury shares [Member] | Share premium [Member] | Other reserve [Member] | Share-based payment reserve [Member] | Accumulated losses [Member] | |
Balance at the beginning (in Shares) (Previously stated [Member]) at Dec. 31, 2020 | 386,741,005 | 26,365,915 | ||||||
Balance at the beginning (in Shares) at Dec. 31, 2020 | 27,721,202 | 1,889,882 | ||||||
Balance at the beginning (Previously stated [Member]) at Dec. 31, 2020 | $ (127,933,000) | $ 39,000 | $ (3,252,000) | $ 11,748,000 | $ 1,620,000 | $ 3,455,000 | $ (141,543,000) | |
Balance at the beginning at Dec. 31, 2020 | (127,931,000) | $ 3,000 | $ (3,252,000) | 11,786,000 | 1,620,000 | 3,455,000 | (141,543,000) | |
Recapitalization of Apollomics at Exchange Ratio, (in Shares) (Increase (decrease) due to changes in accounting policy and corrections of prior period errors [Member]) at Dec. 31, 2020 | (359,019,803) | (24,476,033) | ||||||
Recapitalization of Apollomics at Exchange Ratio (Increase (decrease) due to changes in accounting policy and corrections of prior period errors [Member]) at Dec. 31, 2020 | 2,000 | $ (36,000) | 38,000 | |||||
Loss and total comprehensive loss for the year, attributable to owners of the Company | (94,797,000) | (94,797,000) | ||||||
Exercise of share options (in Shares) | [1] | 466,712 | ||||||
Exercise of share options | [1] | 140,000 | 140,000 | 51,000 | (51,000) | |||
Forfeiture of vested share options | (905,000) | 905,000 | ||||||
Restricted share awards vested (in Shares) | [2] | (455,356) | ||||||
Restricted share awards vested | [2] | 64,000 | $ 64,000 | 63,000 | (63,000) | |||
Early exercised share options vested during the year (in Shares) | (424,802) | |||||||
Early exercised share options vested during the year | 1,541 | $ 1,541 | 706 | (706) | ||||
Recognition of equity-settled share-based payment | 8,122 | 8,122 | ||||||
Balance at the ending (in Shares) at Dec. 31, 2021 | 28,187,914 | 1,009,724 | ||||||
Balance at the ending at Dec. 31, 2021 | (212,861,000) | $ 3,000 | $ (1,647,000) | 11,926,000 | 2,440,000 | 9,852,000 | (235,435,000) | |
Loss and total comprehensive loss for the year, attributable to owners of the Company | (240,811,000) | (240,811,000) | ||||||
Exercise of share options (in Shares) | [3] | 613,012 | ||||||
Exercise of share options | [3] | 391,000 | 391,000 | 205,000 | (205,000) | |||
Forfeiture of vested share options | (1,646,000) | 1,646,000 | ||||||
Restricted share awards vested (in Shares) | [2] | (83,482) | ||||||
Restricted share awards vested | [2] | 21,000 | $ 21,000 | 39,000 | (39,000) | |||
Early exercised share options vested during the year (in Shares) | (429,490) | |||||||
Early exercised share options vested during the year | 1,558,000 | $ 1,558,000 | 714,000 | (714,000) | ||||
Recognition of equity-settled share-based payment | 3,582,000 | 3,582,000 | ||||||
Balance at the ending (in Shares) at Dec. 31, 2022 | 28,800,926 | 496,752 | ||||||
Balance at the ending at Dec. 31, 2022 | (448,120,000) | $ 3,000 | $ (68,000) | 12,317,000 | 3,398,000 | 10,830,000 | (474,600,000) | |
Loss and total comprehensive loss for the year, attributable to owners of the Company | (172,601,000) | (172,601,000) | ||||||
Exercise of share options (in Shares) | [4] | 62,443 | ||||||
Exercise of share options | [4] | 85,000 | 85,000 | 33,000 | (33,000) | |||
Forfeiture of vested share options | (198,000) | 198,000 | ||||||
Restricted share awards vested (in Shares) | [2] | (496,752) | ||||||
Restricted share awards vested | [2] | 68,000 | $ 68,000 | 4,000 | (4,000) | |||
Business combination, net of redemptions (in Shares) | 3,312,715 | |||||||
Business combination, net of redemptions | $ 757,000 | $ 757,000 | ||||||
Conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares (in Shares) | 588,291,000 | 54,420,956 | 588,285,000 | |||||
Conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares | $ 6,000 | |||||||
IFRS 2 listing expense | $ 45,524,000 | $ 45,524,000 | ||||||
Post-closing Apollomics Class B Ordinary Shares issued to PIPE Investors, net of transaction costs (in Shares) | 230,000 | |||||||
Post-closing Apollomics Class B Ordinary Shares issued to PIPE Investors, net of transaction costs | 261,000 | 261,000 | ||||||
Reclassification from equity to non-current liabilities for maxpro warrants assumed by apollomics upon Closing | [4] | (7,105,000) | (7,105,000) | |||||
Issuance of post-closing Apollomics Class A ordinary shares upon the conversion of post-closing Apollomics Series A Preferred Shares (in Shares) | 2,668,750 | |||||||
Issuance of post-closing Apollomics Class A ordinary shares upon the conversion of post-closing Apollomics Series A Preferred Shares | 21,350,000 | 21,350,000 | ||||||
Recognition of equity-settled share-based payment | 12,686,000 | 12,686,000 | ||||||
Portion of PIPE issuance costs allocated to PIPE warrants | 38,000 | 38,000 | ||||||
Balance at the ending (in Shares) at Dec. 31, 2023 | 89,495,790 | |||||||
Balance at the ending at Dec. 31, 2023 | $ 41,234,000 | $ 9,000 | $ 661,474,000 | $ 3,435,000 | $ 23,281,000 | $ (646,965,000) | ||
[1] The total number of shares issued from the exercise of stock options consisted of the issuance of 6,511,135 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2021 to December 31, 2021. These Pre-Closing Apollomics Ordinary Shares were exchanged for 466,712 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. All unvested restricted shares were milestone-based restricted shares held by the Chief Executive Officer of Apollomics which vested upon the Closing of the Business Combination. The total number of shares issued from the exercise of stock options consisted of the issuance of 8,552,187 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2022 to December 31, 2022. These Pre-Closing Apollomics Ordinary Shares were exchanged for 613,012 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. The total number of shares issued from the exercise of stock options consisted of the issuance of 435,833 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2023 to March 28, 2023. These Pre-Closing Apollomics Ordinary Shares were exchanged for 31,241 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. The total number of shares issued from the exercise of stock options consisted of the issuance of 31,202 Post-Closing Apollomics Ordinary Shares between March 29, 2023 to December 31, 2023, totaling 62,443 exercise of stock options for the year ended December 31, 2023. |
Consolidated Statements of Ch_2
Consolidated Statements of Changes in Shareholders' Equity Deficit (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Mar. 28, 2023 | Dec. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Accumulated losses | $ (646,965) | $ (646,965) | $ (474,600) | ||
Maxpro Capital Acquisition Corp. [Member] | |||||
Decrease in share premium due to reclassification of warrants from equity to liabilities | 7,100 | ||||
Increase of warrant liability due to recalcification from equity | 1,300 | ||||
Decrease in accumulated losses due to reclassification of warrants from equity to liabilities | 5,800 | ||||
Accumulated losses | $ (5,800) | (5,800) | |||
Net impact of equity by reduction of premium due to recalcification of warrants | $ 1,300 | ||||
Preclosing Apollomics Ordinary Shares [Member] | |||||
Exercise of share options | 435,833 | 8,552,187 | 6,511,135 | ||
Post-Closing Apollomics Ordinary Shares [Member] | |||||
Number of ordinary shares issued in exchange of pre closing business combination ordinary shares | 31,241 | 613,012 | 466,712 | ||
Stock issued during the period exercise of stock options shares | 31,202 | 62,443 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
OPERATING ACTIVITIES | |||
Loss before taxation | $ (172,591) | $ (240,810) | $ (94,796) |
Adjustments for: | |||
Interest income | (821) | (431) | (467) |
Depreciation of plant and equipment | 83 | 162 | 133 |
Depreciation of right-of-use assets | 566 | 593 | 528 |
Amortization of intangible assets | 20 | 20 | 20 |
Impairment loss of an intangible asset | 3,000 | ||
Loss on disposal of fixed assets | 188 | ||
Realized foreign currency gains (losses) | (21) | 663 | |
Fair value change of financial assets at FVTPL | (323) | (2) | |
Fair value change of financial liabilities at FVTPL | (1,597) | ||
Fair value change of preferred shares | 76,430 | 189,646 | 37,424 |
IFRS 2 listing expense | 45,524 | ||
Portion of PIPE issuance costs allocated to PIPE warrants | 38 | ||
Finance costs | 122 | 93 | 83 |
Share-based payment expenses | 12,685 | 3,582 | 8,122 |
Unrealized foreign currency loss | (258) | (2,563) | |
Operating cash flows before movements in working capital | (39,632) | (49,368) | (45,955) |
(Increase) decrease in deposits, prepayments and deferred expenses | (932) | 3,651 | (453) |
Increase (decrease) in other payables and accruals | (2,635) | 2,837 | 3,096 |
NET CASH USED IN OPERATIONS | (43,199) | (42,880) | (43,312) |
Taxation refund | 57 | ||
Tax paid | (10) | (1) | |
NET CASH USED IN OPERATING ACTIVITIES | (43,209) | (42,824) | (43,312) |
INVESTING ACTIVITIES | |||
Interest received | 821 | 431 | 467 |
Proceeds from redemption of long term time deposits with original maturity over three months | 4,308 | 24,000 | 71,948 |
Proceeds from redemption of time deposits with original maturity over three months | 2,872 | (103,790) | |
Purchase of plant and equipment | (6) | (367) | (50) |
Proceeds from disposal of fixed assets | 58 | ||
Purchase of intangible assets | (7,500) | ||
Proceeds from disposal of financial asset at FVTPL | 13,307 | 5,000 | |
Payment for rental deposits | (17) | (25) | |
Refund of rental deposits | 5 | 6 | |
NET CASH (USED IN) FROM INVESTING ACTIVITIES | 21,365 | 29,053 | (38,950) |
FINANCING ACTIVITIES | |||
Proceeds from PIPE Financing and Business Combination, net of transaction costs | 20,249 | ||
Payment of deferred underwriting fees | (2,779) | ||
Proceeds from bank loans | 4,236 | ||
Proceeds from issue of shares upon exercise of share options | 85 | 392 | 141 |
Interest expense | (122) | (93) | (83) |
Accrued issuance costs paid | (1,173) | ||
Repayment of lease liabilities | (444) | (593) | (528) |
NET CASH (USED IN) FROM FINANCING ACTIVITIES | 21,225 | (294) | (1,643) |
NET (DECREASE) IN CASH AND CASH EQUIVALENTS | (619) | (14,065) | (83,905) |
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD | 32,675 | 46,740 | 130,645 |
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD | $ 32,056 | $ 32,675 | $ 46,740 |
General Information
General Information | 12 Months Ended |
Dec. 31, 2023 | |
General Information [Abstract] | |
General Information | 1. GENERAL INFORMATION Apollomics Inc. (“Apollomics” or the “Company”) is a clinical-stage biotechnology company focused on discovering and developing oncology therapies to address unmet medical needs. Since the Company’s founding in 2015, the Company has built a pipeline of nine drug candidates across 11 programs that focus on oncology, of which six drug candidates are in the clinical stage. The Company was originally formed as CB Therapeutics Inc. as a result of a spin-off of Crown Bioscience International, which was completed on December 31, 2015. Prior to December 2015, Crown Bioscience International, through its subsidiaries, was the owner of certain patent rights relating to certain of these drug candidates. In order to focus on its core business, namely providing preclinical contract research organization services, and allow the drug discovery and development related business to be operated and financed separately, Crown Bioscience International spun off its Taiwan subsidiary, Crown Bioscience (Taiwan), and contributed it to the Company. As a result, we became the owner of these patent rights. In addition to its U.S. headquarters, the Company also has locations in Australia (Apollomics (Australia) Pty Ltd, formed in November 2016), Hong Kong (Apollomics (Hong Kong) Limited, formed in June 2019) and China (Zhejiang Crownmab Biotech Co. Ltd. and Zhejiang Crown Bochuang Biopharma Co. Ltd., formed in May 2018 and May 2020, respectively). The Company’s headquarters and global drug development team is based in the United States (San Francisco Bay area), while its discovery and China drug development team is based in China (Hangzhou and Shanghai). The Company operates in both the United States and China, with its headquarters and its global drug development team in the San Francisco Bay Area and its discovery and China drug development team in Hangzhou and Shanghai, China. On March 29, 2023 ( “Closing Date”), Apollomics consummated a business combination (the “Business Combination”) with Maxpro Capital Acquisition Corp. (“Maxpro”), a Delaware corporation and special purpose acquisition company, pursuant to the initial business combination agreement dated September 14, 2022 and subsequent amendment to the business combination agreement dated February 9, 2023 (the “Business Combination Agreement” or “BCA”). In connection with the closing of the Business Combination, Apollomics became a publicly traded company on the Nasdaq Capital Market (“Nasdaq”). The Company’s Class A Ordinary Shares and warrants are listed on Nasdaq under the trading symbols “APLM” and “APLMW,” respectively. Trading on the Nasdaq commenced on March 30, 2023. The consolidated financial statements are presented in U.S. dollars (“$”). The Company's subsidiaries included in the consolidated financial statements are listed below (the Company and its subsidiaries are collectively referred to herein as the “Group”). These consolidated financial statements have been prepared based on the accounting policies which conform with International Financial Reporting Standards (“IFRSs”) as issued by the International Accounting Standards Board (“IASB”) and have been prepared under the assumption the Company operates on a going concern basis. Name of subsidiaries Place of incorporation or establishment/operation and date of incorporation/establishment Principal activities Apollomics, Inc. California, United States January 14, 2016 Research and development of drugs Apollomics (Australia) Pty. Ltd. Melbourne, Australia November 4, 2016 Research and development of drugs Apollomics (Hong Kong) Limited Hong Kong, China June 24,2019 Investment holding Zhejiang Crownmab Biotech Co., Ltd. Hangzhou, China May 29, 2018 Investment holding and research and development of drugs Zhejiang Crown Bochuang Biopharma Co., Ltd. Hangzhou, China May 29, 2020 Research and development of drugs Project Max SPAC Merger Sub, Inc. Delaware, United States August 19, 2022 Investment holding |
Basis of Preparation of the Con
Basis of Preparation of the Consolidated Financial Statements | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Basis of Preparation of Financial Statements Explanatory [Abstract] | |
Basis of Preparation of the Consolidated Financial Statements | 2. BASIS OF PREPARATION OF THE CONSOLIDATED FINANCIAL STATEMENTS The consolidated financial statements have been prepared based on the accounting policies set out in Note 4 which conform with International Financial Reporting Standards (“IFRSs”) as issued by the International Accounting Standards Board (“IASB”). The Group has incurred recurring losses and negative cash flows from operations since inception and had an accumulated loss of $ 646,965 as of December 31, 2023. The Group recorded net assets of $ 41,234 as of December 31, 2023. The Group regularly monitors its current and expected liquidity requirements and, as needed, updates its operating plans, to ensure that it maintains sufficient cash balances to meet its liquidity requirements in the short and long term. Based upon our 2024 operating plan, and our balance of cash, cash equivalents, and a federal money market fund of $ 37.8 million as of December 31, 2023, we estimate that we will have sufficient liquidity to continue as a going concern through at least December 31, 2024. We will require additional capital, from equity, debt or strategic partnerships, to continue as a going concern in the future. It is uncertain whether such capital will be available in amounts or on terms acceptable to us, if at all. If we are not able to obtain additional capital to meet our cash requirements in the future, our business, financial condition, results of operations and prospects could be materially and adversely affected. There can be no assurance that management’s attempts to raise additional capital will be successful, and could ultimately result in reassessing the Company’s ability to continue as a going concern. |
Adoption of New and Amendments
Adoption of New and Amendments to IFRSs | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of expected impact of initial application of new standards or interpretations [abstract] | |
Adoption of New and Amendments to IFRSs | 3. ADOPTION OF NEW AND AMENDMENTS TO IFRSs For the purposes of preparing and presenting the consolidated financial statements, the Group has consistently applied the accounting policies which conform with the IFRSs, which are effective for the Group’s accounting period beginning on January 1, 2023. New and amendments to IFRSs in issue but not yet effective The Group has not early applied the following new and amendments to IFRSs and International Accounting Standards (“IASs”) that have been issued but are not yet effective: Amendments to IFRS 10 and IAS 28 Sale or Contribution of Assets between an Investor and its Associate or Joint Venture 1 Amendments to IFRS 16 Lease Liability in a Sale and Leaseback 2 Amendments to IAS 1 Classification of Liabilities as Current or Non-current 2 Amendments to IAS 1 Non-current Liabilities with Covenant 2 1. Effective for annual periods beginning on or after a date to be determined 2. Effective for annual periods beginning on or after January 1, 2024 Except for the amendments to IFRSs mentioned below, the management of the Company anticipate that the application of the other new and amendments to IFRSs will have no material impact on the Group’s financial performance and positions and/or the disclosures to the Group’s consolidated financial statements in the foreseeable future. Amendments to IAS 1 Classification of Liabilities as Current or Non-current (2020) (the “2020 Amendments”) and Amendments to IAS 1 Non-current Liabilities with Covenants (the “2022 Amendments”) The 2020 Amendments provide clarification and additional guidance on the assessment of right to defer settlement for at least twelve months from reporting date for classification of liabilities as current or non-current, which: • clarify that if a liability has terms that could, at the option of the counterparty, result in its settlement by the transfer of the entity’s own equity instruments, these terms do not affect its classification as current or non-current only if the entity recognizes the option separately as an equity instrument applying IAS 32 Financial Instruments: Presentation . • specify that the classification of liabilities as current or non-current should be based on rights that are in existence at the end of the reporting period. Specifically, the amendments clarify that the classification should not be affected by management intentions or expectations to settle the liability within 12 months. For rights to defer settlement for at least twelve months from reporting date which are conditional on the compliance with covenants, the requirements introduced by the 2020 Amendments have been modified by the 2022 Amendments. The 2022 Amendments specify that only covenants with which an entity is required to comply with on or before the end of the reporting period affect the entity’s right to defer settlement of a liability for at least twelve months after the reporting date. Covenants which are required to comply with only after the reporting period do not affect whether that right exists at the end of the reporting period. In addition, the 2022 Amendments specify the disclosure requirements about information that enables users of financial statements to understand the risk that the liabilities could become repayable within twelve months after the reporting period, if the entity classify liabilities arising from loan arrangements as non-current when the entity’s right to defer settlement of those liabilities is subject to the entity complying with covenants within twelve months after the reporting period. The 2022 Amendments also defer the effective date of applying the 2020 Amendments to annual reporting periods beginning on or after 1 January 2024. The 2022 Amendments, together with the 2020 Amendments, are effective for annual reporting periods beginning on or after 1 January 2024, with early application permitted. If an entity applies the 2020 Amendments for an earlier period after the issue of the 2022 Amendments, the entity should also apply the 2022 Amendments for that period. As at December 31, 2022, the Group’s outstanding convertible preferred shares include counterparty conversion options did not meet equity instruments classification by applying IAS 32 Financial instruments: Presentation . The Group classified as current or non-current based on the earliest date in which the Group had the obligation to redeem these instruments through cash settlement. The convertible preferred shares were designated as fair value through profit or loss (“FVTPL”) with carrying amount of $ 511,861 as of December 31, 2022 and was classified as non-current as set out in Note 25. Upon the application of the 2020 Amendments, in addition to the obligation to redeem through cash settlement, the transfer of equity instruments upon the exercise of the conversion options that did not meet equity instruments classification also constituted settlement of the convertible instruments. The convertible preferred shares designated as FVTPL amounting to $ 511,861 as of December 31, 2022 was classified as current as the Group did not have the right to defer delivery of shares upon the exercise of the conversion options for at least twelve months from the reporting date. On March 29, 2023, all the preferred shares were converted into common shares, and therefore as of December 31, 2023, there were no longer any preferred shares. Except for as disclosed above, the application of the amendments is not expected to have significant impact on the Group’s other financial liabilities recognized in the consolidated financial statements. |
Material Accounting Policies
Material Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Summary of Significant Accounting Policies [Abstract] | |
Material Accounting Policies | 4. MATERIAL ACCOUNTING POLICIES The consolidated financial statements have been prepared in accordance with the following accounting policies set out below which conform with IFRSs issued by the IASB. For the purpose of preparation of the consolidated financial statements, information is considered material if such information is reasonably expected to influence decisions made by primary users. The consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair value at the end of each reporting period, as explained in the accounting policies set out below. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Group takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in the financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of IFRS 2 Share-based Payments , leasing transactions that are within the scope of IFRS 16 Leases , and measurements that have some similarities to fair value but are not fair value, such as net realizable value in IAS 2 Inventories or value in use in IAS 36 Impairment of Assets . For financial instruments which are transacted at fair value and a valuation technique that unobservable inputs are to be used to measure fair value in subsequent periods, the valuation technique is calibrated so that at initial recognition the results of the valuation technique equals the transaction price. In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date; • Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and • Level 3 inputs are unobservable inputs for the asset or liability. The principal accounting policies are set out below. Basis of consolidation The consolidated financial statements incorporate the financial statements of Apollomics and entities controlled by Apollomics and its subsidiaries. Control is achieved when the Company: • has power over the investee; • is exposed, or has rights, to variable returns from its involvement with the investee; and • has the ability to use its power to affect its returns. The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statements of profit or loss and other comprehensive income from the date the Group gains control until the date when the Group ceases to control the subsidiary. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with the Group’s accounting policies. All intragroup assets, liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation. Foreign currencies In preparing the financial statements of each individual group entity, transactions in currencies other than the functional currency of that entity (foreign currencies) are recognized at the rates of exchanges prevailing on the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences arising on the settlement of monetary items, and on the retranslation of monetary items, are recognized in profit or loss in the period in which they arise. Government grants Government grants are not recognized until there is reasonable assurance that the Group will comply with the conditions attaching to them and that the grants will be received. Government grants related to income that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Group with no future related costs are recognized in profit or loss in the period in which they become receivable. Such grants are presented under “other income”. Retirement benefits costs Payments to defined contribution retirement benefit plans, including the defined contribution plan in the US, state-managed retirement benefit schemes in the People’s Republic of China (the “PRC”) are recognized as an expense when employees have rendered service entitling them to the contributions. Short-term employee benefits Short-term employee benefits are recognized at the undiscounted amount of the benefits expected to be paid as and when employees rendered the services. All short-term employee benefits are recognized as an expense unless another IFRS requires or permits the inclusion of the benefit in the cost of an asset. A liability is recognized for benefits accruing to employees (such as wages, salaries and leave entitlement) after deducting any amount already paid. Share-based payments Equity-settled share-based payment transactions Share options and restricted shares granted to employees and others providing similar services Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of the equity instruments at the grant date. The fair value of the equity-settled share-based payments determined at the grant date without taking into consideration all non-market vesting conditions is expensed on a straight-line basis over the vesting period, based on the Group’s estimate of equity instruments that will eventually vest, with a corresponding increase in equity (share-based payment reserve). At the end of each reporting period, the Group revises its estimate of the number of equity instruments expected to vest based on assessment of all relevant non-market vesting conditions. The impact of the revision of the original estimates, if any, is recognized in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the share-based payment reserve. When share options are exercised or the restricted shares are vested, the amount previously recognized in share-based payment reserve will be transferred to other reserve. When the share options are forfeited after the vesting date or are still not exercised at the expiry date, the amount previously recognized in share-based payment reserve will be transferred to accumulated losses. Taxation Income taxation represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable profit for the year. Taxable profit differs from ‘loss before taxation’ because of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of each reporting period. Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognized if the temporary difference arises from the initial recognition of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. Deferred tax liabilities are recognized for taxable temporary differences associated with investments in subsidiaries, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments are only recognized to the extent that it is probable that there will be sufficient taxable profits against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of each reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of each reporting period, to recover or settle the carrying amount of its assets and liabilities. For the purposes of measuring deferred tax for leasing transactions in which the Group recognizes the right-of-use assets and the related lease liabilities, the Group first determines whether the tax deductions are attributable to the right-of-use assets or the lease liabilities. For leasing transactions in which the tax deductions are attributable to the lease liabilities, the Group applies IAS 12 requirements to the leasing transaction as a whole. Temporary differences relating to right-of-use assets and lease liabilities are assessed on a net basis. Excess of depreciation on right-of-use assets over the lease payments for the principal portion of lease liabilities resulting in net deductible temporary differences. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied to the same taxable entity by the same taxation authority. Current and deferred tax are recognized in profit or loss. Plant and equipment Plant and equipment are stated at cost less subsequent accumulated depreciation and subsequent accumulated impairment losses, if any. Depreciation is recognized so as to write off the cost of assets less their residual values over their estimated useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis. An item of plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in profit or loss. Leases Definition of a lease A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group assesses whether a contract is or contains a lease based on the definition under IFRS 16 at inception, modification date or acquisition date, as appropriate. Such contract will not be reassessed unless the terms and conditions of the contract are subsequently changed. The Group as a lessee Allocation of consideration to components of a contract For a contract that contains a lease component and one or more additional lease or non-lease components, the Group allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components. The Group applies practical expedient not to separate non-lease components from lease component, and instead account for the lease component and any associated non-lease components as a single lease component. Short-term leases The Group applies the short-term lease recognition exemption to leases of plant and equipment and laboratory premise, that have a lease term of 12 months or less from the commencement date and do not contain a purchase option. Lease payments on short-term leases is recognized as expense on a straight-line basis over the lease term. Right-of-use assets Except for short-term leases, the Group recognizes right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of the initial measurement of the lease liability. Right-of-use assets in which the Group is reasonably certain to obtain ownership of the underlying leased assets at the end of the lease term is depreciated from commencement date to the end of the useful life. Otherwise, right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. The Group presents right-of-use assets as a separate line item on the consolidated statements of financial position. Refundable rental deposits Refundable rental deposits paid are accounted for under IFRS 9 Financial Instruments and initially measured at fair value. Adjustments to fair value at initial recognition are considered as additional lease payments and included in the cost of right-of-use assets. Lease liabilities At the commencement date of a lease, the Group recognizes and measures the lease liability at the present value of lease payments that are unpaid at that date. In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable. The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The Group presents lease liabilities as a separate line item on the consolidated statements of financial position. Intangible assets Intangible assets acquired separately Intangible assets with finite useful lives that are acquired separately are carried at costs less accumulated amortization and any accumulated impairment losses if any. Amortization for intangible assets with finite useful lives is recognized on a straight-line basis over their estimated useful lives. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets not yet available for use that are acquired separately are carried at cost less any subsequent accumulated impairment losses. Internally-generated intangible assets - research and development expenditure Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally generated intangible asset arising from development activities (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated: • the technical feasibility of completing the intangible asset so that it will be available for use or sale; • the intention to complete the intangible asset and use or sell it; • the ability to use or sell the intangible asset; • how the intangible asset will generate probable future economic benefits; • the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and • the ability to measure reliably the expenditure attributable to the intangible asset during its development. The amount initially recognized for internally-generated intangible asset is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred. Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses (if any), on the same basis as intangible assets that are acquired separately. An intangible asset is derecognized on disposal, or when no future economic benefits are expected from use or disposal. Gains and losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognized in profit or loss when the asset is derecognized. Impairment on plant and equipment, right-of-use assets and intangible assets At the end of each reporting period, the management of the Company reviews the carrying amounts of plant and equipment, right-of-use assets and intangible assets with finite useful lives to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the relevant asset is estimated in order to determine the extent of the impairment loss, if any. Intangible assets not yet available for use are tested for impairment at least annually, and whenever there is an indication that they may be impaired. The recoverable amount of plant and equipment, right-of-use assets and intangible assets is estimated individually. When it is not possible to estimate the recoverable amount of an asset individually, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs. In testing a cash-generating unit for impairment, corporate assets are allocated to the relevant cash-generating unit when a reasonable and consistent basis of allocation can be established, or otherwise they are allocated to the smallest group of cash generating units for which a reasonable and consistent allocation basis can be established. The recoverable amount is determined for the cash-generating unit or group of cash-generating units to which the corporate asset belongs, and is compared with the carrying amount of the relevant cash-generating unit or group of cash-generating units. Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset (or cash-generating unit) for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or a cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. For corporate assets or portion of corporate assets which cannot be allocated on a reasonable and consistent basis to a cash-generating unit, the Group compares the carrying amount of a group of cash-generating units, including the carrying amounts of the corporate assets or portion of corporate assets allocated to that group of cash-generating units, with the recoverable amount of the group of cash-generating units. In allocating the impairment loss, the impairment loss is allocated first to reduce the carrying amount of any goodwill (if applicable) and then to the other assets on a pro-rata basis based on the carrying amount of each asset in the unit. The carrying amount of an asset is not reduced below the highest of its fair value less costs of disposal (if measurable), its value in use (if determinable) and zero. The amount of the impairment loss that would otherwise have been allocated to the asset is allocated pro rata to the other assets of the unit or a group of cash-generating units. An impairment loss is recognized immediately in profit or loss. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit or a group of cash-generating units) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit or a group of cash-generating units) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss. Cash and cash equivalents Cash and cash equivalents presented on the consolidated statements of financial position include: (a) cash, which comprises of cash on hand and demand deposits; and (b) cash equivalents, which comprises of short-term (generally with original maturity of three months or less), highly liquid investments that are readily convertible to a known amount of cash and which are subject to an insignificant risk of changes in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes. For the purposes of the consolidated statements of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above. Financial instruments Financial assets and financial liabilities are recognized when a group entity becomes a party to the contractual provisions of the instrument. All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets or liabilities at FVTPL) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in profit or loss. The effective interest method is a method of calculating the amortized cost of a financial asset or financial liability and of allocating interest income and interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts and payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial asset or financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Financial assets Classification and subsequent measurement of financial assets Financial assets that meet the following conditions are subsequently measured at amortized cost: • the financial asset is held within a business model whose objective is to collect contractual cash flows; and • the contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. All other financial assets are subsequently measured at FVTPL. (i) Amortized cost and interest income Interest income is recognized using the effective interest method for financial assets measured subsequently at amortized cost. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired (see below). For financial assets that have subsequently become credit-impaired, interest income is recognized by applying the effective interest rate to the amortized cost of the financial asset from the next reporting period. If the credit risk on the credit-impaired financial instrument improves so that the financial asset is no longer credit-impaired, interest income is recognized by applying the effective interest rate to the gross carrying amount of the financial asset from the beginning of the reporting period following the determination that the asset is no longer credit impaired. Interest income is recognized in profit or loss and is included in the “other income” line item. (ii) Financial assets at FVTPL Financial assets of the Group that do not meet the criteria for being measured at amortized cost are measured at FVTPL. Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair value gains or losses recognized in profit or loss. The net gain or loss recognized in profit or loss includes any interest earned on the financial asset and is presented as “fair value change of financial assets at FVTPL” line item. Impairment of financial assets The Group performs impairment assessment under expected credit loss (“ECL”) model on financial assets (including deposits, time deposits with original maturity over three months and cash and cash equivalents) which are subject to impairment under IFRS 9. The amount of ECL is updated at each reporting date to reflect changes in credit risk since initial recognition. Lifetime ECL represents the ECL that will result from all possible default events over the expected life of the relevant instrument. In contrast,12-month ECL represents the portion of lifetime ECL that is expected to result from default events that are possible within 12 months after the reporting date. Assessments are done based on the Group’s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current conditions at the reporting date as well as the forecast of future conditions. For all financial instruments, the Group measures the loss allowance equal to12-month ECL, unless when there has been a significant increase in credit risk since initial recognition, the Group recognizes lifetime ECL. The assessment of whether lifetime ECL should be recognized is based on significant increases in the likelihood or risk of a default occurring since initial recognition. (i) Significant increase in credit risk In assessing whether the credit risk on a financial instrument has increased significantly since initial recognition, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition. In making this assessment, the Group considers both quantitative and qualitative information that is reasonable and supportable, including historical experience and forward-looking information that is available without undue cost or effort. Forward-looking information considered includes the future prospects of the industries in which the Group’s debtors operate, obtained from economic expert reports, financial analysts, governmental bodies, relevant think-tanks and other similar organizations, as well as consideration of various external sources of actual and forecast economic information that relate to the Group’s core operations. In particular, the following information is taken into account when assessing whether credit risk has increased significantly: • an actual or expected significant deterioration in the financial instrument’s external (if available) or internal credit rating; • significant deterioration in external market indicators of credit risk for a particular financial instrument, e.g. a significant increase in the credit spread, the credit default swap prices for the debtor; • existing or forecast adverse changes in business, financial or economic conditions that are expected to cause a significant decrease in the debtor’s ability to meet its debt obligations; • an actual or expected significant deterioration in the operating results of the debtor; and • an actual or expected significant adverse change in the regulatory, economic, or technological environment of the debtor that results in a significant decrease in the debtor’s ability to meet its debt obligations. Irrespective of the outcome of the above assessment, the Group presumes that the credit risk on a financial asset has increased significantly since initial recognition when contractual payments are more than 30 days past due, unless the Group has reasonable and supportable information that demonstrates otherwise. Notwithstanding the foregoing, the Group assumes that the credit risk on a debt instrument has not increased significantly since initial recognition if the financial instrument is determined to have low credit risk at the reporting date. A financial instrument is determined to have low credit risk if i) the financial instrument has a low risk of default, ii) the borrower has a strong capacity to meet its contractual cash flow obligations in the near term and iii) adverse changes in economic and business conditions in the longer term may, but will not necessarily, reduce the ability of the borrower to fulfill its contractual cash flow obligations. The Group considers a debt instrument have low credit risk when it has an internal or external credit rating of “investment grade” as per globally understood definition. The Group regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes past due. (ii) Definition of default The Group considers the following as constituting an event of default for internal credit risk management purposes as historical experience indicates that receivables that meet either of the following criteria are generally not recoverable. • when there is a breach of financial covenants by the counterparty; or • information developed internally or obtained from external sources indicates that the debtor is unlikely to pay its creditors, including the Group, in full (without taking into account any collaterals held by the Group). Irrespective of the above analysis, the Group considers that default has occurred when a financial asset is more than 90 days past due unless the Group has reasonable and supportable information to demonstrate that a more lagging default criterion is more appropriate. (iii) Credit-impaired financial assets A financial asset is credit-impaired when one or more events that have a detrimental impact on the estimated future cash flows of that financial asset have occurred. Evidence that a financial asset is credit-impaired includes observable data about the following events: (a) significant financial difficulty of the issuer or the borrower; (b) a breach of contract, such as a default or past due event; (c) the lender(s) of the borrower, for economic or contractual reasons relating to the borrower’s financial difficulty, havin |
Business Combination
Business Combination | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of detailed information about business combination [abstract] | |
Business Combination | 5. BUSINESS COMBINATION As previously outlined in Note 1 – General Information, the Company underwent a Business Combination with Maxpro on March 29, 2023. The Business Combination was effected through the issuance of shares of Apollomics to Maxpro stockholders. Upon the closing of the Business Combination, the following occurred: a. Each Apollomics ordinary share assumed outstanding immediately prior to the closing of the Business Combination, which totaled 401,804,327 shares (other than the exercise of stock option), was exchanged for the right to receive 0.071679 shares of post-closing Apollomics Ordinary Shares (the “Exchange Ratio”). The resulting issuance totaled 28,800,926 shares of Apollomics Class B Ordinary Shares. No Class B Ordinary Share is transferable, except to certain permitted transferees, until the earlier of (i) six (6) months after the Closing Date, which is September 29, 2023, or (ii) in the event that a definitive agreement that contemplates a change of control of is entered into, immediately prior to the consummation of such Change of Control (the “Class B Lock-Up Period”), subject to the conditions set forth in the memorandum and articles of association (“MAA”). Class B Ordinary Shares will be automatically converted into Class A Ordinary Shares on a one -to-one basis upon the end of the Class B Lock-Up Period, provided that the Board may approve such conversion prior to the end of the Class B Lock-Up Period. b. In connection with the Business Combination, Apollomics entered into the PIPE Financing with certain accredited investors for an aggregate of 230,000 Class B Ordinary Shares at a price of $ 10.00 per share, 2,135,000 Series A Preferred Shares at a price of $ 10.00 per share and 57,500 Penny Warrants to purchase Class A Ordinary shares, for a total of $ 23.7 million. c. Each share of Maxpro Class A Common Stock (consisting of non-redeemable Common Stock and redeemable Common Stock that was not redeemed at closing) assumed outstanding immediately prior to the closing of the Business Combination was exchanged for, on a one -for-one basis, shares of Apollomics Class A Ordinary Shares. d. Each share of Maxpro Class B Common Stock (consisting of non-redeemable Common Stock) assumed outstanding immediately prior to the closing of the Business Combination was exchanged for, on a one -for-one basis, shares of Apollomics Class A Ordinary Shares. e. In connection with the Business Combination, Maxpro’s stockholders redeemed 10,270,060 out of the 10,350,000 public shares available, representing 99.2 % of Maxpro’s public float, which resulted in Apollomics receiving nominal cash in connection with the Business Combination other than through the PIPE Financing. At closing of the Business Combination, 10,350,000 Maxpro public warrants and 464,150 Maxpro private warrants outstanding were assumed by Apollomics and recorded as a warrant liability on the Company’s consolidated statement of financial position. The warrant liability will be remeasured each reporting period until the earlier of the warrant expiration date or the warrant exercise date. The Private Warrants or Extension Warrants (including the Class A Ordinary Shares issuable upon exercise of any of such warrants) can not be transferred, assigned or sold until September 29, 2023, the date that is six months after the Closing Date, pursuant to the Lock-Up Agreement effective at the Closing Date. f. Maxpro had a promissory note payable to the Maxpro Sponsor with a principal balance of $ 1.5 million immediately prior to the closing of the Business Combination. The unpaid principal amount was converted into 155,250 shares of Apollomics Class A Ordinary Shares and 155,250 private warrants upon the closing of the Business Combination. The warrants were recorded as a warrant liability on the Company's consolidated statement of financial position. The warrant liability will be remeasured each reporting period until the earlier of the warrant expiration date or the warrant exercise date. g. Each Maxpro warrant issued and outstanding immediately prior to the closing of the Business Combination was assumed by Apollomics and became exercisable, on a one -for-one basis, for Apollomics Class A Ordinary Shares. h. Prior to the closing of the Business Combination, one Apollomics stock option holder elected to exercise all of such holder’s options, resulting in the issuance of 435,833 shares of Apollomics Class A Common Stock, which upon the closing of the Business Combination, were canceled and exchanged for the right to receive .071679 shares of Apollomics Class A Ordinary Shares per share of Apollomics Class A Common Stock, which resulted in the issuance of 31,240 shares of Apollomics Class A Ordinary Shares. In addition, each outstanding option to purchase a Pre-Closing Apollomics Ordinary Share, whether vested or unvested, immediately prior to the Merger, was also adjusted such that each option (i) has the right to acquire a number of Apollomics Class B Shares equal to (as rounded down to the nearest whole number) the product of (A) the number of Pre-Closing Apollomics Ordinary Shares which the option had the right to acquire immediately prior to the Share Split, multiplied by (B) the Exchange Ratio; and (ii) have an exercise price equal to (as rounded up to the nearest whole cent) the quotient of (A) the exercise price of the option immediately prior to the Share Split, divided by (B) the Exchange Ratio. The net proceeds from the PIPE Financing and Business Combination, totaled $ 20.2 million. The following table presents the total Apollomics common stock outstanding immediately after the closing of the Business Combination: Number of Shares Exchange of Maxpro Class A common stock for post-closing Apollomics Class A Ordinary Shares 490,025 Exchange of Maxpro Class B common stock for post-closing Apollomics Class A Ordinary Shares 2,587,500 Exchange of Maxpro Class A common stock subject to possible redemption that was not redeemed for post-closing Apollomics Class A Ordinary Shares 79,940 Issuance of post-closing Apollomics Class A Ordinary Shares to Maxpro Sponsor in connection with 155,250 Subtotal - Business Combination, net of redemptions 3,312,715 Issuance of post-closing Apollomics Class B ordinary shares to PIPE Investors 230,000 Conversion of pre-closing Apollomics convertible preferred shares (converted into pre-closing Apollomics ordinary shares prior to the Business Combination) into Post-Closing Apollomics Ordinary Shares 54,420,956 Issuance of Post-Closing Apollomics Ordinary Shares in connection with the Business Combination due 31,240 Total - Post-Closing Apollomics Ordinary Shares outstanding as a result of Business Combination, PIPE Financing, conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares, and issuance of shares upon Closing due to pre-Closing exercise of stock options (note i) 57,994,911 Note i: In addition to the 57,994,911 shares specified above, the following shares were included in the total 89,495,790 Post- Closing Apollomics Ordinary Shares outstanding as of December 31, 2023 on the consolidated statement of changes in stockholders' deficit: 1) 28,800,926 Post-Closing Apollomics Ordinary Shares were outstanding as a result of the exchange of all Pre-Closing Apollomics Ordinary Shares outstanding as of December 31, 2022 at the Exchange Ratio 2) 2,668,750 Post-Closing Apollomics Ordinary Shares were outstanding as a result of the conversion of Post-Closing Apollomics Series A Preferred Shares into Post-Closing Apollomics Class A Ordinary Shares in May 2023 at a conversion ratio of 1 to 1.25 3) 16,202 Post-Closing Apollomics Ordinary Shares were outstanding as a result of the exercise of stock options in April 2023, and 15,000 Ordinary Shares as a result of the exercise of stock options in November 2023. As Maxpro did not meet the definition of a business in accordance with IFRS 3 (“Business Combinations”), the transaction was accounted for within the scope of IFRS 2 (“Share-based Payment”) as a share-based payment transaction in exchange for a public listing service. As such, the fair value of Apollomics shares transferred to Maxpro stockholders in excess of the net identifiable assets of Maxpro represents compensation for the service of a stock exchange listing for its shares and is accounted for as an expense in post-closing Apollomics at the consummation of the Business Combination. The net identifiable assets of Maxpro were stated at historical cost, with no goodwill or other intangible assets recorded. Apollomics was deemed to be both the legal and accounting acquirer given that subsequent to the Business Combination: a. Apollomics' shareholders have a majority of the voting power of post-closing Apollomics; b. Apollomics’ operations comprise all of the ongoing operations of post-closing Apollomics; c. Apollomics controls a majority of the governing body of post-closing Apollomics; d. Apollomics’ senior management comprise all of the senior management of post-closing Apollomics. Under IFRS 2, Apollomics recorded a one-time share-based expense of $ 45.5 million at the closing of the Business Combination that was calculated based on the excess of the fair value of Apollomics over the fair value of the identifiable net assets of Maxpro that were acquired. The amount of Maxpro’s identifiable net assets acquired at Closing were as follows: Cash and cash equivalents $ 954 Notes payable – sponsor ( 1,999 ) Accrued liabilities ( 1,056 ) Deferred underwriting compensation ( 3,623 ) Total Maxpro identifiable net liabilities at fair value $ ( 5,724 ) The net assets of Maxpro are stated at fair value with no goodwill or other intangible assets recorded. The IFRS 2 listing expense was calculated as follows: Per Share Value Shares Fair Value Maxpro public stockholders $ 10.81 10,350 $ 111,884 Sponsor parties 10.81 3,207 34,668 Underwriter shares 10.81 26 281 Maxpro private warrants 0.12 619 74 Maxpro public warrants 0.12 10,350 1,242 Redemptions of Maxpro class A common stock 10.55 ( 10,270 ) ( 108,349 ) 14,282 39,800 Net liabilities of Maxpro ( 5,724 ) IFRS 2 Listing Expense $ 45,524 The prior year’s shares and per share numbers have been retrospectively adjusted for the Exchange Ratio of 0.071679 . |
Critical Accounting Judgment an
Critical Accounting Judgment and Key Sources of Estimation Uncertainty | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Accounting Judgements and Estimates [Abstract] | |
Critical Accounting Judgment and Key Sources of Estimation Uncertainty | 6. CRITICAL ACCOUNTING JUDGMENT AND KEY SOURCES OF ESTIMATION UNCERTAINTY In the application of the Group’s accounting policies, which are described in Note 4, the management of the Company are required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. Critical judgment in applying accounting policies The following is the critical judgment, apart from those involving estimations (see below), that the Company have made in the process of applying the Group’s accounting policies and that have the most significant effect on the amounts recognized in the consolidated financial statements. Research and development expenses Development costs incurred on the Group’s research and development projects are capitalized and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, the Group’s intention to complete and the Group’s ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the pipeline and the ability to measure reliably the expenditure during the development. Development costs which do not meet these criteria are expensed when incurred. The Company assesses the progress of each of the research and development projects and determines whether the criteria are met for capitalization. During the years ended December 31, 2021, 2022 and 2023, all the related development costs are expensed when incurred. Key sources of estimation uncertainty The key assumptions concerning the future, and other key sources of estimation uncertainty at the end of each reporting period, that may have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the coming twelve months, are described below. Fair value of convertible preferred shares The convertible preferred shares of the Company are measured at fair value for financial reporting purpose. No quoted prices in an active market are available for these financial liabilities. These financial liabilities were valued by the management with reference to valuations carried out by an independent qualified professional valuer not connected with the Group, which has appropriate qualifications and experience in valuation of similar financial instruments. The fair value of these financial liabilities is established by using valuation techniques as disclosed in Note 24. Valuation techniques are certified by the valuer before being implemented for valuation and are calibrated to ensure that outputs reflect market conditions. Valuation models established by the valuer make the maximum use of market inputs and rely as little as possible on the Group’s specific data. However, it should be noted that some inputs, such as the underlying share value of the Company, possibilities under different scenarios such as initial public offerings (“IPO”) and time to liquidation require management estimates. The estimates and assumptions by the management of the Company are reviewed periodically and are adjusted if necessary. Should any of the estimates and assumptions change, it may lead to a change in the fair value of the financial liabilities at FVTPL. The fair values of the convertible preferred shares which are classified as financial liabilities at FVTPL as at December 31, 2022 and 2023 were $ 511,861 and nil , respectively. Upon the IPO, all the pre-closing Apollomics convertible preferred shares converted into Post- Closing Apollomics Ordinary Shares. The fair value loss recognized in the profit or loss during the years ended December 31, 2021, 2022 and 2023 amounted to $ 37,424 , $ 189,646 and $ 76,430 , respectively. Estimated impairment of intangible assets not ready for use Intangible assets not ready for use are tested annually for impairment, or more frequently, if events or changes in circumstances indicate that they might be impaired. The Group obtained in-licenses through separate acquisition to continue research and development work and commercialize the products, which are classified as intangible assets not ready for use. Determining whether intangible assets not ready for use is impaired requires an estimation of recoverable amount of the cash-generating unit to which the intangible assets belong, which is the higher of the value in use or fair value less costs of disposal. The value in use calculation requires the Group to estimate the future cash flows expected to arising from the cash-generating unit and a suitable discount rate in order to calculate the present value. Where the actual future cash flows are less than expected, or change in facts and circumstances which results in downward revision of future cash flows or upward revision of discount rate, a material impairment loss or further loss may arise. The carrying amount of intangible assets not ready for use as at December 31, 2022 and 2023, were $ 14,500 . The impairment loss recognized during the years ended December 31, 2021, 2022 and 2023 amounted to $ 3,000 , nil , and nil , respectively. |
Revenue and Segment Information
Revenue and Segment Information | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Entity Revenue and Reportable Segments [Abstract] | |
Revenue and Segment Information | 7. REVENUE AND SEGMENT INFORMATION Revenue The Group has no t generated any revenue throughout the years ended December 31, 2021, 2022 and 2023. Segment information Operating segments are defined as components of an entity for which separate financial information is made available and is regularly evaluated by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”), and operations are managed as a single segment for the purposes of assessing performance and making operating decisions. The CODM reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one operating and reportable segment and no further analysis of this single segment is presented |
Other Income
Other Income | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Other Income [Abstract] | |
Other Income | 8. OTHER INCOME Years Ended December 31, 2021 2022 2023 Interest income $ 467 $ 431 $ 753 Government grants (note i) 587 1,016 464 Total $ 1,054 $ 1,447 $ 1,217 Notes: (i) Included in the government grants are amounts in thousands of Australian Dollar (“AUD”) nil , AUD 1,353 (equivalent to approximately $ 908 ), and AUD 635 (equivalent to approximately $ 408 ), representing the unconditional subsidies from the Australian government specifically for supporting the research and development activities carried out in Australia for the years ended December 31, 2021, 2022 and 2023 respectively. The remaining amounts represent government subsidies in relation to the research and development activities in the US and the PRC. All the government grants provide immediate financial support with no future related expenses or other obligations. |
Other Gains and Losses
Other Gains and Losses | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Other Gains and Losses [Abstract] | |
Other Gains and Losses | 9. OTHER GAINS AND LOSSES Years ended December 31, 2021 2022 2023 Exchange gains (losses), net $ 36 $ ( 829 ) $ 1,191 The Company primarily operates in the U.S., PRC, and Australia, with most of the transactions settled in the U.S. dollar. The Company's presentation and functional currency is the U.S. dollar. Certain bank balances, deposits and other payables are denominated in Renminbi and Australian dollar, which exposes the Company to foreign currency risk. The Company incurs portions of its expenses in currencies other than the U.S. dollar, in particular, the Renminbi and Australian dollar. As a result, the Company is exposed to foreign currency exchange risk as our results of operations and cash flows are subject to fluctuations in foreign currency exchange rates. Realized and unrealized gains and losses are shown in the table above. The Company has not entered into any derivative contracts to hedge against its exposure to currency risk during the three years ended December 31, 2021, 2022 or 2023. However, Management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise. |
Finance Costs
Finance Costs | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Finance Cost [Abstract] | |
Finance Costs | 10. FINANCE COSTS Years ended December 31, 2021 2022 2023 Interest expenses on lease liabilities $ 83 $ 93 $ 150 |
Income Tax Expenses
Income Tax Expenses | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Income Tax [Abstract] | |
Income Tax Expenses | 11. INCOME TAX EXPENSES The Company is exempted from taxation under the laws of the Cayman Islands. The US Corporate Income Tax (“CIT”) includes (a) federal income tax calculated at a flat rate of 21 % on the US federal taxable income in accordance to the Tax Cuts and Jobs Act of 2017; (b) state income tax is calculated based on the federal taxable income with state tax adjustments, which is then allocated or apportioned to the respective state (i.e. percentage of taxable income that should be apportioned or specially allocated to the respective states in which the Group operates) based on the apportionment factors provided from the state tax returns in previous year, and (c) state minimum tax if there is no assessable profit. The PRC enterprises income tax (“EIT”) is calculated at the prevailing tax rate on the taxable income of the subsidiaries operating in the PRC. Under the Law of the PRC on EIT (the “EIT Law”) and Implementation Regulation of the EIT Law, the applicable tax rate of the PRC subsidiaries is at 25 % during the years ended December 31, 2021, 2022 and 2023. Under the Treasury Law Amendment (Enterprise Tax Plan Base Rate Entities) Bill 2018 of Australia, qualifying base rate entities that meet aggregate turnover threshold can be eligible for a lower corporate tax rate. Upon assessment on the base rate entity qualification on an ongoing basis, Apollomics (Australia) Pty. Ltd., a wholly-owned subsidiary of the Company, applies a corporate tax rate of 26 %, 25 % and 25 % for the years ended December 31, 2021, 2022 and 2023, respectively. Hong Kong Profits Tax is calculated at 16.5 % of the estimated assessable profit for a Hong Kong incorporated subsidiary. Years ended December 31, 2021 2022 2023 US CIT — current year $ 1 $ 1 $ 10 — over-provision in respect of prior years — — — Deferred tax (Note 18) — — — $ 1 $ 1 $ 10 Other than the subsidiary operating in the US, no provision for income taxation has been made as the Company and the other subsidiaries either had no assessable profit or incurred tax losses in the PRC, Australia and Hong Kong for the years ended December 31, 2021, 2022 and 2023. The income tax (credit) expense for the years ended December 31, 2021, 2022 and 2023 can be reconciled to the loss before taxation per the consolidated statements of profit or loss and other comprehensive income as follows: Years ended December 31, 2021 2022 2023 Loss before taxation $ ( 94,796 ) ( 240,810 $ ( 172,591 ) Tax at the US federal tax rate of 21 % ( 19,907 ) ( 50,570 ) ( 36,244 ) Tax effect of expenses not deductible for tax purpose 20,419 45,739 568 Tax effect of income not taxable for tax purpose ( 309 ) ( 257 ) — Tax effect of additional qualified expenses deductible for — ( 1,517 ) ( 741 ) Tax effect of R&D Credits — — ( 2,311 ) Tax effect of tax losses not recognized 360 7,027 10,277 Tax effect of foreign tax differential rates ( 562 ) ( 421 ) 28,461 Income tax expense for the year $ 1 $ 1 $ 10 Note: The amount represents additional 75 % income tax deduction in respect of qualifying research and development expenditures incurred for the year. |
Loss for the Year
Loss for the Year | 12 Months Ended |
Dec. 31, 2023 | |
Profit (loss) [abstract] | |
Loss for the Year | 12. LOSS FOR THE YEAR Years ended December 31, 2021 2022 2023 Loss for the year has been arrived at after charging: Staff costs: Salaries and other allowances $ 18,871 $ 14,966 $ 10,356 Retirement benefits scheme contributions 749 662 499 Share-based payment expenses 8,122 3,582 12,685 Total staff costs 27,742 19,210 23,540 Depreciation of plant and equipment 133 162 87 Depreciation of right-of-use assets 528 593 587 Amortization of intangible assets 20 20 20 Impairment loss of an intangible asset 3,000 — — Other expense (note) $ 4,522 $ 6,608 $ 46,003 Note: Other expense represented the expenses incurred and the expense-off of the previous deferred issue costs for a public offering application pursuing in other capital market which was suspended in 2022. For the year ended December 31, 2022, the other expense also includes the expenses incurred for an ongoing public offering application through acquisition of a listed Special Purpose Acquisition Company (“De-SPAC”) in the Nasdaq capital market. For the year ended December 31, 2023, the other expense also includes expenses incurred in connection with the Business Combination. Refer to Note 5 – Business Combination for further information. |
Dividends
Dividends | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure Of Dividends [Abstract] | |
Dividends | 13. DIVIDENDS No dividend was declared or paid by the Company during the years ended December 31, 2021, 2022 and 2023, nor has any dividend been proposed since the end of the year ended December 31, 2023. |
Loss Per Share
Loss Per Share | 12 Months Ended |
Dec. 31, 2023 | |
Earnings per share [abstract] | |
Loss Per Share | 14. LOSS PER SHARE The calculations of the basic and diluted loss per share are based on the following data: Years ended December 31, 2021 2022 2023 Loss: Loss for the year attributable to owners of the Company for the $ ( 94,797 ) $ ( 240,811 ) $ ( 172,601 ) Number of shares (‘000): Weighted average number of ordinary shares for the purpose of 28,107 28,528 74,411 Loss per share – Basic and diluted $ $ ( 3.37 ) $ ( 8.44 ) $ ( 2.32 ) The exchange ratio has been applied to the weighted average number of ordinary shares for the purpose of calculating basic and diluted loss per share shown as 28,107 and 28,528 for the years ended December 2021 and 2022 to give effect to the Business Combination of March 29, 2023, which were 404,186 and 390,944 , respectively and the loss per share - basic and diluted shown as ($ 3.37 ) and ($ 8.44 ) were ($ 0.23 ) and ($ 0.62 ), respectively, prior to the Business Combination. The diluted loss per share for the years ended December 31, 2021, 2022 and 2023 does not include the effect of the following instruments held as of December 31, 2021, 2022 and 2023 as their inclusion would be anti-dilutive. As of December 31, 2021 and 2022, Series A1, A2, B and C convertible preferred shares, unvested restricted shares and share options outstanding were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive. As of December 31, 2023 share options outstanding and the private and public warrants were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive. As of December 31, 2021 (Note i) 2022 (Note i) 2023 (Note i) Number of series A1 convertible preferred shares (“Series A1 9,465,754 9,465,754 — Number of series A2 convertible preferred shares (“Series A2 5,259,170 5,259,170 — Number of series B convertible preferred shares (“Series B 21,313,959 21,313,959 — Number of series C convertible preferred shares (“Series C 18,382,073 18,382,073 — Unvested restricted shares 580,234 496,752 — Share options 11,114,487 9,746,889 12,132,460 Apollomics private warrants — — 619,400 Apollomics public warrants — — 10,350,000 Note i: The exchange ratio has been applied to these instruments to give effect to the Business Combination As of December 31, 2021 (Note ii) 2022 (Note ii) 2023 Number of series A1 convertible preferred shares (“Series A1 132,057,583 132,057,583 — Number of series A2 convertible preferred shares (“Series A2 73,371,157 73,371,157 — Number of series B convertible preferred shares (“Series B 297,352,949 297,352,949 — Number of series C convertible preferred shares (“Series C 256,449,944 256,449,944 — Unvested restricted shares 8,094,901 6,930,235 — Share options 155,059,183 135,979,705 12,132,460 Apollomics private warrants — — 619,400 Apollomics public warrants — — 10,350,000 Penny warrants — — 57,500 Note ii: This was the presentation of these instruments as of December 31, 2021 and 2022, respectively, prior to the application of the exchange ratio used in the Business Combination |
Plant and Equipment
Plant and Equipment | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of detailed information about property, plant and equipment [abstract] | |
Plant and Equipment | 15. PLANT AND EQUIPMENT Leasehold Furniture Total COST As of January 1, 2022 $ 135 $ 426 $ 561 Additions — 367 367 As of December 31, 2022 135 793 928 Additions — — — Disposals — ( 363 ) ( 363 ) As of December 31, 2023 135 430 565 ACCUMULATED DEPRECIATION As of January 1, 2022 ( 80 ) ( 201 ) ( 281 ) Provided for the year ( 34 ) ( 128 ) ( 162 ) As of December 31, 2022 ( 114 ) ( 329 ) ( 443 ) Accumulated depreciation removal for disposals — 75 75 Provided for the year ( 18 ) ( 18 ) ( 36 ) As of December 31, 2023 ( 132 ) ( 272 ) ( 404 ) CARRYING VALUES As of December 31, 2022 $ 21 $ 464 $ 485 As of December 31, 2023 $ 3 $ 158 $ 161 The above items of plant and equipment are depreciated over their estimated useful lives between 3 to 5 years , using straight-line method after taking into account the residual values, at the following rates per annum: Leasehold improvements Over the shorter of the relevant lease term or 20 % Furniture and other equipment 14 % - 33 % |
Right-of-Use Assets
Right-of-Use Assets | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of quantitative information about right-of-use assets [abstract] | |
Right-of-Use Assets | 16. RIGHT-OF-USE ASSETS Plant and Offices equipment Total COST As of January 1, 2022 $ 2,367 $ 62 $ 2,429 Additions 538 10 548 Derecognized upon end of lease term ( 40 ) ( 13 ) ( 53 ) As of December 31, 2022 2,865 59 2,924 Additions — 12 12 Derecognized upon end of lease term ( 291 ) ( 46 ) ( 337 ) As of December 31, 2023 2,574 25 2,599 ACCUMULATED DEPRECIATION As of January 1, 2022 ( 1,349 ) ( 44 ) ( 1,393 ) Provided for the year ( 579 ) ( 14 ) ( 593 ) Derecognized upon end of lease term 40 13 53 As of December 31, 2022 ( 1,888 ) ( 45 ) ( 1,933 ) Provided for the year ( 568 ) ( 19 ) ( 587 ) Derecognized upon end of lease term and foreign exchange effect 296 50 346 As of December 31, 2023 ( 2,160 ) ( 14 ) ( 2,174 ) CARRYING VALUES As of December 31, 2022 $ 977 $ 14 $ 991 As of December 31, 2023 $ 414 $ 11 $ 425 The right-of-use assets are depreciated over the lease terms using straight-line method. Years ended December 31, 2021 2022 2023 Expense relating to short-term leases $ 56 $ 96 $ 122 Total cash outflow for leases $ 667 $ 782 $ 566 Lease contracts are entered into for fixed terms of 12 months to 60 months , without extension and termination options. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. In determining the lease term and assessing the length of the non-cancellable period, the Group applies the definition of a contract and determines the period for which the contract is enforceable. The Group regularly entered into short-term leases for plant and equipment and laboratory premises. As of December 31, 2022 and 2023, the portfolio of short-term leases is similar to the portfolio of short-term leases to which the short-term lease expense disclosed above. Restrictions or covenants on leases In addition, lease liabilities of $ 991 and $ 425 are recognized with related right-of-use assets of $ 991 and $ 425 as of December 31, 2022 and 2023 , respectively. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes. |
Intangible Assets
Intangible Assets | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of detailed information about intangible assets [abstract] | |
Intangible Assets | 17. INTANGIBLE ASSETS Patent rights Patent rights Total (note i) (note ii) COST As of January 1, 2021 $ 375 $ 11,000 $ 11,375 Addition — 7,500 7,500 As of December 31, 2021, 2022 and 2023 375 18,500 18,875 AMORTIZATION AND IMPAIRMENT As of January 1, 2021 ( 57 ) ( 1,000 ) ( 1,057 ) Charge for the year ( 20 ) — ( 20 ) Impairment loss recognized — ( 3,000 ) ( 3,000 ) As of December 31, 2021 ( 77 ) ( 4,000 ) ( 4,077 ) Charge for the year ( 20 ) — ( 20 ) As of December 31, 2022 ( 97 ) ( 4,000 ) ( 4,097 ) Charge for the year ( 21 ) — ( 21 ) As of December 31, 2023 ( 118 ) ( 4,000 ) ( 4,118 ) CARRYING VALUES As of December 31, 2021 $ 298 $ 14,500 $ 14,798 As of December 31, 2022 $ 278 $ 14,500 $ 14,778 As of December 31, 2023 $ 257 $ 14,500 $ 14,757 Notes: (i) The patent rights grant the Group the right to use certain scientific data for research and manufacture of pipelines, namely APL-501, APL-502 and APL-509. (ii) These patent rights are not yet available for use by the Group as the Group is still undergoing pre-clinical study application or clinical trials on the relevant drugs in designated territories under the patent rights and has yet to obtain regulatory approval for the new drug to be launched to the market. The patent rights are tested for impairment annually and whenever there is an indication that they may be impaired. Amortization will commence when the patent rights are available for use (i.e. when they are ready for commercialization and have obtained the regulatory new drug application approval in the designated territories) by the Group. During the years ended December 31, 2021, 2022 and 2023, patent rights with carrying amount of $ 3,000 , nil , and nil were impaired, respectively. For these patent rights, as they were acquired for combination trial of an existing drug candidate, which was subsequently replaced by another formulation, or acquired for self-development that the Group cannot proceed further research due to the failure in providing drug supplies by the original vendor according to the agreement. Accordingly, the Group has fully impaired the patent rights with reference to their respective recoverable amounts determined on value in use calculations. The patent rights (available for use) have finite lives and are amortized on a straight-line basis. The useful lives of patent rights ranged between 10 to 18 years for the years ended December 31, 2021, 2022 and 2023 . The useful lives of patent rights were determined by the management of the Group taking into account the period over which the patent rights are expected to be available for use by the Group and the stability of the industry. |
Deferred Taxation
Deferred Taxation | 12 Months Ended |
Dec. 31, 2023 | |
Deferred tax assets and liabilities [abstract] | |
Deferred Taxation | 18. DEFERRED TAXATION For the purpose of presentation in the consolidated financial statements, the deferred tax assets and liabilities have been offset. The major deferred tax assets (liabilities) recognized and movements thereon during the years ended December 31, 2021, 2022 and 2023 are as follows: Accelerated tax Accrual Total As of January 1, 2021 $ ( 46 ) $ 46 $ — Credit (charge) to profit or loss (Note 10) 14 ( 14 ) — As of December 31, 2021 ( 32 ) 32 — Credit (charge) to profit or loss (Note 10) ( 19 ) 19 — As of December 31, 2022 ( 51 ) 51 — (Charge) credit to profit or loss (Note 10) 40 ( 40 ) — As of December 31, 2023 $ ( 11 ) $ 11 $ — The Group had unused tax losses of $ 62,866 available for offset against future profits as of December 31, 2022. The Group had unused tax losses, temporary differences and unused tax credits of $ 97,607 , $ 17,221 and $ 7,462 , respectively, as of December 31, 2023. No deferred tax asset has been recognized due to the unpredictability of future profit streams. As of December 31, 2022 and 2023, the unrecognized tax losses and temporary differences will be carried forward and expire in years as follows: As of December 31, 2022 2023 Unused tax losses 2024 $ 2,364 $ 2,319 2025 4,634 4,973 2026 7,025 10,144 2027 15,757 9,176 2028 — 9,571 Indefinite 33,086 61,424 Total unused tax losses $ 62,866 $ 97,607 Tax effected deductible temporary differences Indefinite 15,506 17,221 $ 15,506 $ 17,221 As of December 31, 2023 the unused credits will be carried forward and expire in years as follows: Unused tax credits 2038 $ 62 2039 229 2040 1,320 2041 1,800 2042 2,589 2043 1,462 Total unused tax credits $ 7,462 Management has estimated the expected outcome of the disputes by using the expected value method to determine the provisions for uncertain tax treatment. The Group reported uncertain tax treatment of $ 2,190 as of December 31, 2023, netted in the deferred tax assets, that are not recognized in the financial statements. |
Deposits, Prepayments and Defer
Deposits, Prepayments and Deferred Expenses | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Deposits Prepayments and Deferred Expenses [Abstract] | |
Deposits, Prepayments and Deferred Expenses | 19. DEPOSITS, PREPAYMENTS AND DEFERRED EXPENSES As of December 31, 2022 2023 Other prepayments $ 624 $ 1,073 Prepaid taxes — 312 Value-Added Tax recoverable 547 466 Deposits 5 7 Payment in advance to suppliers — 250 $ 1,176 $ 2,108 |
Short Term Bank Loans
Short Term Bank Loans | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of detailed information about borrowings [abstract] | |
Short Term Bank Loans | 20. SHORT TERM BANK LOANS In November 2023 we established two lines of credit totaling RMB 80 million (approximately $ 11.2 million) with two banks in China. Against one line of credit of RMB 50 million (approximately $ 7.0 million) we drew down RMB 20 million (approximately $ 2.8 million) for 8 months due July 2024 at 3.7 % interest. Against the second bank’s line of credit of RMB 30 million (approximately $ 4.2 million) we drew down RMB 10 million (approximately $ 1.4 million) for 6 months due May 2024 at 3.2 % interest. |
Time Deposits with Original Mat
Time Deposits with Original Maturity Over Three Months/Cash and Cash Equivalents | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Time Deposits with Banks [Abstract] | |
Time Deposits with Original Maturity Over Three Months/Cash and Cash Equivalents | 21. TIME DEPOSITS WITH ORIGINAL MATURITY OVER THREE MONTHS/CASH AND CASH EQUIVALENTS The time deposits with original maturity over three months were placed with licensed commercial banks in the PRC, carry interest at a fixed rate of 3.70 % per annum. As of December 31, 2023 all these time deposits with original maturity over three months had matured and there are no longer any time deposits as of December 31, 2023. Bank balances include demand deposits, presenting as cash and cash equivalent, carry interest at prevailing market interest rates ranging from 0.01 % to 0.05 % and from 0.01 % to 3.05 % for the years ended December 31, 2022 and 2023, respectively. |
Other Payables and Accruals
Other Payables and Accruals | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure Of Other Payables And Accruals [Abstract] | |
Other Payables and Accruals | 22. OTHER PAYABLES AND ACCRUALS As of December 31, 2022 2023 Payables in respect of research and development expenses $ 5,435 $ 4,471 Accrued salaries and bonuses 2,475 2,166 Accrued other expenses 1,662 1,025 Deposit received for a potential out-licensing drug patent (note) 1,000 1,000 Other payables 1,103 500 $ 11,675 $ 9,162 Note: During the year ended December 31, 2020, the Group signed an exclusive right of negotiation agreement with an independent third party (the “Independent Third Party”) to negotiate out-licensing a drug patent to the Independent Third Party. Under the exclusive right of negotiation agreement, we received a deposit of $ 1,000 which may be considered as consideration for the exclusive right of negotiation if the Independent Third Party has not identified any negative findings (as stated in the exclusive right of negotiation agreement) by March 2, 2021. As of the date of this report, despite no negative findings have been identified, we considered the negotiation will not proceed further, and the Independent Third Party has not requested a refund of the balance. |
Financial Liabilities Arising f
Financial Liabilities Arising from Unvested Restricted Shares | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of financial liabilities [abstract] | |
Financial Liabilities Arising from Unvested Restricted Shares | 23. FINANCIAL LIABILITIES ARISING FROM UNVESTED RESTRICTED SHARES As of December 31, 2022 2023 Payables in respect of unvested restricted shares Dr. Yu (the chief executive of the Company) $ 68 $ — The amounts represented the repurchase option held by the Company in relation to (i) the unvested restricted shares granted to directors and an employee of the Company; and (ii) the unvested restricted shares issued to a director of the Company who was the share option holder and had elected to early exercise the share options during the vesting period. Details of the restricted share award and share options are set out in Note 26. |
Lease Liabilities
Lease Liabilities | 12 Months Ended |
Dec. 31, 2023 | |
Lease liabilities [abstract] | |
Lease Liabilities | 24. LEASE LIABILITIES As of December 31, 2022 2023 Lease liabilities payable: Within one year $ 614 $ 158 More than one year, but not exceeding two years 126 126 More than two years, but not exceeding five years 251 141 991 425 Less: Amount due for settlement within 12 months shown ( 614 ) ( 158 ) Amount due for settlement after 12 months shown $ 377 $ 267 The Group leased various offices, and plant and equipment as disclosed in Note 15 for its administration, and research and development activities. These lease liabilities were measured at the present value of the lease payments that are not yet paid. The Group does not face a significant liquidity risk with regard to its lease liabilities. The lease agreements did not contain any contingent rent nor any purchase option for the leases. The weighted average incremental borrowing rates applied to lease liabilities range from 4.75 % to 6.00 % during the years ended December 31, 2022 and 2023. |
Convertible Preferred Shares
Convertible Preferred Shares | 12 Months Ended |
Dec. 31, 2023 | |
Convertible Preferred Shares [Abstract] | |
Convertible Preferred Shares | 25. CONVERTIBLE PREFERRED SHARES The Company entered into preferred share subscription agreements with several independent investors and the details of issued preferred shares (the “Preferred Shares”) are set out as follows: Date of issue Total number of Subscription Subscription July 26, 2016 to Series A1 Preferred Shares July 28, 2016 88,038,389 $ 0.04543 $ 4,000 January 31, 2019 44,019,194 0.04543 2,000 132,057,583 6,000 Series A2 Preferred Shares July 21, 2017 to July 25, 2017 73,371,157 0.05111 3,750 September 19, 2018 to Series B Preferred Shares December 27, 2018 260,709,579 0.3329 86,800 January 8, 2019 to March 25, 2019 36,643,370 0.3329 12,200 297,352,949 99,000 September 10, 2020 to Series C Preferred Shares September 30, 2020 141,692,465 0.4845 68,650 October 5, 2020 to November 5, 2020 114,757,479 0.4845 55,600 256,449,944 124,250 The exchange ratio has been applied to these preferred shares to give effect to the Business Combination of March 29, 2023 and these would have been as follows: Date of issue Total number of Subscription Subscription July 26, 2016 to Series A1 Preferred Shares July 28, 2016 6,310,503 $ 0.6338 $ 4,000 January 31, 2019 3,155,252 0.6338 2,000 9,465,755 6,000 Series A2 Preferred Shares July 21, 2017 to July 25, 2017 5,259,170 0.7130 3,750 September 19, 2018 to Series B Preferred Shares December 27, 2018 18,687,400 4.6443 86,800 January 8, 2019 to March 25, 2019 2,626,559 4.6443 12,200 21,313,959 99,000 September 10, 2020 to Series C Preferred Shares September 30, 2020 10,156,372 6.7593 68,650 October 5, 2020 to November 5, 2020 8,225,701 6.7593 55,600 18,382,073 124,250 The key terms of the Preferred Shares are as follows: (a) Dividends rights The Company cannot declare, pay or set aside any dividends on ordinary shares in any year unless the Preferred Shares holders shall first receive, or simultaneously receive, such dividends. Should any dividends be declared as determined by the Company, the Company will declare dividends at a rate of 8 % per annum of the original issue price of Series A1 Preferred Shares, Series A2 Preferred Shares, Series B Preferred Shares and Series C Preferred Shares on each Series A1 Preferred Share, Series A2 Preferred Share, Series B Preferred Share and Series C Preferred Share, respectively. Payments of any dividends to the holders of the Preferred Shares shall be on a pro rata, pari passu basis in proportion to the dividend rates for each series of the Preferred Shares. Such dividends shall be non-cumulative. After payment of such dividends, any additional dividends shall be distributed among the holders of the Preferred Shares and ordinary shares pro rata based on the number of ordinary shares or as-if converted basis then held by each holder. No dividends have been declared by the Company up to the date of this report. (b) Conversion feature Each holder of the Preferred Shares shall have the rights to convert the Preferred Shares into ordinary shares at any time after the issuance date into such number of fully paid and non-assessable ordinary shares as determined by dividing the relevant issue price by the then-effective conversion price. The “Conversion Price” shall initially be the Preferred Shares issue price, resulting in an initial conversion ratio of 1:1, and shall be subject to adjustment and readjustment (including but not limited to share splits and subdivision, additional ordinary shares issued and adjustment upon issuance of any other Preferred Shares for less than the Conversion Price). As of December 31, 2022 and March 29, 2023, the applicable conversion ratio was 1 :1. All outstanding Preferred Shares shall automatically be converted upon listing, at the applicable conversion ratio in effect at the time of conversion, without the payment of any additional consideration, into fully-paid and non-assessable ordinary shares upon the earlier of (i) the closing of a qualified initial public offering (“QIPO”), or (ii) the date specified by vote or written consent of the holders of at least a majority of the then outstanding Preferred Shares, voting together as a single class, at the Conversion Price in effect at such time. QIPO means the closing of a firm commitment underwritten registered public offering by the Company of its ordinary shares on a nationally recognized securities exchange in the US, Hong Kong or the PRC or any other jurisdiction approved by the board of directors of the Company, that reflects a pre-offering valuation of the Company which is not less than a value as stated in the convertible Preferred Share subscription agreements. (c) Redemption feature Series A Preferred Shares Neither the holders of Series A Preferred Shares nor the Company shall have the unilateral right to call or redeem or cause to have called or redeemed any of the outstanding Series A Preferred Shares. Series B Preferred Shares and Series C Preferred Shares Upon the written request of any holders of Series B Preferred Shares and Series C Preferred Shares, the Company shall redeem the outstanding Series B Preferred Shares and Series C Preferred Shares (collectively as the “Redeeming Preferred Shares”) of such holder(s) of Series B Preferred Shares and Series C Preferred Shares (collectively as the “Redeeming Preferred Shareholders”), respectively, if the Company has not completed a QIPO by December 31, 2021 and such redemption has to be completed within eighteen (18) months after redemption notice is served. In August, September and December 2022, the Company received written requests from certain convertible preferred shareholders to redeem the preferred shares held by them in accordance with the contractual redemption terms. The redemption feature shall be automatically terminated upon the submission of application of QIPO (“Listing Application”) and will be automatically restored to the fullest effect immediately upon (i) the Company withdrawing its Listing Application, or (ii) the Listing Application failing to consummate within 18 months from closing date of Series C Preferred Shares (i.e. May 2022). As at 31 December 2022, the redemption feature was fully restored. The redemption price shall be paid by the Company to each of the Redeeming Preferred Shareholders in an amount equal to the higher of the following: (i) the sum of (a) 100 % of the original issue price of the Redeeming Preferred Shares; (b) annual interest calculated at a simple interest of 12 % per annum on the original issue price of the Redeeming Preferred Shares for the period of time from the date on which the Redeeming Preferred Shares are first issued by the Company until the date of full payment of the redemption price for the Redeeming Preferred Shares; and (c) all accrued or declared but unpaid dividends on the Redeeming Preferred Shares as calculated on day of receipt by the Company of the redemption notice given by the Redeeming Preferred Shareholders; and (ii) a fraction, the numerator of which is the latest amount of the audited net assets of the Company prior to the day of full payment of redemption price, and the denominator of which is the total number of ordinary shares of the Company (on an as converted and fully diluted basis) on the day of receipt by the Company of the redemption notice given by the Redeeming Preferred Shareholders. As at December 31, 2022, the Group classified the Preferred Shares as non-current liabilities on the basis that the Group has the unconditional right to defer settlement for at least twelve months from the reporting date. With the completion of De-SPAC, all the Series A, B, C Preferred Shares had been converted into ordinary shares of the Company on March 29, 2023, those previously received redemption notices were not valid anymore. On March 29, 2023, all the preferred shares were converted into common shares, and therefore as of December 31, 2023, there are no longer any Preferred Shares. (d) Liquidation preferences Series A Preferred Shares If there are any assets or funds remaining after the aggregate Series B Preference Amount (as defined below under “Series B Preferred Shares”) and Series C Preference Amount (as defined below under “Series C Preferred Shares”) have been distributed or paid in full to the holders of Series B Preferred Shares and Series C Preferred Shares, the holders of the Series A Preferred Shares shall receive 100 % of the Series A Preferred Shares original issue price plus all accrued or declared but unpaid dividends. If upon the occurrence of a Liquidation Event, there is insufficient fund to pay the aforesaid amount to the holders of the Series A Preferred Shares, then the entire assets and funds of the Company legally available for distribution to all members of the Company shall be distributed ratably among the holders of Series A Preferred Shares, on a pari passu basis with each other, in proportion to the aggregate amount to be paid to each such Series A Preferred Shares holder is otherwise entitled to receive. Series B Preferred Shares If there are any assets or funds remaining after the aggregate Series C Preference Amount has been distributed or paid in full to the holders of Series C Preferred Shares, the Series B Preferred Shares holders shall be paid out of the remaining legally available funds for distribution and in preference to any distribution of any of the assets or funds of the Company to the holders of the Series A Preferred Shares and the holders of ordinary shares an amount equal to 100 % of the Series B Preferred Shares original issue price plus a simple interest at the rate of 12 % per annum plus all accrued or declared but unpaid dividends (the “Series B Preference Amount”). If upon the occurrence of a Liquidation Event, there is insufficient fund to pay the Series B Preference Amount, then the entire assets and funds of the Company legally available for distribution to all members of the Company shall be distributed ratably among the holders of the Series B Preferred Shares, on a pari passu basis with each other, in proportion to the aggregate Series B Preference Amount to be paid to each such Series B Preferred Shares holder is otherwise entitled to receive. Series C Preferred Shares In the event of a Liquidation Event of the Company, the holders of Series C Preferred Shares shall be entitled to receive, pari passu with each other, in preference and prior to any distribution of any of the assets of the Company to the holders of ordinary shares or members of any other class or series of shares by reason of their status as such holder or member, an amount equal to 100 % of the Series C Preferred Shares original issue price plus a simple interest at the rate of 12 % per annum plus all accrued or declared but unpaid dividends (the “Series C Preference Amount”). If upon the occurrence of a Liquidation Event, the assets and funds thus distributed among the holders of the Series C Preferred Shares shall be insufficient to permit the payment of the aggregate Series C Preference Amount, then the entire assets and funds of the Company legally available for distribution to all holders of Series C Preferred Shares shall be distributed ratably among the holders of the Series C Preferred Shares, pari passu with each other, in proportion to the aggregate Series C Preference Amount to be paid to each such holder is otherwise entitled to receive. Liquidation Event means any liquidation, dissolution, winding up, merger, acquisition, consolidation, issuance or transfer of equity securities or other transaction or series of transactions which causes the then members of the Company to lose controlling or majority voting rights in the Company or the surviving person (if not the Company), or any transaction or series of transactions in which all or substantially all assets including intellectual property of the Company are disposed via sale, lease or other arrangement, or the grant of an exclusive license to all or substantially all of the Company’s intellectual property (other than to one or more wholly-owned subsidiaries of the Company). (e) Voting rights Holders of the Preferred Shares are entitled to the number of votes equal to the number of ordinary shares into which the Preferred Shares are convertible. Except as otherwise required by law, the holders of ordinary shares, as such, shall not be entitled to vote on any amendment to the articles of the Company that relates solely to the rights, preferences, privileges and restrictions of the Preferred Shares, if the holders of the Preferred Shares, as applicable, are entitled to vote thereon as a separate class pursuant to the articles of the Company or pursuant to applicable law. Presentation and Classification The Company elected to designate the Preferred Shares as financial liabilities at FVTPL as a whole. The fair value change of the Preferred Shares is charged/credited to fair value change of Preferred Shares in profit or loss except for the portion attributable to credit risk change which shall be charged/credited to other comprehensive income, if any. The fair value change recognized in profit or loss includes any interest paid, if any, on the financial liabilities. The management of the Company considered that there is insignificant credit risk change on the financial liabilities that drives the fair value change of the Preferred Shares during the years ended December 31, 2021, 2022 and 2023. The movement of the Preferred Shares at the end of each reporting period is as follows: Preferred shares As of January 1, 2021 $ 284,791 Change in fair value 37,424 As of December 31, 2021 322,215 Change in fair value 189,646 As of December 31, 2022 511,861 Change in fair value 76,424 Conversion of convertible preferred shares into post-closing ordinary shares ( 588,285 ) As of December 31, 2023 $ — The Preferred Shares were valued by the management of the Company with reference to valuations carried out by an independent qualified professional valuer not connected with the Group, which has appropriate qualifications and experiences in valuation of similar instruments. The Company used the Black-Scholes model to determine the underlying share value of the Company and performed an equity allocation based on option pricing model (the “OPM” model) to arrive the fair value of the Preferred Shares at the end of each reporting period. In addition to the underlying share value of the Company determined by Black-Scholes model, other key valuation assumptions used in the OPM model to determine the fair value of the Preferred Shares are as follows: 2021 2022 Time to liquidation 1.5 years 1.25 years Risk-free rate 0.56 % 4.65 % Expected volatility (note) 72.5 % 75 % Dividend yield 0 % 0 % Possibility under IPO scenario 25 % 85 % Possibility under liquidation scenario 75 % 15 % Note: The expected volatility measured at the standard deviation is based on the historical data of the daily share price movement of comparable companies. On March 29, 2023, all the preferred shares were converted into common shares, and therefore as of December 31, 2023, there were no longer any preferred shares. |
Share Capital_Treasury Shares
Share Capital/Treasury Shares | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Share Capital Reserves and other Equity Interest [Abstract] | |
Share Capital/Treasury Shares | 26. SHARE CAPITAL/TREASURY SHARES Share capital The share capital as of December 31, 2021 and 2022 represented the issued ordinary share capital of the Company. Number of Par value Notes shares per share Amount Authorized: As of January 1, 2021, December 31, 2021 and 2022 444,343,488 $ 44 Issued and fully paid: As of January 1, 2021 386,741,005 39 Exercise of share options vested (i) 6,511,135 $ 0.0001 1 As of December 31, 2021 393,252,140 40 Exercise of share options vested (ii) 8,552,187 0.0001 1 As of December 31, 2022 401,804,327 41 The share capital as of January 1, 2021, December 31, 2021, 2022 and 2023 have been presented to give effect to the Business Combination of March 29, 2023 and the recapitalization at the exchange ratio of 0.071679, except for the authorized shares, and these are as follows: Number of Par value Notes shares per share Amount Authorized: As of December 31, 2023 600,000,000 $ 3 Issued and fully paid: As of January 1, 2021 27,721,202 3 Exercise of share options (i) 466,712 $ 0.0001 — As of December 31, 2021 28,187,914 3 Exercise of share options vested (ii) 613,012 0.0001 — As of December 31, 2022 28,800,926 3 Exercise of share options vested (iii) 62,443 0.0001 Business combination, net of redemptions 3,312,715 0.0001 Conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares 54,420,956 0.0001 6 Post-closing Apollomics Class B Ordinary Shares issued to PIPE Investors, net of transaction costs 230,000 0.0001 Issuance of post-closing Apollomics Class A Ordinary Shares upon the conversion of post-closing Apollomics Series A Preferred Shares 2,668,750 0.0001 As of December 31, 2023 89,495,790 9 All the ordinary shares and restricted shares issued during the years ended December 31, 2021, 2022 and 2023 rank pari passu with the existing shares in all respects. Notes: (i) During the year ended December 31, 2021, share option holders exercised their rights to subscribe for 6,511,135 ordinary shares made up as follows: 6,004,989 , 134,375 and 371,771 ordinary shares in the Company at an exercise price of $ 0.01 , $ 0.02 and $ 0.21 per share, respectively. To present this to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679 , these would have been 466,712 ordinary shares made up as follows: 430,432 , 9,632 and 26,648 ordinary shares in the Company at an exercise price of $ 0.14 , $ 0.28 and $ 2.93 per share, respectively. (ii) During the year ended December 31, 2022, share option holders exercised their rights to subscribe for 8,552,187 ordinary shares made up as follows: 498,958 , 7,088,541 , 101,146 and 863,542 ordinary shares in the Company at an exercise price of $ 0.01 , $ 0.02 , $ 0.21 and $ 0.26 per share, respectively. To present this to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679 , these would have been 613,013 ordinary shares made up as follows: 35,765 , 508,100 , 7,250 and 61,898 ordinary shares in the Company at an exercise price of $ 0.14 , $ 0.28 , $ 2.93 and $ 3.63 per share, respectively. (iii) During the year ended December 31, 2023, share option holders exercised their rights to subscribe for 62,443 ordinary shares made up as follows: 38,893 , 16,202 , 4,122 and 3,226 ordinary shares in the Company at an exercise price of $ 0.28 , $ 2.93 , $ 3.63 and $ 4.32 per share, respectively. Treasury shares Number of Subscription treasury price per shares share Amount As of January 1, 2021 26,365,915 $ 3,252 Restricted shares vested ( 6,352,715 ) $ 0.01 ( 64 ) Early exercised share options vested ( 5,926,452 ) 0.26 ( 1,541 ) As of December 31, 2021 14,086,748 1,647 Restricted shares vested ( 1,164,666 ) 0.01 ( 21 ) Early exercised share options vested ( 5,991,847 ) 0.26 ( 1,558 ) As of December 31, 2022 6,930,235 68 Early exercised share options vested ( 6,930,235 ) 0.26 ( 68 ) As of December 31, 2023 — — To present these treasury shares to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679 , these would have been presented as follows: Number of Subscription treasury price per shares share Amount As of January 1, 2021 1,889,882 $ 3,252 Restricted shares vested ( 455,356 ) $ 0.14 ( 64 ) Early exercised share options vested ( 424,802 ) 3.63 ( 1,541 ) As of December 31, 2021 1,009,724 1,647 Restricted shares vested ( 83,482 ) 0.14 ( 21 ) Early exercised share options vested ( 429,490 ) 3.63 ( 1,558 ) As of December 31, 2022 496,752 68 Early exercised share options vested ( 496,752 ) 3.63 ( 68 ) As of December 31, 2023 — — Treasury shares represented unvested restricted shares granted to the directors of the Company and an employee of the Group and the unvested restricted shares issued upon the early exercise of share options as elected by the director of the Company during the vesting period. |
Share-Based Payment Transaction
Share-Based Payment Transactions | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of terms and conditions of share-based payment arrangement [abstract] | |
Share-Based Payment Transactions | 27. SHARE-BASED PAYMENT TRANSACTIONS On July 19, 2016, the shareholders of the Company approved the adoption of the 2016 equity incentive plans (the “2016 Plan”) for the purpose to secure and retain employees, directors and consultants of the Company (the “Eligible Persons”), provide incentives for them to exert maximum efforts for the success of the Company and any affiliate and provide means by which the Eligible Persons may benefit from increases in value of the ordinary shares of the Company. The 2016 Plan provides for the grant of the following types of share awards: (i) restricted share awards, (ii) share options, (iii) share appreciation rights, (iv) restricted share unit awards, and (v) other share awards. The overall limit on the number of underlying shares which may be delivered pursuant to all awards granted under the 2016 Plan is 337,225,866 and 337,225,866 ordinary shares of the Company as of December 31, 2022 and 2023, respectively, subject to any adjustments for other dilutive issuances. In connection with the Business Combination, the Apollomics Board adopted the 2023 Incentive Award Plan (as amended from time to time), which is referred to in this Annual Report as the “ 2023 Incentive Plan ” and became effective as of the Closing. The 2023 Incentive Plan allows us to make equity and equity-based incentive awards to officers, employees, non-employee directors and our consultants and affiliates. Our Board anticipates that providing such persons with a direct stake in us will assure a closer alignment of the interests of such individuals with our interests and the interests of our shareholders, thereby stimulating their efforts on our behalf and strengthening their desire to remain with us and our affiliates. Restricted share awards All the restricted shares shall be subject to repurchase at the option by the Company at the subscription price paid by Eligible Persons upon voluntary or involuntary termination of his employment with the Company (the “Repurchase Option”). The Repurchase Option shall be exercised by the Company and/or the designees of the Company as to the number of unreleased shares, within sixty days after the termination of his employment with the Company giving written notice to Eligible Persons. The aforesaid arrangement has been accounted for as share-based payment transactions. Accordingly, the Group measured the fair value of the unvested restricted shares as of the grant date and is recognizing the amount as compensation expense over the vesting period for each separately vesting portion of the unvested restricted shares. The subscription price received by the Group in relation to the unvested restricted shares that are subject to the Repurchase Option held by the Company have been recognized as financial liabilities arising from unvested restricted shares as disclosed in Note 22. The total expense recognized in the consolidated statements of profit or loss and other comprehensive income for the restricted shares granted are approximately $ 7 and $ 39 and nil , for the years ended December 31, 2021, 2022 and 2023, respectively. The following table summarized the Group’s restricted shares movement during the years ended December 31, 2021, 2022 and 2023: 2021 2022 2023 Number of Number of Number of Outstanding at January 1, 14,447,616 8,094,901 6,930,235 Vested ( 6,352,715 ) ( 1,164,666 ) ( 6,930,235 ) Outstanding at December 31, 8,094,901 6,930,235 — To present these restricted shares to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679, these would have been presented as follows: 2021 2022 2023 Number of Number of Number of Outstanding at January 1, 1,889,882 1,009,724 496,752 Vested ( 880,158 ) ( 512,972 ) ( 496,752 ) Outstanding at December 31, 1,009,724 496,752 — The range of subscription price for the restricted shares is $ 0.003 to $ 0.01 per share. The time-based restricted shares shall be entirely vested ratably on a monthly basis over 48 -monthsvesting period or with 25 % be vested on the first anniversary of the vesting inception date and remaining portion vested ratably on a monthly basis over 36 -months vesting period. The milestone-based restricted shares will be vested upon achievement of specified performance conditions. The expected vesting period is estimated by the management of the Company based on the most likely outcome of each of the performance condition. During the year ended December 31, 2021, 2022 and 2023, nil , nil , and 496,752 milestone-based restricted shares have been vested, respectively. Share options The following table discloses movements of the Company’s share options under the 2016 Plan held by grantees during the years ended December 31, 2021 and 2022: 2021 2022 Number of Weighted- Number of Weighted- Outstanding at January 1, 151,133,235 $ 0.169 155,059,183 $ 0.203 Granted 39,715,000 0.279 11,500,000 0.310 Exercised ( 6,511,135 ) 0.022 ( 8,552,187 ) 0.046 Forfeited ( 29,277,917 ) 0.169 ( 22,027,291 ) 0.232 Outstanding at December 31, 155,059,183 0.203 135,979,705 0.217 Exercisable at the end of the year 78,269,054 67,667,737 To present the Company's share options to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679, these share options would have been presented as follows during the years ended December 31, 2021, 2022 and 2023: 2021 2022 2023 Number of Weighted- Number of Weighted- Number of Weighted- Outstanding at January 1, 10,833,079 $ 2.358 11,114,486 $ 2.832 9,746,889 $ 3.027 Options granted 2,846,731 3.892 824,309 4.325 3,048,310 9.927 Exercised ( 466,712 ) 0.307 ( 613,012 ) 0.642 ( 62,443 ) 1.397 Forfeited ( 2,098,612 ) 2.238 ( 1,578,894 ) 3.237 ( 808,341 ) 0.570 Outstanding at December 31, 11,114,486 2.832 9,746,889 3.027 11,924,415 4.615 Exercisable at the end of the year 5,610,248 4,850,356 7,859,478 No share options granted in the above table under the 2016 Plan will be exercisable after the expiration of 10 years from the date of its grant. The share options outstanding as of December 31, 2021, 2022 and 2023 had a weighted average remaining contractual life of 8.2 years, 7.4 years, and 6.25 years, respectively. During the year ended December 31, 2021, 2022 and 2023, the weighted average fair value of the share options granted were $ 2.28 per share, $ 0.2035 per share, and $ 7.13 per share, respectively. The weighted average fair value of the share options granted during the years ended December 31, 2021, and 2022 were presented as $ 0.16337 per share, and $ 0.2035 per share, respectively before giving effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679 .The time-based share options will be vested ratably on a monthly basis over a range of a 24 month to 48 month vesting period or with 50 % or 25 % vested on the first anniversary of the vesting inception date and the remaining portion vested ratably on a monthly basis over the remaining 12 months to 36 months vesting period. The milestone-based share options will be vested upon achievement of specified performance conditions. The expected vesting period is estimated by the management of the Company based on the most likely outcome of each of the performance conditions. During the years ended December 31, 2021, 2022, and 2023, of the 853,575 time-based share options had been early exercised by Dr. Yu and subject to the Repurchase Option, the remaining unvested early exercised share options as of December 31, 2021, 2022, and 2023 are 429,490 , nil and nil , respectively. The Option Pricing Model (“OPM”) was used to determine the fair value of the option granted. The key inputs into the model were as follows: Years ended December 2021 2022 2023 Grant date option fair value per share $ 0.1430 - 0.1544 $ 0.0933 - 0.1517 $ 0.01 - 0.511 Exercise price $ 0.26 - 0.31 $ 0.31 $ 0.07 - 0.72 Grant date option fair value per share $ 1.995 - 2.154 $ 1.302 - 2.116 $ 0.14 - 7.127 Exercise price as converted $ 3.63 - 4.32 $ 4.32 $ 0.94 - 10.01 Expected volatility (note i) 75 %- 80 % 75 %- 77.5 % 72.5 % Expected life 6.078 years 6.078 years 6.250 years Risk-free rate 0.51 %- 1.09 % 1.35 %- 3.98 % 3.67 % Expected dividend yield — % — % — % Note: The expected volatility measured at the standard deviation is based on the historical data of the daily share price movement of comparable companies. The total expense recognized in the consolidated statements of profit or loss and other comprehensive income for share options and restricted stocks granted under the 2016 and 2023 Plans are approximately $ 8,115 , $ 3,543 , and $ 12,685 , and expenses for consultancy fees of approximately $ 129 , $ 27 , and $ 19 for the years ended December 31, 2021, 2022 and 2023, respectively. Restricted stock There were no restricted stocks issued under the 2016 Plan during the years ended December 31, 2021 and 2022. Under the 2023 Plan, the following table discloses movements of the Company’s restricted stocks under the 2023 Plan for the year December 31, 2023. Year ended December 31, 2023 Number of Weighted- Outstanding at January 1, 2023 — $ — Restricted stock granted 207,945 $ 5.410 Outstanding at December 31, 2023 207,945 $ 5.410 Exercisable at the end of the year — |
Capital Risk Management
Capital Risk Management | 12 Months Ended |
Dec. 31, 2023 | |
Capital Risk Management [Abstract] | |
Capital Risk Management | 28. CAPITAL RISK MANAGEMENT The Group manages its capital to ensure the Group will be able to continue as a going concern while maximizing the return to stakeholders through the optimization of the debt and equity balance. The Group’s overall strategy remains unchanged throughout the years ended December 31, 2021, 2022 and 2023. The capital structure of the Group consists of net debt, which includes lease liabilities and Preferred Shares as disclosed in Notes 23 and 24, respectively, net of cash and cash equivalents, and equity attributable to owners of the Company, comprising issued share capital, share premium, accumulated losses and various reserves. We regularly review the capital structure from time to time. As part of this review, we consider the cost of capital and the risks associated with each class of capital. We may balance our overall capital structure through the payment of dividends, new share issues as well as raising new debt or redemption of existing debts. |
Financial Instruments
Financial Instruments | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of detailed information about financial instruments [abstract] | |
Financial Instruments | 29. FINANCIAL INSTRUMENTS Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis. Some of the Group's financial assets and financial liabilities are measured at fair value at the end of each reporting period. The following table gives information about how the fair values of these financial assets and financial liabilities are determined (in particular, the valuation techniques and inputs used). Fair value as of December 31, 2023 December 31, 2022 Fair Valuation technique(s) Significant Relationship of Financial assets Money market fund $ 5,761 $ 19,067 Level 1 Redemption value quoted by banks with reference to the expected return of the underlying assets N/A N/A Financial liabilities Convertible preferred — 511,861 Level 3 Black-Scholes model and OPM method - the key inputs are: time to liquidation, risk-free rate, expected volatility and possibilities for IPO/liquidation scenario Possibility The higher the possibility for IPO scenario, the higher the fair value, and vice versa Maxpro public warrants 259 — Level 1 The public warrants are traded on the Nasdaq, the valuation is based on unadjusted quoted prices in active markets for identical assets or liabilities N/A N/A Maxpro private warrants 15 — Level 2 Private warrants are considered to be economically equivalent to the public warrants. As such, the valuation of the public warrants was used to value the private warrants N/A N/A Penny warrants (Note 5) 56 — Level 3 Black-Scholes model - the key inputs are: underlying share price, expected life in years, risk-free rate, expected volatility, and exercise price N/A N/A Total warrant liabilities: 330 Note: A 10 % increase or decrease in the possibility for IPO scenario holding all other variables constant will increase or decrease the fair value of preferred shares by $ 42.9 million or $ 42.0 million as of December 31, 2022. On March 29, 2023 the preferred shares were converted into ordinary shares and as of December 31, 2023 no preferred shares remain outstanding. (i) Reconciliation of Level 3 fair value measurements Details of reconciliation of Level 3 fair value measurement for the preferred shares are set out in Note 21. All the unrealized fair value changes gain of $ 189.6 million and loss of $ 76.4 million for the years ended December 31, 2022 and 2023, respectively, relate to the fair value change of the Preferred Shares and is charged/credited to fair value change of Preferred Shares in profit or loss. (ii) Fair value of financial assets and financial liabilities that are not measured at fair value The management of the Company consider that the carrying amount of the Group's financial assets and financial liabilities recorded at amortized cost in the consolidated financial statements approximate their fair values. Such fair values have been determined in accordance with generally accepted pricing models based on a discounted cash flow analysis. a. Categories of financial instruments As of December 31, 2022 2023 Financial assets Financial assets at FVTPL $ 19,067 $ 5,761 Amortized cost 39,983 32,166 Financial liabilities Financial liability at FVTPL 511,861 330 Amortized cost 7,606 5,970 The financial assets at FVTPL of $ 19,067 and $ 5,761 as of December 31, 2022 and 2023, respectively, represents investment in a money market fund in the US, which solely holds investments in the US treasury bonds. b. Financial risk management objectives and policies Financial risk factors The Group’s major financial instruments include rental deposits, financial asset at FVTPL, time deposits with original maturity over three months, cash and cash equivalents, other payables, financial liabilities arising from unvested restricted shares and convertible preferred shares. Details of the financial instruments are disclosed in respective notes. The Group’s activities expose it to a variety of financial risks: market risk (including currency risk, interest rate risk and other price risk), credit and counterparty risk and liquidity risk. The policies on how to mitigate these risks are set out below. The management of the Company manage and monitor these exposures to ensure appropriate measures are implemented on a timely and effective manner. Market risk Currency risk Certain bank balances, deposits and other payables are denominated in currencies other than the functional currency of the group entities, which exposes the Group to foreign currency risk. The Group currently does not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise. The carrying amounts of the Group’s foreign currency denominated monetary assets and monetary liabilities at the end of each reporting period are as follows: Assets Liabilities As of December 31, As of December 31, 2022 2023 2022 2023 Renminbi (“RMB”) $ 8,940 $ 6,071 $ 1,210 $ 5,443 Australian Dollars (“AUD”) 1,300 796 1,449 771 $ 10,240 $ 6,867 $ 2,659 $ 6,214 Sensitivity analysis The Group is mainly exposed to the fluctuation of foreign exchange rate of RMB and AUD. The following table details the Group’s sensitivity to a 5 % decrease in the functional currency of the relevant group entities against the relevant foreign currencies. The following sensitivity analysis includes only outstanding monetary items denominated in foreign currencies and adjusts their translation at the year end for a 5 % change in foreign currency exchange rate, which is the sensitivity rates used when reporting foreign currency risk internally to key management personnel and represents management’s assessment of the reasonably possible change in currencies exchange rates. A positive (negative) number below indicates a decrease (increase) in loss for the year when the foreign currency below strengthen 5 % against the functional currency of the relevant group entities. For a 5 % weakening of these foreign currencies against the functional currency of the relevant group entities, there would be an equal and opposite impact on the loss for the year. 2021 2022 2023 Impact of RMB on loss for the year $ 295 $ 386 $ 659 Impact of AUD on loss for the year 22 ( 7 ) 26 In management’s opinion, the sensitivity analysis is unrepresentative of the inherent foreign exchange risk as the year end exposure does not reflect the exposure during the years ended December 31, 2021, 2022 and 2023. Interest rate risk The Group are exposed to fair value interest rate risk in relation to time deposits, lease liabilities and Preferred Shares as disclosed in Notes 20, 23 and 24, respectively. The Group are also exposed to cash flow interest rate risk in relation to variable-rate bank balances as disclosed in Note 20. The Group’s cash flow interest rate risk are mainly concentrated on the fluctuation of interest rates on bank balances. The management of the Company consider that the exposure of cash flow interest rate risk arising from variable-rate bank balances is insignificant, therefore no sensitivity analysis on such risk has been prepared. Other price risk The Group are exposed to other price risk arising from Preferred Shares and the investment in a money market fund in the US. Sensitivity analysis Investment in money market fund in the US No sensitivity analysis is performed as the management of the Company consider that the exposure of other price risk arising from the investment in a money market fund in the US is insignificant because the investment is mainly on US treasury bonds with high credit rating and liquidity. Credit and counterparty risk Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting financial loss to the Group. In order to minimize the credit risk, the Company reviews the recoverable amount of each individual debt at the end of each reporting period to ensure that adequate impairment losses are made for irrecoverable amounts. In this regard, the management of the Company consider that the Group’s credit risk are significantly reduced. The Group’s internal credit risk grading assessment comprises the following categories: Internal credit rating Description Financial assets at Low risk The counterparty has a low risk of default and does not have any past-due amounts 12-month ECL Watch list Debtor frequently repays after due dates but settles the amounts in full 12-month ECL Doubtful There have been significant increases in credit risk since initial recognition through information developed internally or external resources Lifetime ECL - not credit-impaired Loss There is evidence indicating the asset is credit-impaired Lifetime ECL - credit-impaired Write-off There is evidence indicating that the debtor is in severe financial difficulty and the Group has no realistic prospect of recovery Amount is written off External The Group credit Internal 12-month ECL As of December 31, rating credit rating or lifetime ECL 2022 2023 Financial assets Deposits N/A Low risk 12-month ECL $ 129 $ 110 Time deposits with maturity less than twelve months A3 N/A 12-month ECL 2,872 — Time deposits with maturity greater than twelve months A3 N/A 12-month ECL 4,307 — Cash and cash equivalents A3 to Aa2 N/A 12-month ECL 32,675 32,056 $ 39,983 $ 32,166 Deposits The Group assessed the ECL for its deposits individually based on internal credit rating which, in the opinion of the management of the Company, have no significant increase in credit risk since initial recognition. ECL is estimated based on historical observed default rates over the expected life of debtors and is adjusted for forward-looking information that is available without undue cost or effort. No12-month ECL was made as of December 31, 2022 and 2023, as the counterparties involved are considered with low risk (based on the internal credit rating) and the ECL involved is not material. Cash and cash equivalents and time deposits with original maturity over three months A significant portion of the Group’s bank balances and deposits are placed with international banks in the US. The credit risks on bank balances and deposits are limited because the counterparties are banks with high credit ratings assigned by international credit-rating agencies and are all classified as low risk by the Group by reference to available external credit rating. Other than the credit risks mentioned above, the Group do not have any other significant concentration of credit risk. No 12-month ECL has been provided during the years ended December 31, 2021, 2022 and 2023. The management of the Company has assessed the impact and concluded the ECL involved is not material. Liquidity risk As at December 31, 2023, the Group recorded net assets of $ 41,234 . In the management of liquidity risk, the management of the Company have reviewed the Group’s cash flow projections to ensure the Group maintains a level of cash and cash equivalents deemed adequate by the management to finance the Group’s operations and mitigate the effects of fluctuations in cash flows. The following table details the Group’s remaining contractual maturity for its non-derivative financial liabilities and lease liabilities. The table has been drawn up based on the undiscounted cash flows of financial liabilities and lease liabilities based on the earliest date on which the Group can be required to pay. The table includes both interest and principal cash flows. To the extent that interest flows are floating rate, the undiscounted amount is derived from interest rate at the end of each reporting period. On demand Weighted or less Total average than 1 1 to 3 3 Months 1 to 2 2 to 4 undiscounted Carrying interest rate Month Months to 1 Year Years Years cash flows amount % $ $ $ $ $ $ $ December 31, 2022 Convertible Preferred Shares (note) 12 — — — 338,492 — 338,492 378,332 Other payables N/A 7,538 — — — — 7,538 7,538 Financial liabilities arising from unvested restricted shares N/A 68 — — — — 68 68 Total 7,606 — — 338,492 — 346,098 385,938 Lease liabilities 5.38 49 268 391 143 260 1,111 991 December 31, 2023 Other payables N/A 5,970 — — — — 5,970 5,970 Total 5,970 — — — — 5,970 5,970 Lease liabilities 4.85 44 31 83 216 50 495 425 Note: The cash outflow for Preferred Shares included those for Series B Preferred Shares and Series C Preferred Shares which have redemption feature as disclosed in Note 24(c). There is no redemption feature for Series A Preferred Shares and the Series A Preferred Shares with carrying amounts of $ 133,529 and zero as of December 31, 2022 and 2023, respectively, have not been presented in above table. The timing of the cash outflow and the weighted average interest rate for the Preferred Shares are determined based on the date of the management expected to redeem the Redeeming Preferred Shared as of December 31, 2022 and 2023, respectively. c. Fair values measurements of financial instruments (i) Fair value of the Group’s financial assets and financial liabilities that are measured at fair value on a recurring basis Some of the Group’s financial assets and financial liabilities are measured at fair value at the end of each reporting period. The following table gives information about how the fair values of these financial assets and financial liabilities are determined (in particular, the valuation techniques and inputs used). Relationship of Fair value as of Significant unobservable December 31, Fair value Valuation technique(s) and key unobservable inputs to fair 2022 2023 hierarchy inputs inputs value Financial assets Money market fund $ 19,067 $ 5,761 Level 1 Redemption value quoted by banks with reference to the expected return of the underlying assets N/A N/A Financial liabilities Convertible Preferred 511,861 — Level 3 Black-Scholes model and OPM method — the key inputs are: time to liquidation, risk- free rate, expected volatility and possibilities for IPO/liquidation scenario Possibility for IPO scenario (note) The higher the possibility for IPO scenario, the higher the fair value, and vice versa Warrants — 330 Level 1 Public warrants and private warrants are based on the valuation of the public price of APLMW which is directly observable market (level 1) while the penny warrants are based on the underlying share price of APLM, also a directly observable market (level 1) N/A N/A Note: A 10 % increase or decrease in the possibility for IPO scenario holding all other variables constant will increase or decrease the fair value of convertible Preferred Shares by $ 22,166 or zero and $ 41,969 or zero as of December 31, 2022 and 2023, respectively. (ii) Reconciliation of Level 3 fair value measurements Details of reconciliation of Level 3 fair value measurement for the convertible Preferred Shares are set out in Note 24. All the unrealized fair value changes of $ 37,424 , $ 189,646 and $ 76,430 for the years ended December 31, 2021, 2022 and 2023, respectively, relate to the convertible Preferred Shares were recognized in the profit or loss. (iii) Fair value of financial assets and financial liabilities that are not measured at fair value The management of the Company consider that the carrying amount of the Group’s financial assets and financial liabilities recorded at amortized cost in the consolidated financial statements approximate their fair values. Such fair values have been determined in accordance with generally accepted pricing models based on a discounted cash flow analysis. |
Retirement Benefits Plan
Retirement Benefits Plan | 12 Months Ended |
Dec. 31, 2023 | |
Employee benefits [Abstract] | |
Retirement Benefits Plan | 30. RETIREMENT BENEFITS PLAN The employees employed by the PRC subsidiary are members of the state-managed retirement benefits scheme operated by the PRC government. The PRC subsidiary is required to contribute a certain percentage of their payroll to the retirement benefits schemes to fund the benefits. The only obligation of the Group with respect to the retirement benefits schemes is to make the required contributions under the scheme. The Group maintains multiple qualified contributory saving plans as allowed under Section 401(k) of the Internal Revenue Code in the US. These plans are defined contribution plans covering employees employed in the US and provide for voluntary contributions by employees, subject to certain limits. The contributions are made by both the employees and the employer. The employees’ contributions are primarily based on specified dollar amounts or percentages of employee compensation. The total cost charged to profit or loss of $ 749 , $ 662 and $ 499 , respectively, represents contributions paid or payable to the above schemes by the Group for the years ended December 31, 2021, 2022 and 2023. At the end of each reporting period, there were no forfeited contributions which arose upon employees leaving the schemes prior to their interests in the Group’s contribution becoming fully vested and which are available to reduce the contributions payable by the Group in future years. |
Related Party Disclosures
Related Party Disclosures | 12 Months Ended |
Dec. 31, 2023 | |
Related Party Disclosures [Abstract] | |
Related Party Disclosures | 31. RELATED PARTY DISCLOSURES (i) Compensation of key management personnel The remuneration of directors of the Company and other members of key management were as follows: For the year ended December 31, 2021 2022 2023 Short term benefits $ 2,214 $ 2,473 $ 4,112 Retirement benefit scheme contributions 12 12 21 Share-based payment 6,131 1,820 9,419 $ 8,357 $ 4,305 $ 13,552 The remuneration of key management personnel is determined by the directors of the Company having regard to the performance of individuals and market trends. |
Reconciliation of Liabilities A
Reconciliation of Liabilities Arising from Financing Activities | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of reconciliation of liabilities arising from financing activities [abstract] | |
Reconciliation of Liabilities Arising from Financing Activities | 32. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES The table below details changes in the Group’s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group’s consolidated statements of cash flows as cash flows from financing activities. Convertible Lease Accrued share Total As of January 1, 2021 $ 284,791 $ 1,511 $ 511 $ 286,813 Financing cash flows — ( 611 ) ( 1,173 ) ( 1,784 ) Non-cash changes: Fair value change 37,424 — — 37,424 New leases entered — 53 — 53 Issue costs accrued — — 1,306 1,306 Interest expense — 83 — 83 As of December 31, 2021 322,215 1,036 644 323,895 Financing cash flows — ( 686 ) — ( 686 ) Non-cash changes: Fair value change 189,646 — — 189,646 New leases entered — 548 — 548 Reversal on accrued share issue costs — — ( 644 ) ( 644 ) Interest expense — 93 — 93 As of December 31, 2022 511,861 991 — 512,852 Financing cash flows — ( 688 ) — ( 688 ) Non-cash changes: Fair value change 76,424 — — 76,424 Preferred shares converted to common stock ( 588,285 ) — — ( 588,285 ) Reversal on accrued share issue costs — — — — Interest expense — 122 — 122 As of December 31, 2023 $ — $ 425 $ — $ 425 |
Major Non-Cash Transactions
Major Non-Cash Transactions | 12 Months Ended |
Dec. 31, 2023 | |
Major Non-Cash Transactions [Abstract] | |
Major Non-Cash Transactions | 33. MAJOR NON-CASH TRANSACTIONS During the years ended December 31, 2021, 2022 and 2023: (i) the Group entered into new lease agreements for the use of offices and, plant and equipment for 12 months to 60 months. On the lease commencement, the Group recognized $ 53 , $ 548 and nil of right-of-use asset and lease liabilities, respectively; (ii) financial liabilities arising from unvested restricted shares and treasury shares of $ 1,605 , $ 1,579 and $ 68 , respectively, have been derecognized upon vesting of restricted shares. |
Restricted Net Assets
Restricted Net Assets | 12 Months Ended |
Dec. 31, 2023 | |
Restricted Assets [Abstract] | |
Restricted Net Assets | 34. RESTRICTED NET ASSETS The Company’s ability to pay dividends may depend on the Company receiving distributions of funds from its subsidiaries. The Company’s PRC subsidiaries are subject to relevant PRC statutory laws and regulations which permit payments of dividends only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with IFRSs differ from those reflected in the statutory financial statements of the Company’s PRC subsidiaries. Foreign exchange and other regulations in the PRC further restrict the Company’s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances. As of December 31, 2022 and 2023, amounts restricted are the paid-in capital of the Company’s PRC subsidiaries, which amounted to $ 52,298 and $ 35,000 , respectively. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of non-adjusting events after reporting period [abstract] | |
Subsequent Events | 35. SUBSEQUEN T EVENTS We have evaluated subsequent events through the filing of this annual report on form 20-F, and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements. |
Schedule I - Additional Financi
Schedule I - Additional Financial Information of Parent Company | 12 Months Ended |
Dec. 31, 2023 | |
Additional information [abstract] | |
Schedule I - Additional Financial Information of Parent Company | Schedule I - Additional financial in formation of parent company APOLLOMICS INC. Condensed Statement of Loss and Other Comprehensive Loss (All amounts in thousands of $) Years ended December 31, 2021 2022 2023 Other income $ 42 $ 112 $ 49 Fair value change of financial assets at FVTPL 2 323 821 Fair value change of financial liabilities at FVTPL — — 1,597 Fair value change of convertible preferred shares ( 37,424 ) ( 189,646 ) ( 76,430 ) Research and development expenses ( 2,643 ) ( 992 ) ( 7,772 ) Administrative expenses ( 4,494 ) ( 1,982 ) ( 13,215 ) Finance costs — — ( 28 ) Other expense ( 4,522 ) ( 5,532 ) ( 46,003 ) Share of loss in subsidiaries ( 45,757 ) ( 43,094 ) ( 31,610 ) Loss before taxation ( 94,796 ) ( 240,811 ) ( 172,591 ) Income tax expense — — ( 10 ) Loss and total comprehensive loss for the year, attributable to owners $ ( 94,796 ) $ ( 240,811 ) $ ( 172,601 ) Schedule I - Additional financial inf ormation of parent company APOLLOMICS INC. Condensed Statements of Financial Position (All amounts in thousands of $) As of December 31, 2022 2023 Non-current assets Intangible assets $ 1,778 $ 1,759 Amount due from subsidiaries 70,560 70,103 Total non-current assets 72,338 71,862 Current assets Deposits, prepayments and deferred expenses — 630 Financial assets at FVTPL 19,067 5,761 Cash and cash equivalents 6,001 2,330 Total current assets 25,068 8,721 Total assets 97,406 80,583 Current liabilities Other payables and accruals 2,986 366 Financial liabilities arising from unvested restricted shares 68 — Total current liabilities 3,054 366 Net current assets 22,014 8,355 Total assets less current liabilities 94,352 80,217 Non-current liabilities Convertible preferred shares 511,861 — Warrant liabilities — 330 Deficit in subsidiaries 30,611 38,653 Total non-current liabilities 542,472 38,983 Net assets (liabilities) $ ( 448,120 ) $ 41,234 Equity Share capital 41 9 Treasury shares ( 68 ) — Share premium 12,279 661,474 Reserves 14,228 26,716 Accumulated losses ( 474,600 ) ( 646,965 ) $ ( 448,120 ) $ 41,234 Schedule I - Additional financial information of parent company APOLLOMICS INC. Condensed Statements of Cash Flows (All amounts in thousands of $) Years ended December 31, 2021 2022 2023 OPERATING ACTIVITIES Loss before taxation $ ( 94,796 ) $ ( 240,811 ) $ ( 172,591 ) Adjustments for: Share of loss in subsidiaries 45,757 43,094 31,610 Interest income ( 42 ) ( 112 ) ( 49 ) Amortization of intangible assets 20 20 20 Fair value change of financial assets at FVTPL ( 2 ) ( 323 ) ( 821 ) Fair value change of financial liabilities at FVTPL — — ( 1,597 ) Fair value change of convertible preferred shares 37,424 189,646 76,430 IFRS 2 listing expense — — 45,524 Portion of PIPE issuance costs allocated to PIPE warrants — — 38 Share-based payment expenses 4,056 818 12,685 Non-cash adjustments to other expenses — ( 2,563 ) 2,484 Operating cash flows before movements in working capital ( 7,583 ) ( 10,231 ) ( 6,267 ) (Increase)/decrease in deposits, prepayments and deferred expenses 162 2,812 ( 630 ) Increase/(decrease) in other payables and accruals 1,119 859 ( 2,620 ) NET CASH USED IN OPERATIONS ( 6,302 ) ( 6,560 ) ( 9,517 ) Taxation paid — — ( 10 ) NET CASH USED IN OPERATING ACTIVITIES ( 6,302 ) ( 6,560 ) ( 9,527 ) INVESTING ACTIVITIES Interest received 42 112 49 Investment in subsidiaries ( 27,150 ) ( 25,926 ) ( 8,042 ) Advance to subsidiaries ( 4,818 ) ( 2,013 ) — Repayment from subsidiaries — 2,135 457 Purchase of intangible assets ( 1,500 ) — — Proceeds from disposal of financial asset at FVTPL — 5,000 13,307 NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES ( 33,426 ) ( 20,692 ) 5,771 FINANCING ACTIVITIES Proceeds on issue of convertible preferred shares — — — Proceeds from issue of shares upon exercise of share options 141 392 85 Accrued issuance costs paid ( 1,173 ) — — NET CASH FROM (USED IN) FINANCING ACTIVITIES ( 1,032 ) 392 85 NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS ( 40,760 ) ( 26,860 ) ( 3,671 ) CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR 73,621 32,861 6,001 CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR $ 32,861 $ 6,001 $ 2,330 Schedule I - Additional financial information of parent company APOLLOMICS INC. Notes to the condensed Financial Information of Parent Company 1. Schedule I has been provided pursuant to the requirements of Rule12-04(a) and 5-04(c) of Regulation S-X, which require condensed financial information as to the financial position, changes in financial position and results of operations of a parent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. 2. The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in its subsidiaries. For the purpose of this Schedule I, Apollomics Inc., as the parent company, records its investments in subsidiaries under the equity method of accounting in accordance with International Accounting Standards 27 Separate Financial Statements , as issued by the International Accounting Standards Board. Such investments are presented on the Condensed Statements of Financial Position as “Investment in subsidiaries”. Ordinarily under the equity, an investor in an equity method investee would cease to recognize its share of the losses of an investee once the carrying value of the investment has been reduce to nil absent an undertaking by the investor to provide continuing support and fund losses. For the purpose of this Schedule I, the parent company has continued to reflect its share, based on its proportionate interest, of the losses of subsidiaries in investment in subsidiaries regardless of the carrying value of the investment in subsidiaries even though the parent company is not obligated to provide continuing support or fund losses. The excess amount is recorded as “Deficit in subsidiaries” on the Condensed Statements of Financial Position. 3. Certain information and footnote disclosures normally included in financial statements prepared in accordance with IFRSs have been condensed or omitted. The footnote disclosures provide certain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the accompanying consolidated financial statements. 4. As of December 31, 2022 and 2023, there were no material contingencies, significant provisions of long-term obligations, mandatory dividend or guarantees of Apollomics Inc. |
Material Accounting Policies (P
Material Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Summary of Significant Accounting Policies [Abstract] | |
Basis of consolidation | Basis of consolidation The consolidated financial statements incorporate the financial statements of Apollomics and entities controlled by Apollomics and its subsidiaries. Control is achieved when the Company: • has power over the investee; • is exposed, or has rights, to variable returns from its involvement with the investee; and • has the ability to use its power to affect its returns. The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statements of profit or loss and other comprehensive income from the date the Group gains control until the date when the Group ceases to control the subsidiary. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with the Group’s accounting policies. All intragroup assets, liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation. |
Foreign currencies | Foreign currencies In preparing the financial statements of each individual group entity, transactions in currencies other than the functional currency of that entity (foreign currencies) are recognized at the rates of exchanges prevailing on the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences arising on the settlement of monetary items, and on the retranslation of monetary items, are recognized in profit or loss in the period in which they arise. |
Government grants | Government grants Government grants are not recognized until there is reasonable assurance that the Group will comply with the conditions attaching to them and that the grants will be received. Government grants related to income that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Group with no future related costs are recognized in profit or loss in the period in which they become receivable. Such grants are presented under “other income”. |
Retirement benefits costs | Retirement benefits costs Payments to defined contribution retirement benefit plans, including the defined contribution plan in the US, state-managed retirement benefit schemes in the People’s Republic of China (the “PRC”) are recognized as an expense when employees have rendered service entitling them to the contributions. |
Short-term employee benefits | Short-term employee benefits Short-term employee benefits are recognized at the undiscounted amount of the benefits expected to be paid as and when employees rendered the services. All short-term employee benefits are recognized as an expense unless another IFRS requires or permits the inclusion of the benefit in the cost of an asset. A liability is recognized for benefits accruing to employees (such as wages, salaries and leave entitlement) after deducting any amount already paid. |
Share-based payments | Share-based payments Equity-settled share-based payment transactions Share options and restricted shares granted to employees and others providing similar services Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of the equity instruments at the grant date. The fair value of the equity-settled share-based payments determined at the grant date without taking into consideration all non-market vesting conditions is expensed on a straight-line basis over the vesting period, based on the Group’s estimate of equity instruments that will eventually vest, with a corresponding increase in equity (share-based payment reserve). At the end of each reporting period, the Group revises its estimate of the number of equity instruments expected to vest based on assessment of all relevant non-market vesting conditions. The impact of the revision of the original estimates, if any, is recognized in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the share-based payment reserve. When share options are exercised or the restricted shares are vested, the amount previously recognized in share-based payment reserve will be transferred to other reserve. When the share options are forfeited after the vesting date or are still not exercised at the expiry date, the amount previously recognized in share-based payment reserve will be transferred to accumulated losses. |
Taxation | Taxation Income taxation represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable profit for the year. Taxable profit differs from ‘loss before taxation’ because of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of each reporting period. Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognized if the temporary difference arises from the initial recognition of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. Deferred tax liabilities are recognized for taxable temporary differences associated with investments in subsidiaries, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments are only recognized to the extent that it is probable that there will be sufficient taxable profits against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of each reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of each reporting period, to recover or settle the carrying amount of its assets and liabilities. For the purposes of measuring deferred tax for leasing transactions in which the Group recognizes the right-of-use assets and the related lease liabilities, the Group first determines whether the tax deductions are attributable to the right-of-use assets or the lease liabilities. For leasing transactions in which the tax deductions are attributable to the lease liabilities, the Group applies IAS 12 requirements to the leasing transaction as a whole. Temporary differences relating to right-of-use assets and lease liabilities are assessed on a net basis. Excess of depreciation on right-of-use assets over the lease payments for the principal portion of lease liabilities resulting in net deductible temporary differences. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied to the same taxable entity by the same taxation authority. Current and deferred tax are recognized in profit or loss. |
Plant and equipment | Plant and equipment Plant and equipment are stated at cost less subsequent accumulated depreciation and subsequent accumulated impairment losses, if any. Depreciation is recognized so as to write off the cost of assets less their residual values over their estimated useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis. An item of plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in profit or loss. |
Leases | Leases Definition of a lease A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group assesses whether a contract is or contains a lease based on the definition under IFRS 16 at inception, modification date or acquisition date, as appropriate. Such contract will not be reassessed unless the terms and conditions of the contract are subsequently changed. The Group as a lessee Allocation of consideration to components of a contract For a contract that contains a lease component and one or more additional lease or non-lease components, the Group allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components. The Group applies practical expedient not to separate non-lease components from lease component, and instead account for the lease component and any associated non-lease components as a single lease component. Short-term leases The Group applies the short-term lease recognition exemption to leases of plant and equipment and laboratory premise, that have a lease term of 12 months or less from the commencement date and do not contain a purchase option. Lease payments on short-term leases is recognized as expense on a straight-line basis over the lease term. Right-of-use assets Except for short-term leases, the Group recognizes right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of the initial measurement of the lease liability. Right-of-use assets in which the Group is reasonably certain to obtain ownership of the underlying leased assets at the end of the lease term is depreciated from commencement date to the end of the useful life. Otherwise, right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. The Group presents right-of-use assets as a separate line item on the consolidated statements of financial position. Refundable rental deposits Refundable rental deposits paid are accounted for under IFRS 9 Financial Instruments and initially measured at fair value. Adjustments to fair value at initial recognition are considered as additional lease payments and included in the cost of right-of-use assets. Lease liabilities At the commencement date of a lease, the Group recognizes and measures the lease liability at the present value of lease payments that are unpaid at that date. In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable. The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The Group presents lease liabilities as a separate line item on the consolidated statements of financial position. |
Intangible assets | Intangible assets Intangible assets acquired separately Intangible assets with finite useful lives that are acquired separately are carried at costs less accumulated amortization and any accumulated impairment losses if any. Amortization for intangible assets with finite useful lives is recognized on a straight-line basis over their estimated useful lives. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets not yet available for use that are acquired separately are carried at cost less any subsequent accumulated impairment losses. Internally-generated intangible assets - research and development expenditure Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally generated intangible asset arising from development activities (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated: • the technical feasibility of completing the intangible asset so that it will be available for use or sale; • the intention to complete the intangible asset and use or sell it; • the ability to use or sell the intangible asset; • how the intangible asset will generate probable future economic benefits; • the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and • the ability to measure reliably the expenditure attributable to the intangible asset during its development. The amount initially recognized for internally-generated intangible asset is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred. Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses (if any), on the same basis as intangible assets that are acquired separately. An intangible asset is derecognized on disposal, or when no future economic benefits are expected from use or disposal. Gains and losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognized in profit or loss when the asset is derecognized. |
Impairment on plant and equipment, right-of-use assets and intangible assets | Impairment on plant and equipment, right-of-use assets and intangible assets At the end of each reporting period, the management of the Company reviews the carrying amounts of plant and equipment, right-of-use assets and intangible assets with finite useful lives to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the relevant asset is estimated in order to determine the extent of the impairment loss, if any. Intangible assets not yet available for use are tested for impairment at least annually, and whenever there is an indication that they may be impaired. The recoverable amount of plant and equipment, right-of-use assets and intangible assets is estimated individually. When it is not possible to estimate the recoverable amount of an asset individually, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs. In testing a cash-generating unit for impairment, corporate assets are allocated to the relevant cash-generating unit when a reasonable and consistent basis of allocation can be established, or otherwise they are allocated to the smallest group of cash generating units for which a reasonable and consistent allocation basis can be established. The recoverable amount is determined for the cash-generating unit or group of cash-generating units to which the corporate asset belongs, and is compared with the carrying amount of the relevant cash-generating unit or group of cash-generating units. Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset (or cash-generating unit) for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or a cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. For corporate assets or portion of corporate assets which cannot be allocated on a reasonable and consistent basis to a cash-generating unit, the Group compares the carrying amount of a group of cash-generating units, including the carrying amounts of the corporate assets or portion of corporate assets allocated to that group of cash-generating units, with the recoverable amount of the group of cash-generating units. In allocating the impairment loss, the impairment loss is allocated first to reduce the carrying amount of any goodwill (if applicable) and then to the other assets on a pro-rata basis based on the carrying amount of each asset in the unit. The carrying amount of an asset is not reduced below the highest of its fair value less costs of disposal (if measurable), its value in use (if determinable) and zero. The amount of the impairment loss that would otherwise have been allocated to the asset is allocated pro rata to the other assets of the unit or a group of cash-generating units. An impairment loss is recognized immediately in profit or loss. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit or a group of cash-generating units) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit or a group of cash-generating units) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss. |
Cash and cash equivalents | Cash and cash equivalents Cash and cash equivalents presented on the consolidated statements of financial position include: (a) cash, which comprises of cash on hand and demand deposits; and (b) cash equivalents, which comprises of short-term (generally with original maturity of three months or less), highly liquid investments that are readily convertible to a known amount of cash and which are subject to an insignificant risk of changes in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes. For the purposes of the consolidated statements of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above. |
Financial instruments | Financial instruments Financial assets and financial liabilities are recognized when a group entity becomes a party to the contractual provisions of the instrument. All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets or liabilities at FVTPL) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in profit or loss. The effective interest method is a method of calculating the amortized cost of a financial asset or financial liability and of allocating interest income and interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts and payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial asset or financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Financial assets Classification and subsequent measurement of financial assets Financial assets that meet the following conditions are subsequently measured at amortized cost: • the financial asset is held within a business model whose objective is to collect contractual cash flows; and • the contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. All other financial assets are subsequently measured at FVTPL. (i) Amortized cost and interest income Interest income is recognized using the effective interest method for financial assets measured subsequently at amortized cost. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired (see below). For financial assets that have subsequently become credit-impaired, interest income is recognized by applying the effective interest rate to the amortized cost of the financial asset from the next reporting period. If the credit risk on the credit-impaired financial instrument improves so that the financial asset is no longer credit-impaired, interest income is recognized by applying the effective interest rate to the gross carrying amount of the financial asset from the beginning of the reporting period following the determination that the asset is no longer credit impaired. Interest income is recognized in profit or loss and is included in the “other income” line item. (ii) Financial assets at FVTPL Financial assets of the Group that do not meet the criteria for being measured at amortized cost are measured at FVTPL. Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair value gains or losses recognized in profit or loss. The net gain or loss recognized in profit or loss includes any interest earned on the financial asset and is presented as “fair value change of financial assets at FVTPL” line item. Impairment of financial assets The Group performs impairment assessment under expected credit loss (“ECL”) model on financial assets (including deposits, time deposits with original maturity over three months and cash and cash equivalents) which are subject to impairment under IFRS 9. The amount of ECL is updated at each reporting date to reflect changes in credit risk since initial recognition. Lifetime ECL represents the ECL that will result from all possible default events over the expected life of the relevant instrument. In contrast,12-month ECL represents the portion of lifetime ECL that is expected to result from default events that are possible within 12 months after the reporting date. Assessments are done based on the Group’s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current conditions at the reporting date as well as the forecast of future conditions. For all financial instruments, the Group measures the loss allowance equal to12-month ECL, unless when there has been a significant increase in credit risk since initial recognition, the Group recognizes lifetime ECL. The assessment of whether lifetime ECL should be recognized is based on significant increases in the likelihood or risk of a default occurring since initial recognition. (i) Significant increase in credit risk In assessing whether the credit risk on a financial instrument has increased significantly since initial recognition, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition. In making this assessment, the Group considers both quantitative and qualitative information that is reasonable and supportable, including historical experience and forward-looking information that is available without undue cost or effort. Forward-looking information considered includes the future prospects of the industries in which the Group’s debtors operate, obtained from economic expert reports, financial analysts, governmental bodies, relevant think-tanks and other similar organizations, as well as consideration of various external sources of actual and forecast economic information that relate to the Group’s core operations. In particular, the following information is taken into account when assessing whether credit risk has increased significantly: • an actual or expected significant deterioration in the financial instrument’s external (if available) or internal credit rating; • significant deterioration in external market indicators of credit risk for a particular financial instrument, e.g. a significant increase in the credit spread, the credit default swap prices for the debtor; • existing or forecast adverse changes in business, financial or economic conditions that are expected to cause a significant decrease in the debtor’s ability to meet its debt obligations; • an actual or expected significant deterioration in the operating results of the debtor; and • an actual or expected significant adverse change in the regulatory, economic, or technological environment of the debtor that results in a significant decrease in the debtor’s ability to meet its debt obligations. Irrespective of the outcome of the above assessment, the Group presumes that the credit risk on a financial asset has increased significantly since initial recognition when contractual payments are more than 30 days past due, unless the Group has reasonable and supportable information that demonstrates otherwise. Notwithstanding the foregoing, the Group assumes that the credit risk on a debt instrument has not increased significantly since initial recognition if the financial instrument is determined to have low credit risk at the reporting date. A financial instrument is determined to have low credit risk if i) the financial instrument has a low risk of default, ii) the borrower has a strong capacity to meet its contractual cash flow obligations in the near term and iii) adverse changes in economic and business conditions in the longer term may, but will not necessarily, reduce the ability of the borrower to fulfill its contractual cash flow obligations. The Group considers a debt instrument have low credit risk when it has an internal or external credit rating of “investment grade” as per globally understood definition. The Group regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes past due. (ii) Definition of default The Group considers the following as constituting an event of default for internal credit risk management purposes as historical experience indicates that receivables that meet either of the following criteria are generally not recoverable. • when there is a breach of financial covenants by the counterparty; or • information developed internally or obtained from external sources indicates that the debtor is unlikely to pay its creditors, including the Group, in full (without taking into account any collaterals held by the Group). Irrespective of the above analysis, the Group considers that default has occurred when a financial asset is more than 90 days past due unless the Group has reasonable and supportable information to demonstrate that a more lagging default criterion is more appropriate. (iii) Credit-impaired financial assets A financial asset is credit-impaired when one or more events that have a detrimental impact on the estimated future cash flows of that financial asset have occurred. Evidence that a financial asset is credit-impaired includes observable data about the following events: (a) significant financial difficulty of the issuer or the borrower; (b) a breach of contract, such as a default or past due event; (c) the lender(s) of the borrower, for economic or contractual reasons relating to the borrower’s financial difficulty, having granted to the borrower a concession(s) that the lender(s) would not otherwise consider; or (d) it is becoming probable that the borrower will enter bankruptcy or other financial reorganization. (iv) Write-off policy The Group writes off a financial asset when there is information indicating that the counterparty is in severe financial difficulty and there is no realistic prospect of recovery, e.g. when the counterparty has been placed under liquidation or has entered into bankruptcy proceedings, whichever occurs sooner. Financial assets written off may still be subject to enforcement activities under the Group’s recovery procedures, taking into account legal advice where appropriate. A write-off constitutes a derecognition event. Any subsequent recoveries are recognized in profit or loss. (v) Measurement and recognition of ECL The measurement of ECL is a function of the probability of default, loss given default (i.e. the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data and forward-looking information as described above. Estimation of ECL reflects an unbiased and probability-weighted amount that is determined with the respective risk of default occurring as the weights. Generally, the ECL is the difference between all contractual cash flows that are due to the Group in accordance with the contract and the cash flows that the Group expects to receive, discounted at the effective interest rate determined at initial recognition. Interest income is calculated based on the gross carrying amount of the financial asset unless the financial asset is credit-impaired, in which case interest income is calculated based on amortized cost of the financial asset. The Group recognizes an impairment gain or loss in profit or loss for all financial instruments by adjusting their carrying amount. Derecognition of financial assets The Group derecognizes a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity. If the Group neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Group recognizes its retained interest in the asset and an associated liability for amounts it may have to pay. If the Group retains substantially all the risks and rewards of ownership of a transferred financial asset, the Group continues to recognize the financial asset and also recognizes a collateralized borrowing for the proceeds received. On derecognition of a financial asset measured at amortized cost, the difference between the asset’s carrying amount and the sum of the consideration received and receivable is recognized in profit or loss. Financial liabilities and equity Classification as debt or equity Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. Equity instruments An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue costs. Treasury shares Our own equity instruments held by the Company or the Group (treasury shares) are recognized directly in equity at cost. No gain or loss is recognized in the profit or loss on the purchase, sale, issue or cancelation of the Company’s own equity instruments. Financial liabilities All financial liabilities are subsequently measured at amortized cost using the effective interest method or at FVTPL. Financial liabilities at FVTPL Financial liabilities are classified as at FVTPL when the financial liability is (i) contingent consideration of an acquirer in a business combination to which IFRS 3 Business Combinations applies, (ii) held for trading or (iii) it is designated as at FVTPL. A financial liability is held for trading if: • it has been acquired principally for the purpose of repurchasing it in the near term; or • on initial recognition it is part of a portfolio of identified financial instruments that the Group manages together and has a recent actual pattern of short-term profit-taking; or • it is a derivative, except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument. A financial liability other than a financial liability held for trading or contingent consideration of an acquirer in a business combination may be designated as at FVTPL upon initial recognition if: • such designation eliminates or significantly reduces a measurement or recognition inconsistency that would otherwise arise; or • the financial liability forms part of a group of financial assets or financial liabilities or both, which is managed and its performance is evaluated on a fair value basis, in accordance with the Group’s documented risk management or investment strategy, and information about the grouping is provided internally on that basis; or • it forms part of a contract containing one or more embedded derivatives, and IFRS 9 permits the entire combined contract to be designated as at FVTPL. For financial liabilities that are designated as at FVTPL, the amount of change in the fair value of the financial liability that is attributable to changes in the credit risk of that liability is recognized in other comprehensive income, unless the recognition of the effects of changes in the liability’s credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss. For financial liabilities that contain embedded derivatives, such as convertible preferred shares, the changes in fair value of the embedded derivatives are excluded in determining the amount to be presented in other comprehensive income. The remaining amount of change in the fair value of liability is recognized in profit or loss. Changes in fair value attributable to a financial liability’s credit risk that are recognized in other comprehensive income are not subsequently reclassified to profit or loss; instead, they are transferred to accumulated losses upon derecognition of the financial liability. Preferred shares Preferred shares, which contain redemption features and other embedded derivatives, are designated as at financial liabilities at FVTPL. Financial liabilities at amortized cost Financial liabilities representing other payables and financial liabilities arising from unvested restricted shares are subsequently measured at amortized cost, using the effective interest method. Derecognition of financial liabilities The Group derecognizes financial liabilities when, and only when, the Group’s obligations are discharged, canceled or have expired. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable is recognized in profit or loss. Derivative financial instruments Derivatives are initially recognized at fair value at the date when derivative contracts are entered into and are subsequently remeasured to their fair value at the end of each reporting period. The resulting gain or loss is recognized in profit or loss. Embedded derivatives Derivatives embedded in non-derivative host contracts that are not financial assets within the scope of IFRS 9 are treated as separate derivatives when they meet the definition of a derivative, their risks and characteristics are not closely related to those of the host contracts and the host contracts are not measured at FVTPL. Generally, multiple embedded derivatives in a single instrument that are separated from the host contracts are treated as a single compound embedded derivative unless those derivatives relate to different risk exposures and are readily separable and independent of each other. |
Business Combination (Tables)
Business Combination (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of detailed information about business combination [abstract] | |
Summary of Common Stock Outstanding | The following table presents the total Apollomics common stock outstanding immediately after the closing of the Business Combination: Number of Shares Exchange of Maxpro Class A common stock for post-closing Apollomics Class A Ordinary Shares 490,025 Exchange of Maxpro Class B common stock for post-closing Apollomics Class A Ordinary Shares 2,587,500 Exchange of Maxpro Class A common stock subject to possible redemption that was not redeemed for post-closing Apollomics Class A Ordinary Shares 79,940 Issuance of post-closing Apollomics Class A Ordinary Shares to Maxpro Sponsor in connection with 155,250 Subtotal - Business Combination, net of redemptions 3,312,715 Issuance of post-closing Apollomics Class B ordinary shares to PIPE Investors 230,000 Conversion of pre-closing Apollomics convertible preferred shares (converted into pre-closing Apollomics ordinary shares prior to the Business Combination) into Post-Closing Apollomics Ordinary Shares 54,420,956 Issuance of Post-Closing Apollomics Ordinary Shares in connection with the Business Combination due 31,240 Total - Post-Closing Apollomics Ordinary Shares outstanding as a result of Business Combination, PIPE Financing, conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares, and issuance of shares upon Closing due to pre-Closing exercise of stock options (note i) 57,994,911 Note i: In addition to the 57,994,911 shares specified above, the following shares were included in the total 89,495,790 Post- Closing Apollomics Ordinary Shares outstanding as of December 31, 2023 on the consolidated statement of changes in stockholders' deficit: 1) 28,800,926 Post-Closing Apollomics Ordinary Shares were outstanding as a result of the exchange of all Pre-Closing Apollomics Ordinary Shares outstanding as of December 31, 2022 at the Exchange Ratio 2) 2,668,750 Post-Closing Apollomics Ordinary Shares were outstanding as a result of the conversion of Post-Closing Apollomics Series A Preferred Shares into Post-Closing Apollomics Class A Ordinary Shares in May 2023 at a conversion ratio of 1 to 1.25 3) 16,202 Post-Closing Apollomics Ordinary Shares were outstanding as a result of the exercise of stock options in April 2023, and 15,000 Ordinary Shares as a result of the exercise of stock options in November 2023. |
Schedule of Identifiable Net Assets Acquired | The amount of Maxpro’s identifiable net assets acquired at Closing were as follows: Cash and cash equivalents $ 954 Notes payable – sponsor ( 1,999 ) Accrued liabilities ( 1,056 ) Deferred underwriting compensation ( 3,623 ) Total Maxpro identifiable net liabilities at fair value $ ( 5,724 ) |
Schedule of IFRS 2 Listing Expense | The net assets of Maxpro are stated at fair value with no goodwill or other intangible assets recorded. The IFRS 2 listing expense was calculated as follows: Per Share Value Shares Fair Value Maxpro public stockholders $ 10.81 10,350 $ 111,884 Sponsor parties 10.81 3,207 34,668 Underwriter shares 10.81 26 281 Maxpro private warrants 0.12 619 74 Maxpro public warrants 0.12 10,350 1,242 Redemptions of Maxpro class A common stock 10.55 ( 10,270 ) ( 108,349 ) 14,282 39,800 Net liabilities of Maxpro ( 5,724 ) IFRS 2 Listing Expense $ 45,524 The prior year’s shares and per share numbers have been retrospectively adjusted for the Exchange Ratio of 0.071679 . |
General Information (Tables)
General Information (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
General Information [Abstract] | |
Summary of Information about Consolidated Financial Statements and Company Principal Subsidiaries | Name of subsidiaries Place of incorporation or establishment/operation and date of incorporation/establishment Principal activities Apollomics, Inc. California, United States January 14, 2016 Research and development of drugs Apollomics (Australia) Pty. Ltd. Melbourne, Australia November 4, 2016 Research and development of drugs Apollomics (Hong Kong) Limited Hong Kong, China June 24,2019 Investment holding Zhejiang Crownmab Biotech Co., Ltd. Hangzhou, China May 29, 2018 Investment holding and research and development of drugs Zhejiang Crown Bochuang Biopharma Co., Ltd. Hangzhou, China May 29, 2020 Research and development of drugs Project Max SPAC Merger Sub, Inc. Delaware, United States August 19, 2022 Investment holding |
Other Income (Tables)
Other Income (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Detailed Information about Other Income [Line Items] | |
Summary of Information about Other Income | Years Ended December 31, 2021 2022 2023 Interest income $ 467 $ 431 $ 753 Government grants (note i) 587 1,016 464 Total $ 1,054 $ 1,447 $ 1,217 |
Other Gains and Losses (Tables)
Other Gains and Losses (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Other Gains and Losses [Abstract] | |
Summary of Information about Other Gains and Losses | Years ended December 31, 2021 2022 2023 Exchange gains (losses), net $ 36 $ ( 829 ) $ 1,191 |
Finance Costs (Tables)
Finance Costs (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Finance Cost [Abstract] | |
Summary of Information about Finance Costs | Years ended December 31, 2021 2022 2023 Interest expenses on lease liabilities $ 83 $ 93 $ 150 |
Income Tax Expenses (Tables)
Income Tax Expenses (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Income Tax [Abstract] | |
Summary of Information about Components of Tax Expense Income | Years ended December 31, 2021 2022 2023 US CIT — current year $ 1 $ 1 $ 10 — over-provision in respect of prior years — — — Deferred tax (Note 18) — — — $ 1 $ 1 $ 10 |
Summary of Income Tax Expense Income Reconciled to Loss Before Taxation as Per Consolidated Statements | The income tax (credit) expense for the years ended December 31, 2021, 2022 and 2023 can be reconciled to the loss before taxation per the consolidated statements of profit or loss and other comprehensive income as follows: Years ended December 31, 2021 2022 2023 Loss before taxation $ ( 94,796 ) ( 240,810 $ ( 172,591 ) Tax at the US federal tax rate of 21 % ( 19,907 ) ( 50,570 ) ( 36,244 ) Tax effect of expenses not deductible for tax purpose 20,419 45,739 568 Tax effect of income not taxable for tax purpose ( 309 ) ( 257 ) — Tax effect of additional qualified expenses deductible for — ( 1,517 ) ( 741 ) Tax effect of R&D Credits — — ( 2,311 ) Tax effect of tax losses not recognized 360 7,027 10,277 Tax effect of foreign tax differential rates ( 562 ) ( 421 ) 28,461 Income tax expense for the year $ 1 $ 1 $ 10 |
Loss for the Year (Tables)
Loss for the Year (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Profit (loss) [abstract] | |
Summary of Detailed Information about Loss After Charging Expenses | Years ended December 31, 2021 2022 2023 Loss for the year has been arrived at after charging: Staff costs: Salaries and other allowances $ 18,871 $ 14,966 $ 10,356 Retirement benefits scheme contributions 749 662 499 Share-based payment expenses 8,122 3,582 12,685 Total staff costs 27,742 19,210 23,540 Depreciation of plant and equipment 133 162 87 Depreciation of right-of-use assets 528 593 587 Amortization of intangible assets 20 20 20 Impairment loss of an intangible asset 3,000 — — Other expense (note) $ 4,522 $ 6,608 $ 46,003 |
Loss Per Share (Tables)
Loss Per Share (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Earnings per share [abstract] | |
Disclosure of Basic and Diluted Loss Per Share | The calculations of the basic and diluted loss per share are based on the following data: Years ended December 31, 2021 2022 2023 Loss: Loss for the year attributable to owners of the Company for the $ ( 94,797 ) $ ( 240,811 ) $ ( 172,601 ) Number of shares (‘000): Weighted average number of ordinary shares for the purpose of 28,107 28,528 74,411 Loss per share – Basic and diluted $ $ ( 3.37 ) $ ( 8.44 ) $ ( 2.32 ) |
Disclosure of Detailed Information about Anti Dilutive Securities Excluded from Computation of Diluted Loss Per Share | As of December 31, 2021 and 2022, Series A1, A2, B and C convertible preferred shares, unvested restricted shares and share options outstanding were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive. As of December 31, 2023 share options outstanding and the private and public warrants were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive. As of December 31, 2021 (Note i) 2022 (Note i) 2023 (Note i) Number of series A1 convertible preferred shares (“Series A1 9,465,754 9,465,754 — Number of series A2 convertible preferred shares (“Series A2 5,259,170 5,259,170 — Number of series B convertible preferred shares (“Series B 21,313,959 21,313,959 — Number of series C convertible preferred shares (“Series C 18,382,073 18,382,073 — Unvested restricted shares 580,234 496,752 — Share options 11,114,487 9,746,889 12,132,460 Apollomics private warrants — — 619,400 Apollomics public warrants — — 10,350,000 Note i: The exchange ratio has been applied to these instruments to give effect to the Business Combination As of December 31, 2021 (Note ii) 2022 (Note ii) 2023 Number of series A1 convertible preferred shares (“Series A1 132,057,583 132,057,583 — Number of series A2 convertible preferred shares (“Series A2 73,371,157 73,371,157 — Number of series B convertible preferred shares (“Series B 297,352,949 297,352,949 — Number of series C convertible preferred shares (“Series C 256,449,944 256,449,944 — Unvested restricted shares 8,094,901 6,930,235 — Share options 155,059,183 135,979,705 12,132,460 Apollomics private warrants — — 619,400 Apollomics public warrants — — 10,350,000 Penny warrants — — 57,500 Note ii: This was the presentation of these instruments as of December 31, 2021 and 2022, respectively, prior to the application of the exchange ratio used in the Business Combination |
Plant and Equipment (Tables)
Plant and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Summary of Property, Plant and Equipment | Leasehold Furniture Total COST As of January 1, 2022 $ 135 $ 426 $ 561 Additions — 367 367 As of December 31, 2022 135 793 928 Additions — — — Disposals — ( 363 ) ( 363 ) As of December 31, 2023 135 430 565 ACCUMULATED DEPRECIATION As of January 1, 2022 ( 80 ) ( 201 ) ( 281 ) Provided for the year ( 34 ) ( 128 ) ( 162 ) As of December 31, 2022 ( 114 ) ( 329 ) ( 443 ) Accumulated depreciation removal for disposals — 75 75 Provided for the year ( 18 ) ( 18 ) ( 36 ) As of December 31, 2023 ( 132 ) ( 272 ) ( 404 ) CARRYING VALUES As of December 31, 2022 $ 21 $ 464 $ 485 As of December 31, 2023 $ 3 $ 158 $ 161 |
Summary of Depreciation Rates of Property Plant and Equipment | The above items of plant and equipment are depreciated over their estimated useful lives between 3 to 5 years , using straight-line method after taking into account the residual values, at the following rates per annum: Leasehold improvements Over the shorter of the relevant lease term or 20 % Furniture and other equipment 14 % - 33 % |
Right-of-Use Assets (Tables)
Right-of-Use Assets (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of quantitative information about right-of-use assets [abstract] | |
Summary of Quantitative Information about Right-of-Use Assets | Plant and Offices equipment Total COST As of January 1, 2022 $ 2,367 $ 62 $ 2,429 Additions 538 10 548 Derecognized upon end of lease term ( 40 ) ( 13 ) ( 53 ) As of December 31, 2022 2,865 59 2,924 Additions — 12 12 Derecognized upon end of lease term ( 291 ) ( 46 ) ( 337 ) As of December 31, 2023 2,574 25 2,599 ACCUMULATED DEPRECIATION As of January 1, 2022 ( 1,349 ) ( 44 ) ( 1,393 ) Provided for the year ( 579 ) ( 14 ) ( 593 ) Derecognized upon end of lease term 40 13 53 As of December 31, 2022 ( 1,888 ) ( 45 ) ( 1,933 ) Provided for the year ( 568 ) ( 19 ) ( 587 ) Derecognized upon end of lease term and foreign exchange effect 296 50 346 As of December 31, 2023 ( 2,160 ) ( 14 ) ( 2,174 ) CARRYING VALUES As of December 31, 2022 $ 977 $ 14 $ 991 As of December 31, 2023 $ 414 $ 11 $ 425 |
Summary of Right-of-Use-Assets Depreciated Over Lease Term | The right-of-use assets are depreciated over the lease terms using straight-line method. Years ended December 31, 2021 2022 2023 Expense relating to short-term leases $ 56 $ 96 $ 122 Total cash outflow for leases $ 667 $ 782 $ 566 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of detailed information about intangible assets [abstract] | |
Summary of Intangible Assets | Patent rights Patent rights Total (note i) (note ii) COST As of January 1, 2021 $ 375 $ 11,000 $ 11,375 Addition — 7,500 7,500 As of December 31, 2021, 2022 and 2023 375 18,500 18,875 AMORTIZATION AND IMPAIRMENT As of January 1, 2021 ( 57 ) ( 1,000 ) ( 1,057 ) Charge for the year ( 20 ) — ( 20 ) Impairment loss recognized — ( 3,000 ) ( 3,000 ) As of December 31, 2021 ( 77 ) ( 4,000 ) ( 4,077 ) Charge for the year ( 20 ) — ( 20 ) As of December 31, 2022 ( 97 ) ( 4,000 ) ( 4,097 ) Charge for the year ( 21 ) — ( 21 ) As of December 31, 2023 ( 118 ) ( 4,000 ) ( 4,118 ) CARRYING VALUES As of December 31, 2021 $ 298 $ 14,500 $ 14,798 As of December 31, 2022 $ 278 $ 14,500 $ 14,778 As of December 31, 2023 $ 257 $ 14,500 $ 14,757 Notes: (i) The patent rights grant the Group the right to use certain scientific data for research and manufacture of pipelines, namely APL-501, APL-502 and APL-509. (ii) These patent rights are not yet available for use by the Group as the Group is still undergoing pre-clinical study application or clinical trials on the relevant drugs in designated territories under the patent rights and has yet to obtain regulatory approval for the new drug to be launched to the market. The patent rights are tested for impairment annually and whenever there is an indication that they may be impaired. Amortization will commence when the patent rights are available for use (i.e. when they are ready for commercialization and have obtained the regulatory new drug application approval in the designated territories) by the Group. During the years ended December 31, 2021, 2022 and 2023, patent rights with carrying amount of $ 3,000 , nil , and nil were impaired, respectively. For these patent rights, as they were acquired for combination trial of an existing drug candidate, which was subsequently replaced by another formulation, or acquired for self-development that the Group cannot proceed further research due to the failure in providing drug supplies by the original vendor according to the agreement. Accordingly, the Group has fully impaired the patent rights with reference to their respective recoverable amounts determined on value in use calculations. |
Deferred Taxation (Tables)
Deferred Taxation (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of temporary difference, unused tax losses and unused tax credits [abstract] | |
Disclosure of Detailed Information about Unrecognized Tax Losses Explanatory | The major deferred tax assets (liabilities) recognized and movements thereon during the years ended December 31, 2021, 2022 and 2023 are as follows: Accelerated tax Accrual Total As of January 1, 2021 $ ( 46 ) $ 46 $ — Credit (charge) to profit or loss (Note 10) 14 ( 14 ) — As of December 31, 2021 ( 32 ) 32 — Credit (charge) to profit or loss (Note 10) ( 19 ) 19 — As of December 31, 2022 ( 51 ) 51 — (Charge) credit to profit or loss (Note 10) 40 ( 40 ) — As of December 31, 2023 $ ( 11 ) $ 11 $ — |
Summary of Unrecognized Tax Losses Temporary Differences and Unused Credits will be Carried Forward and Expire in Years | As of December 31, 2022 and 2023, the unrecognized tax losses and temporary differences will be carried forward and expire in years as follows: As of December 31, 2022 2023 Unused tax losses 2024 $ 2,364 $ 2,319 2025 4,634 4,973 2026 7,025 10,144 2027 15,757 9,176 2028 — 9,571 Indefinite 33,086 61,424 Total unused tax losses $ 62,866 $ 97,607 Tax effected deductible temporary differences Indefinite 15,506 17,221 $ 15,506 $ 17,221 As of December 31, 2023 the unused credits will be carried forward and expire in years as follows: Unused tax credits 2038 $ 62 2039 229 2040 1,320 2041 1,800 2042 2,589 2043 1,462 Total unused tax credits $ 7,462 |
Deposits, Prepayments and Def_2
Deposits, Prepayments and Deferred Expenses (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Deposits Prepayments and Deferred Expenses [Abstract] | |
Disclosure of Detailed Information about Deposits Prepayments and Deferred Expenses Explanatory | As of December 31, 2022 2023 Other prepayments $ 624 $ 1,073 Prepaid taxes — 312 Value-Added Tax recoverable 547 466 Deposits 5 7 Payment in advance to suppliers — 250 $ 1,176 $ 2,108 |
Other Payables and Accruals (Ta
Other Payables and Accruals (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure Of Other Payables And Accruals [Abstract] | |
Summary of Other Payables And Accruals | As of December 31, 2022 2023 Payables in respect of research and development expenses $ 5,435 $ 4,471 Accrued salaries and bonuses 2,475 2,166 Accrued other expenses 1,662 1,025 Deposit received for a potential out-licensing drug patent (note) 1,000 1,000 Other payables 1,103 500 $ 11,675 $ 9,162 |
Financial Liabilities Arising_2
Financial Liabilities Arising from Unvested Restricted Shares (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of financial liabilities [abstract] | |
Summary of Financial Liabilities Arising From Unvested Restricted Shares | As of December 31, 2022 2023 Payables in respect of unvested restricted shares Dr. Yu (the chief executive of the Company) $ 68 $ — |
Lease Liabilities (Tables)
Lease Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Lease liabilities [abstract] | |
Summary of Detailed Information About Contractual Maturities of Lease Liabilities | As of December 31, 2022 2023 Lease liabilities payable: Within one year $ 614 $ 158 More than one year, but not exceeding two years 126 126 More than two years, but not exceeding five years 251 141 991 425 Less: Amount due for settlement within 12 months shown ( 614 ) ( 158 ) Amount due for settlement after 12 months shown $ 377 $ 267 |
Convertible Preferred Shares (T
Convertible Preferred Shares (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Convertible Preferred Shares [Abstract] | |
Disclosure of Preferred Shares Issued Pursuant to Subscription Agreement | The Company entered into preferred share subscription agreements with several independent investors and the details of issued preferred shares (the “Preferred Shares”) are set out as follows: Date of issue Total number of Subscription Subscription July 26, 2016 to Series A1 Preferred Shares July 28, 2016 88,038,389 $ 0.04543 $ 4,000 January 31, 2019 44,019,194 0.04543 2,000 132,057,583 6,000 Series A2 Preferred Shares July 21, 2017 to July 25, 2017 73,371,157 0.05111 3,750 September 19, 2018 to Series B Preferred Shares December 27, 2018 260,709,579 0.3329 86,800 January 8, 2019 to March 25, 2019 36,643,370 0.3329 12,200 297,352,949 99,000 September 10, 2020 to Series C Preferred Shares September 30, 2020 141,692,465 0.4845 68,650 October 5, 2020 to November 5, 2020 114,757,479 0.4845 55,600 256,449,944 124,250 The exchange ratio has been applied to these preferred shares to give effect to the Business Combination of March 29, 2023 and these would have been as follows: Date of issue Total number of Subscription Subscription July 26, 2016 to Series A1 Preferred Shares July 28, 2016 6,310,503 $ 0.6338 $ 4,000 January 31, 2019 3,155,252 0.6338 2,000 9,465,755 6,000 Series A2 Preferred Shares July 21, 2017 to July 25, 2017 5,259,170 0.7130 3,750 September 19, 2018 to Series B Preferred Shares December 27, 2018 18,687,400 4.6443 86,800 January 8, 2019 to March 25, 2019 2,626,559 4.6443 12,200 21,313,959 99,000 September 10, 2020 to Series C Preferred Shares September 30, 2020 10,156,372 6.7593 68,650 October 5, 2020 to November 5, 2020 8,225,701 6.7593 55,600 18,382,073 124,250 |
Disclosure of Movement in Preference Shares at End of Each Reporting Period | The movement of the Preferred Shares at the end of each reporting period is as follows: Preferred shares As of January 1, 2021 $ 284,791 Change in fair value 37,424 As of December 31, 2021 322,215 Change in fair value 189,646 As of December 31, 2022 511,861 Change in fair value 76,424 Conversion of convertible preferred shares into post-closing ordinary shares ( 588,285 ) As of December 31, 2023 $ — |
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares | In addition to the underlying share value of the Company determined by Black-Scholes model, other key valuation assumptions used in the OPM model to determine the fair value of the Preferred Shares are as follows: 2021 2022 Time to liquidation 1.5 years 1.25 years Risk-free rate 0.56 % 4.65 % Expected volatility (note) 72.5 % 75 % Dividend yield 0 % 0 % Possibility under IPO scenario 25 % 85 % Possibility under liquidation scenario 75 % 15 % Note: The expected volatility measured at the standard deviation is based on the historical data of the daily share price movement of comparable companies. On March 29, 2023, all the preferred shares were converted into common shares, and therefore as of December 31, 2023, there were no longer any preferred shares. |
Share Capital_Treasury Shares (
Share Capital/Treasury Shares (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of classes of share capital [abstract] | |
Summary of Share Capital | Share capital The share capital as of December 31, 2021 and 2022 represented the issued ordinary share capital of the Company. Number of Par value Notes shares per share Amount Authorized: As of January 1, 2021, December 31, 2021 and 2022 444,343,488 $ 44 Issued and fully paid: As of January 1, 2021 386,741,005 39 Exercise of share options vested (i) 6,511,135 $ 0.0001 1 As of December 31, 2021 393,252,140 40 Exercise of share options vested (ii) 8,552,187 0.0001 1 As of December 31, 2022 401,804,327 41 The share capital as of January 1, 2021, December 31, 2021, 2022 and 2023 have been presented to give effect to the Business Combination of March 29, 2023 and the recapitalization at the exchange ratio of 0.071679, except for the authorized shares, and these are as follows: Number of Par value Notes shares per share Amount Authorized: As of December 31, 2023 600,000,000 $ 3 Issued and fully paid: As of January 1, 2021 27,721,202 3 Exercise of share options (i) 466,712 $ 0.0001 — As of December 31, 2021 28,187,914 3 Exercise of share options vested (ii) 613,012 0.0001 — As of December 31, 2022 28,800,926 3 Exercise of share options vested (iii) 62,443 0.0001 Business combination, net of redemptions 3,312,715 0.0001 Conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares 54,420,956 0.0001 6 Post-closing Apollomics Class B Ordinary Shares issued to PIPE Investors, net of transaction costs 230,000 0.0001 Issuance of post-closing Apollomics Class A Ordinary Shares upon the conversion of post-closing Apollomics Series A Preferred Shares 2,668,750 0.0001 As of December 31, 2023 89,495,790 9 All the ordinary shares and restricted shares issued during the years ended December 31, 2021, 2022 and 2023 rank pari passu with the existing shares in all respects. Notes: (i) During the year ended December 31, 2021, share option holders exercised their rights to subscribe for 6,511,135 ordinary shares made up as follows: 6,004,989 , 134,375 and 371,771 ordinary shares in the Company at an exercise price of $ 0.01 , $ 0.02 and $ 0.21 per share, respectively. To present this to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679 , these would have been 466,712 ordinary shares made up as follows: 430,432 , 9,632 and 26,648 ordinary shares in the Company at an exercise price of $ 0.14 , $ 0.28 and $ 2.93 per share, respectively. (ii) During the year ended December 31, 2022, share option holders exercised their rights to subscribe for 8,552,187 ordinary shares made up as follows: 498,958 , 7,088,541 , 101,146 and 863,542 ordinary shares in the Company at an exercise price of $ 0.01 , $ 0.02 , $ 0.21 and $ 0.26 per share, respectively. To present this to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679 , these would have been 613,013 ordinary shares made up as follows: 35,765 , 508,100 , 7,250 and 61,898 ordinary shares in the Company at an exercise price of $ 0.14 , $ 0.28 , $ 2.93 and $ 3.63 per share, respectively. (iii) During the year ended December 31, 2023, share option holders exercised their rights to subscribe for 62,443 ordinary shares made up as follows: 38,893 , 16,202 , 4,122 and 3,226 ordinary shares in the Company at an exercise price of $ 0.28 , $ 2.93 , $ 3.63 and $ 4.32 per share, respectively. |
Summary of Treasury Shares | Treasury shares Number of Subscription treasury price per shares share Amount As of January 1, 2021 26,365,915 $ 3,252 Restricted shares vested ( 6,352,715 ) $ 0.01 ( 64 ) Early exercised share options vested ( 5,926,452 ) 0.26 ( 1,541 ) As of December 31, 2021 14,086,748 1,647 Restricted shares vested ( 1,164,666 ) 0.01 ( 21 ) Early exercised share options vested ( 5,991,847 ) 0.26 ( 1,558 ) As of December 31, 2022 6,930,235 68 Early exercised share options vested ( 6,930,235 ) 0.26 ( 68 ) As of December 31, 2023 — — To present these treasury shares to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679 , these would have been presented as follows: Number of Subscription treasury price per shares share Amount As of January 1, 2021 1,889,882 $ 3,252 Restricted shares vested ( 455,356 ) $ 0.14 ( 64 ) Early exercised share options vested ( 424,802 ) 3.63 ( 1,541 ) As of December 31, 2021 1,009,724 1,647 Restricted shares vested ( 83,482 ) 0.14 ( 21 ) Early exercised share options vested ( 429,490 ) 3.63 ( 1,558 ) As of December 31, 2022 496,752 68 Early exercised share options vested ( 496,752 ) 3.63 ( 68 ) As of December 31, 2023 — — |
Share-Based Payment Transacti_2
Share-Based Payment Transactions (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of terms and conditions of share-based payment arrangement [abstract] | |
Summary of Group's Restricted Shares Movement | The following table summarized the Group’s restricted shares movement during the years ended December 31, 2021, 2022 and 2023: 2021 2022 2023 Number of Number of Number of Outstanding at January 1, 14,447,616 8,094,901 6,930,235 Vested ( 6,352,715 ) ( 1,164,666 ) ( 6,930,235 ) Outstanding at December 31, 8,094,901 6,930,235 — To present these restricted shares to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679, these would have been presented as follows: 2021 2022 2023 Number of Number of Number of Outstanding at January 1, 1,889,882 1,009,724 496,752 Vested ( 880,158 ) ( 512,972 ) ( 496,752 ) Outstanding at December 31, 1,009,724 496,752 — |
Summary of Company's Share Options | The following table discloses movements of the Company’s share options under the 2016 Plan held by grantees during the years ended December 31, 2021 and 2022: 2021 2022 Number of Weighted- Number of Weighted- Outstanding at January 1, 151,133,235 $ 0.169 155,059,183 $ 0.203 Granted 39,715,000 0.279 11,500,000 0.310 Exercised ( 6,511,135 ) 0.022 ( 8,552,187 ) 0.046 Forfeited ( 29,277,917 ) 0.169 ( 22,027,291 ) 0.232 Outstanding at December 31, 155,059,183 0.203 135,979,705 0.217 Exercisable at the end of the year 78,269,054 67,667,737 To present the Company's share options to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679, these share options would have been presented as follows during the years ended December 31, 2021, 2022 and 2023: 2021 2022 2023 Number of Weighted- Number of Weighted- Number of Weighted- Outstanding at January 1, 10,833,079 $ 2.358 11,114,486 $ 2.832 9,746,889 $ 3.027 Options granted 2,846,731 3.892 824,309 4.325 3,048,310 9.927 Exercised ( 466,712 ) 0.307 ( 613,012 ) 0.642 ( 62,443 ) 1.397 Forfeited ( 2,098,612 ) 2.238 ( 1,578,894 ) 3.237 ( 808,341 ) 0.570 Outstanding at December 31, 11,114,486 2.832 9,746,889 3.027 11,924,415 4.615 Exercisable at the end of the year 5,610,248 4,850,356 7,859,478 |
Summary of Share-Based Payment Transactions | The key inputs into the model were as follows: Years ended December 2021 2022 2023 Grant date option fair value per share $ 0.1430 - 0.1544 $ 0.0933 - 0.1517 $ 0.01 - 0.511 Exercise price $ 0.26 - 0.31 $ 0.31 $ 0.07 - 0.72 Grant date option fair value per share $ 1.995 - 2.154 $ 1.302 - 2.116 $ 0.14 - 7.127 Exercise price as converted $ 3.63 - 4.32 $ 4.32 $ 0.94 - 10.01 Expected volatility (note i) 75 %- 80 % 75 %- 77.5 % 72.5 % Expected life 6.078 years 6.078 years 6.250 years Risk-free rate 0.51 %- 1.09 % 1.35 %- 3.98 % 3.67 % Expected dividend yield — % — % — % Note: The expected volatility measured at the standard deviation is based on the historical data of the daily share price movement of comparable companies. |
Summary of Restricted stock | There were no restricted stocks issued under the 2016 Plan during the years ended December 31, 2021 and 2022. Under the 2023 Plan, the following table discloses movements of the Company’s restricted stocks under the 2023 Plan for the year December 31, 2023. Year ended December 31, 2023 Number of Weighted- Outstanding at January 1, 2023 — $ — Restricted stock granted 207,945 $ 5.410 Outstanding at December 31, 2023 207,945 $ 5.410 Exercisable at the end of the year — |
Related Party Disclosures (Tabl
Related Party Disclosures (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Related Party Disclosures [Abstract] | |
Summary of Transactions with Related Party | (i) Compensation of key management personnel The remuneration of directors of the Company and other members of key management were as follows: For the year ended December 31, 2021 2022 2023 Short term benefits $ 2,214 $ 2,473 $ 4,112 Retirement benefit scheme contributions 12 12 21 Share-based payment 6,131 1,820 9,419 $ 8,357 $ 4,305 $ 13,552 |
Reconciliation of Liabilities_2
Reconciliation of Liabilities Arising from Financing Activities (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of reconciliation of liabilities arising from financing activities [abstract] | |
Summary of Detailed Information about Reconciliation of Liabilities Arising from Financing Activities | The table below details changes in the Group’s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group’s consolidated statements of cash flows as cash flows from financing activities. Convertible Lease Accrued share Total As of January 1, 2021 $ 284,791 $ 1,511 $ 511 $ 286,813 Financing cash flows — ( 611 ) ( 1,173 ) ( 1,784 ) Non-cash changes: Fair value change 37,424 — — 37,424 New leases entered — 53 — 53 Issue costs accrued — — 1,306 1,306 Interest expense — 83 — 83 As of December 31, 2021 322,215 1,036 644 323,895 Financing cash flows — ( 686 ) — ( 686 ) Non-cash changes: Fair value change 189,646 — — 189,646 New leases entered — 548 — 548 Reversal on accrued share issue costs — — ( 644 ) ( 644 ) Interest expense — 93 — 93 As of December 31, 2022 511,861 991 — 512,852 Financing cash flows — ( 688 ) — ( 688 ) Non-cash changes: Fair value change 76,424 — — 76,424 Preferred shares converted to common stock ( 588,285 ) — — ( 588,285 ) Reversal on accrued share issue costs — — — — Interest expense — 122 — 122 As of December 31, 2023 $ — $ 425 $ — $ 425 |
Financial Instruments (Tables)
Financial Instruments (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of detailed information about financial instruments [abstract] | |
Summary of Financial Assets and Financial Liabilities are Measured at Fair Value | Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis. Some of the Group's financial assets and financial liabilities are measured at fair value at the end of each reporting period. The following table gives information about how the fair values of these financial assets and financial liabilities are determined (in particular, the valuation techniques and inputs used). Fair value as of December 31, 2023 December 31, 2022 Fair Valuation technique(s) Significant Relationship of Financial assets Money market fund $ 5,761 $ 19,067 Level 1 Redemption value quoted by banks with reference to the expected return of the underlying assets N/A N/A Financial liabilities Convertible preferred — 511,861 Level 3 Black-Scholes model and OPM method - the key inputs are: time to liquidation, risk-free rate, expected volatility and possibilities for IPO/liquidation scenario Possibility The higher the possibility for IPO scenario, the higher the fair value, and vice versa Maxpro public warrants 259 — Level 1 The public warrants are traded on the Nasdaq, the valuation is based on unadjusted quoted prices in active markets for identical assets or liabilities N/A N/A Maxpro private warrants 15 — Level 2 Private warrants are considered to be economically equivalent to the public warrants. As such, the valuation of the public warrants was used to value the private warrants N/A N/A Penny warrants (Note 5) 56 — Level 3 Black-Scholes model - the key inputs are: underlying share price, expected life in years, risk-free rate, expected volatility, and exercise price N/A N/A Total warrant liabilities: 330 (i) Fair value of the Group’s financial assets and financial liabilities that are measured at fair value on a recurring basis Some of the Group’s financial assets and financial liabilities are measured at fair value at the end of each reporting period. The following table gives information about how the fair values of these financial assets and financial liabilities are determined (in particular, the valuation techniques and inputs used). Relationship of Fair value as of Significant unobservable December 31, Fair value Valuation technique(s) and key unobservable inputs to fair 2022 2023 hierarchy inputs inputs value Financial assets Money market fund $ 19,067 $ 5,761 Level 1 Redemption value quoted by banks with reference to the expected return of the underlying assets N/A N/A Financial liabilities Convertible Preferred 511,861 — Level 3 Black-Scholes model and OPM method — the key inputs are: time to liquidation, risk- free rate, expected volatility and possibilities for IPO/liquidation scenario Possibility for IPO scenario (note) The higher the possibility for IPO scenario, the higher the fair value, and vice versa Warrants — 330 Level 1 Public warrants and private warrants are based on the valuation of the public price of APLMW which is directly observable market (level 1) while the penny warrants are based on the underlying share price of APLM, also a directly observable market (level 1) N/A N/A |
Disclosure of detailed information about financial instruments [text block] | a. Categories of financial instruments As of December 31, 2022 2023 Financial assets Financial assets at FVTPL $ 19,067 $ 5,761 Amortized cost 39,983 32,166 Financial liabilities Financial liability at FVTPL 511,861 330 Amortized cost 7,606 5,970 |
Summary of Categories of Financial Instruments | a. Categories of financial instruments As of December 31, 2022 2023 Financial assets Financial assets at FVTPL $ 19,067 $ 5,761 Amortized cost 39,983 32,166 Financial liabilities Financial liability at FVTPL 511,861 330 Amortized cost 7,606 5,970 |
Summary of Assets and Liabilities Denominated in Foreign Currencies | The carrying amounts of the Group’s foreign currency denominated monetary assets and monetary liabilities at the end of each reporting period are as follows: Assets Liabilities As of December 31, As of December 31, 2022 2023 2022 2023 Renminbi (“RMB”) $ 8,940 $ 6,071 $ 1,210 $ 5,443 Australian Dollars (“AUD”) 1,300 796 1,449 771 $ 10,240 $ 6,867 $ 2,659 $ 6,214 |
Summary of Sensitivity Analysis of Foreign Exchange Rate | 2021 2022 2023 Impact of RMB on loss for the year $ 295 $ 386 $ 659 Impact of AUD on loss for the year 22 ( 7 ) 26 |
Summary of Internal Credit Risk Grading Assessment Comprises | The Group’s internal credit risk grading assessment comprises the following categories: Internal credit rating Description Financial assets at Low risk The counterparty has a low risk of default and does not have any past-due amounts 12-month ECL Watch list Debtor frequently repays after due dates but settles the amounts in full 12-month ECL Doubtful There have been significant increases in credit risk since initial recognition through information developed internally or external resources Lifetime ECL - not credit-impaired Loss There is evidence indicating the asset is credit-impaired Lifetime ECL - credit-impaired Write-off There is evidence indicating that the debtor is in severe financial difficulty and the Group has no realistic prospect of recovery Amount is written off |
Summary of Credit Risk Exposure | External The Group credit Internal 12-month ECL As of December 31, rating credit rating or lifetime ECL 2022 2023 Financial assets Deposits N/A Low risk 12-month ECL $ 129 $ 110 Time deposits with maturity less than twelve months A3 N/A 12-month ECL 2,872 — Time deposits with maturity greater than twelve months A3 N/A 12-month ECL 4,307 — Cash and cash equivalents A3 to Aa2 N/A 12-month ECL 32,675 32,056 $ 39,983 $ 32,166 |
Summary of Liquidity and Interest Risk | On demand Weighted or less Total average than 1 1 to 3 3 Months 1 to 2 2 to 4 undiscounted Carrying interest rate Month Months to 1 Year Years Years cash flows amount % $ $ $ $ $ $ $ December 31, 2022 Convertible Preferred Shares (note) 12 — — — 338,492 — 338,492 378,332 Other payables N/A 7,538 — — — — 7,538 7,538 Financial liabilities arising from unvested restricted shares N/A 68 — — — — 68 68 Total 7,606 — — 338,492 — 346,098 385,938 Lease liabilities 5.38 49 268 391 143 260 1,111 991 December 31, 2023 Other payables N/A 5,970 — — — — 5,970 5,970 Total 5,970 — — — — 5,970 5,970 Lease liabilities 4.85 44 31 83 216 50 495 425 |
General Information - Summary o
General Information - Summary of Information about Consolidated Financial Statements and Company Principal Subsidiaries (Detail) | 12 Months Ended |
Dec. 31, 2023 | |
Apollomics Inc [Member] | |
Disclosure of subsidiaries [line items] | |
Name of subsidiaries | Apollomics, Inc. |
Country of incorporation | California, United States |
Date of incorporation | Jan. 14, 2016 |
Principal activities | Research and development of drugs |
Apollomics Australia Pty Ltd [Member] | |
Disclosure of subsidiaries [line items] | |
Name of subsidiaries | Apollomics (Australia) Pty. Ltd. |
Country of incorporation | Melbourne, Australia |
Date of incorporation | Nov. 04, 2016 |
Principal activities | Research and development of drugs |
Apollomics Hong Kong Limited [Member] | |
Disclosure of subsidiaries [line items] | |
Name of subsidiaries | Apollomics (Hong Kong) Limited |
Country of incorporation | Hong Kong, China |
Date of incorporation | Jun. 24, 2019 |
Principal activities | Investment holding |
Zhejiang Crownmab Biotech Co Ltd [Member] | |
Disclosure of subsidiaries [line items] | |
Name of subsidiaries | Zhejiang Crownmab Biotech Co., Ltd. |
Country of incorporation | Hangzhou, China |
Date of incorporation | May 29, 2018 |
Principal activities | Investment holding and research and development of drugs |
Zhejiang Crown Bochuang Biopharma Co Ltd [Member] | |
Disclosure of subsidiaries [line items] | |
Name of subsidiaries | Zhejiang Crown Bochuang Biopharma Co., Ltd. |
Country of incorporation | Hangzhou, China |
Date of incorporation | May 29, 2020 |
Principal activities | Research and development of drugs |
Project Max SPAC Merger Sub Inc [Member] | |
Disclosure of subsidiaries [line items] | |
Name of subsidiaries | Project Max SPAC Merger Sub, Inc. |
Country of incorporation | Delaware, United States |
Date of incorporation | Aug. 19, 2022 |
Principal activities | Investment holding |
Basis of Preparation of the C_2
Basis of Preparation of the Consolidated Financial Statements - Additional Information (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Disclosure of Basis of Preparation of Financial Statements Explanatory [Abstract] | ||
Accumulated loss | $ 646,965 | $ 474,600 |
Net assets | 55,387 | 76,475 |
Net Assets | 41,234 | $ (448,120) |
Federal money market fund | $ 37,800 |
Adoption of New and Amendment_2
Adoption of New and Amendments to IFRSs - Additional Information (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Disclosure of expected impact of initial application of new standards or interpretations [line items] | ||
Financial liabilities at fair value through profit or loss | $ 330 | $ 511,861 |
Right-of-use assets | 425 | 991 |
Lease liabilities | 425 | 991 |
Convertible Preferred Shares [Member] | ||
Disclosure of expected impact of initial application of new standards or interpretations [line items] | ||
Financial liabilities at fair value through profit or loss | $ 0 | 511,861 |
Convertible Preferred Shares [Member] | Classification of Liabilities as Current or Non-current [member] | ||
Disclosure of expected impact of initial application of new standards or interpretations [line items] | ||
Financial liabilities at fair value through profit or loss | $ 511,861 |
Material Accounting Policies -
Material Accounting Policies - Additional Information (Detail) $ in Thousands | 12 Months Ended |
Dec. 31, 2023 USD ($) | |
Disclosure of Summary of Significant Accounting Policies [Abstract] | |
Impairment loss | $ 0 |
Proceeds from sale or issue of treasury shares | $ 0 |
Critical Accounting Judgment _2
Critical Accounting Judgment and Key Sources of Estimation Uncertainty - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | ||
Disclosure Of Accounting Judgements And Estimates [Line Items] | ||||
Financial liabilities at fair value through profit or loss | $ 330 | $ 511,861 | ||
Fair value change of convertible preferred shares | 76,430 | 189,646 | $ 37,424 | |
Intangible assets other than goodwill | 14,757 | 14,778 | 14,798 | |
Impairment and derecognition of intangible assets | 0 | 0 | 3,000 | |
Patent Rights (not yet available for use) [Member] | ||||
Disclosure Of Accounting Judgements And Estimates [Line Items] | ||||
Intangible assets other than goodwill | [1] | 14,500 | 14,500 | $ 14,500 |
Convertible Preferred Shares [Member] | ||||
Disclosure Of Accounting Judgements And Estimates [Line Items] | ||||
Financial liabilities at fair value through profit or loss | $ 0 | $ 511,861 | ||
[1] These patent rights are not yet available for use by the Group as the Group is still undergoing pre-clinical study application or clinical trials on the relevant drugs in designated territories under the patent rights and has yet to obtain regulatory approval for the new drug to be launched to the market. The patent rights are tested for impairment annually and whenever there is an indication that they may be impaired. Amortization will commence when the patent rights are available for use (i.e. when they are ready for commercialization and have obtained the regulatory new drug application approval in the designated territories) by the Group. During the years ended December 31, 2021, 2022 and 2023, patent rights with carrying amount of $ 3,000 , nil , and nil were impaired, respectively. For these patent rights, as they were acquired for combination trial of an existing drug candidate, which was subsequently replaced by another formulation, or acquired for self-development that the Group cannot proceed further research due to the failure in providing drug supplies by the original vendor according to the agreement. Accordingly, the Group has fully impaired the patent rights with reference to their respective recoverable amounts determined on value in use calculations. |
Business Combination - Addition
Business Combination - Additional Information (Detail) | 1 Months Ended | ||||
Mar. 29, 2023 USD ($) $ / shares shares | Mar. 28, 2023 USD ($) shares | Nov. 30, 2023 shares | Apr. 30, 2023 shares | Dec. 31, 2022 shares | |
Disclosure of detailed information about business combination [line items] | |||||
Promissory note payable principal balance | $ | $ 1,500,000 | ||||
One-time share-based expense on business combination | $ | $ 45,500,000 | ||||
Other intangible assets | $ | $ 0 | ||||
Class A Common Stock [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Exercise of share options | 435,833 | ||||
Post-Closing Apollomics Ordinary Shares [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares outstanding | 28,800,926 | ||||
Exercise of share options | 16,202 | ||||
Common Stock Shares Issued In Exchange Of Ordinary Shares Held In The Previous Company [Member] | Class A Common Stock [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Common stock shares conversion ratio for each share held in the previous company | 1 | ||||
Common Stock Shares Issued In Exchange Of Ordinary Shares Held In The Previous Company [Member] | Class B Common Stock [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Common stock shares conversion ratio for each share held in the previous company | 1 | ||||
PIPE Financing and Business Combination [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares outstanding | 57,994,911 | ||||
Ordinary Shares [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares outstanding | 401,804,327 | ||||
Exercise of share options | 15,000 | ||||
Ordinary Shares [Member] | Post-Closing Apollomics Ordinary Shares [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares issued and fully paid exchange ratio pursuant to business combination | 0.071679 | ||||
Class A ordinary Shares [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares issued | 28,800,926 | ||||
Number of warrants entitled for each share purchased | 57,500 | ||||
Class A ordinary Shares [Member] | Post-Closing Apollomics Ordinary Shares [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares issued and fully paid exchange ratio pursuant to business combination | 0.071679 | ||||
Number of shares issued | 31,240 | ||||
Class A ordinary Shares [Member] | Pipe Subscription Agreement [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Gross proceeds from issuance of shares | $ | $ 23,700,000 | ||||
Class of warrant or rights number of shares to be issued on exercise of each warrant | 1 | ||||
Class B ordinary Shares [Member] | Pipe Subscription Agreement [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Increase (decrease) in number of ordinary shares issued | 230,000 | ||||
Share issued price | $ / shares | $ 10 | ||||
Series A Preferred Shares [Member] | Pipe Subscription Agreement [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Increase (decrease) in number of ordinary shares issued | 2,135,000 | ||||
Share issued price | $ / shares | $ 10 | ||||
Maxpro Capital Acquisition Corp. [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares outstanding | 10,350,000 | ||||
Number of shares redeemed | 10,270,060 | ||||
Percentage of redemption of shares in connection with public shares available | 99.20% | ||||
Maxpro Capital Acquisition Corp. [Member] | Post-Closing Apollomics Ordinary Shares [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares outstanding | 54,420,956 | ||||
Maxpro Capital Acquisition Corp. [Member] | Pipe Subscription Agreement [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Proceeds from financing and business combination | $ | $ 20,200,000 | ||||
Maxpro Capital Acquisition Corp. [Member] | PIPE Financing and Business Combination [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares outstanding | 57,994,911 | ||||
Maxpro Capital Acquisition Corp. [Member] | Private Warrants [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Class of warrants or rights outstanding | 464,150 | ||||
Unpaid principal amount converted into shares | 155,250 | ||||
Maxpro Capital Acquisition Corp. [Member] | Public Warrants [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Class of warrants or rights outstanding | 10,350,000 | ||||
Maxpro Capital Acquisition Corp. [Member] | Class A ordinary Shares [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Unpaid principal amount converted into shares | 155,250 | ||||
Maxpro Capital Acquisition Corp. [Member] | Class A ordinary Shares [Member] | Class A Common Stock [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares outstanding | 490,025 | ||||
Maxpro Capital Acquisition Corp. [Member] | Class A ordinary Shares [Member] | Class B Common Stock [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares outstanding | 2,587,500 | ||||
Maxpro Capital Acquisition Corp. [Member] | Class A ordinary Shares [Member] | Post-Closing Apollomics Ordinary Shares [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares outstanding | 31,240 | ||||
Maxpro Capital Acquisition Corp. [Member] | Class B ordinary Shares [Member] | Pipe Subscription Agreement [Member] | |||||
Disclosure of detailed information about business combination [line items] | |||||
Number of shares outstanding | 230,000 |
Business Combination - Schedule
Business Combination - Schedule of Common Stock Outstanding (Detail) - shares | Mar. 29, 2023 | Dec. 31, 2022 |
PIPE Financing and Business Combination [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 57,994,911 | |
Post-Closing Apollomics Ordinary Shares [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 28,800,926 | |
Maxpro Capital Acquisition Corp. [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 10,350,000 | |
Maxpro Capital Acquisition Corp. [Member] | PIPE Financing and Business Combination [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 57,994,911 | |
Maxpro Capital Acquisition Corp. [Member] | Post-Closing Apollomics Ordinary Shares [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 54,420,956 | |
Class A ordinary Shares [Member] | Maxpro Capital Acquisition Corp. [Member] | Class A Common Stock [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 490,025 | |
Class A ordinary Shares [Member] | Maxpro Capital Acquisition Corp. [Member] | Class B Common Stock [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 2,587,500 | |
Class A ordinary Shares [Member] | Maxpro Capital Acquisition Corp. [Member] | Class A Common Stock Subject to Possible Redemption [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 79,940 | |
Class A ordinary Shares [Member] | Maxpro Capital Acquisition Corp. [Member] | Post-Closing Apollomics Ordinary Shares [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 31,240 | |
Class A ordinary Shares [Member] | Maxpro Capital Acquisition Corp. [Member] | Conversion of Convertible Promissory Note [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 155,250 | |
Class A Ordinary Shares Net of Redemptions [Member] | Maxpro Capital Acquisition Corp. [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 3,312,715 | |
Class B ordinary Shares [Member] | Maxpro Capital Acquisition Corp. [Member] | Pipe Subscription Agreement [Member] | ||
Disclosure of detailed information about business combination [line items] | ||
Number of shares outstanding | 230,000 |
Business Combination - Schedu_2
Business Combination - Schedule of Common Stock Outstanding (Parenthetical) (Detail) | 1 Months Ended | 12 Months Ended | |||||||||
Nov. 30, 2023 shares | May 31, 2023 shares | Apr. 30, 2023 shares | Dec. 31, 2023 shares | Dec. 31, 2022 shares | Dec. 31, 2021 shares | Mar. 29, 2023 shares | Dec. 31, 2020 shares | ||||
PIPE Financing and Business Combination [Member] | |||||||||||
Disclosure of detailed information about business combination [line items] | |||||||||||
Number of shares outstanding | 57,994,911 | ||||||||||
Share capital [Member] | |||||||||||
Disclosure of detailed information about business combination [line items] | |||||||||||
Number of shares outstanding | 89,495,790 | 28,800,926 | 28,187,914 | 27,721,202 | |||||||
Exercise of share options | 62,443 | [1] | 613,012 | [2] | 466,712 | [3] | |||||
Ordinary Shares [Member] | |||||||||||
Disclosure of detailed information about business combination [line items] | |||||||||||
Number of shares outstanding | 401,804,327 | ||||||||||
Exercise of share options | 15,000 | ||||||||||
Post-Closing Apollomics Ordinary Shares [Member] | |||||||||||
Disclosure of detailed information about business combination [line items] | |||||||||||
Number of shares outstanding | 28,800,926 | ||||||||||
Exercise of share options | 16,202 | ||||||||||
Conversion of convertible preferred A stock into common stock | 2,668,750 | ||||||||||
Conversion ratio for conversion of preferred stock into common stock | 1.25 | ||||||||||
[1] The total number of shares issued from the exercise of stock options consisted of the issuance of 435,833 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2023 to March 28, 2023. These Pre-Closing Apollomics Ordinary Shares were exchanged for 31,241 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. The total number of shares issued from the exercise of stock options consisted of the issuance of 31,202 Post-Closing Apollomics Ordinary Shares between March 29, 2023 to December 31, 2023, totaling 62,443 exercise of stock options for the year ended December 31, 2023. The total number of shares issued from the exercise of stock options consisted of the issuance of 8,552,187 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2022 to December 31, 2022. These Pre-Closing Apollomics Ordinary Shares were exchanged for 613,012 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. The total number of shares issued from the exercise of stock options consisted of the issuance of 6,511,135 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2021 to December 31, 2021. These Pre-Closing Apollomics Ordinary Shares were exchanged for 466,712 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. |
Business Combination - Schedu_3
Business Combination - Schedule of Identifiable Net Assets Acquired (Details) $ in Thousands | Mar. 29, 2023 USD ($) |
Disclosure of detailed information about business combination [abstract] | |
Cash and cash equivalents | $ 954 |
Notes payable - sponsor | (1,999) |
Accrued liabilities | (1,056) |
Deferred underwriting compensation | (3,623) |
Total Maxpro identifiable net liabilities at fair value | $ (5,724) |
Business Combination - Schedu_4
Business Combination - Schedule of IFRS 2 Listing Expense (Detail) $ in Thousands | Mar. 29, 2023 USD ($) $ / shares |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Shares | 14,282 |
Fair Value | $ 39,800 |
Net liabilities of Maxpro | (5,724) |
IFRS 2 Listing Expense | $ 45,524 |
Maxpro Public Stockholders [Member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Per Share Value | $ / shares | $ 10.81 |
Shares | 10,350 |
Fair Value | $ 111,884 |
Sponsor Parties [Member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Per Share Value | $ / shares | $ 10.81 |
Shares | 3,207 |
Fair Value | $ 34,668 |
Underwriter shares [Member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Per Share Value | $ / shares | $ 10.81 |
Shares | 26 |
Fair Value | $ 281 |
Maxpro Private Warrants [Member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Per Share Value | $ / shares | $ 0.12 |
Shares | 619 |
Fair Value | $ 74 |
Maxpro Public Warrants [Member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Per Share Value | $ / shares | $ 0.12 |
Shares | 10,350 |
Fair Value | $ 1,242 |
Redemptions of Maxpro class A common stock [Member] | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Per Share Value | $ / shares | $ 10.55 |
Redemptions of stock | (10,270) |
Fair Value | $ (108,349) |
Revenue and Segment Informati_2
Revenue and Segment Information - Additional Information (Detail) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure Of Entitys Revenue And Reportable Segments [Line Items] | |||
Revenue | $ 0 | $ 0 | $ 0 |
Other Income - Summary of Infor
Other Income - Summary of Information about Other Income (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of Detailed Information about Other Income [Line Items] | |||
Interest income | $ 753 | $ 431 | $ 467 |
Government grants (note i) | 464 | 1,016 | 587 |
Total | $ 1,217 | $ 1,447 | $ 1,054 |
Other Income - Additional Infor
Other Income - Additional Information (Detail) $ in Thousands | 12 Months Ended | ||||
Dec. 31, 2023 USD ($) | Dec. 31, 2023 AUD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2022 AUD ($) | Dec. 31, 2021 USD ($) | |
Australia [Member] | |||||
Disclosure of Detailed Information about Other Income [Line Items] | |||||
Income from government grants related to research and development activity | $ 408,000 | $ 635 | $ 908,000 | $ 1,353 | $ 0 |
Other Gains and Losses - Summar
Other Gains and Losses - Summary of Information about Other Gains and Losses (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of Other Gains and Losses [Abstract] | |||
Exchange gains (losses), net | $ 1,191 | $ (829) | $ 36 |
Finance Costs - Summary of Inf
Finance Costs - Summary of Information about Finance Costs (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of Finance Cost [Abstract] | |||
Interest expenses on lease liabilities | $ 150 | $ 93 | $ 83 |
Income Tax Expenses - Summary o
Income Tax Expenses - Summary of Information about Components of Tax Expense Income (Detail) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Major components of tax expense (income) [abstract] | |||
current year | $ 10,000 | $ 1,000 | $ 1,000 |
over-provision in respect of prior years | 0 | 0 | 0 |
Deferred tax | 0 | 0 | 0 |
Tax expense (income) | $ 10,000 | $ 1,000 | $ 1,000 |
Income Tax Expenses - Summary_2
Income Tax Expenses - Summary of Income Tax Expense Income Reconciled to Loss Before Taxation as Per Consolidated Statements (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Reconciliation of accounting profit multiplied by applicable tax rates [abstract] | |||
Loss before taxation | $ (172,591) | $ (240,810) | $ (94,796) |
Tax at the US federal tax rate of 21% | (36,244) | (50,570) | (19,907) |
Tax effect of expenses not deductible for tax purpose | 568 | 45,739 | 20,419 |
Tax effect of income not taxable for tax purpose | 0 | (257) | (309) |
Tax effect of additional qualified expenses deductible for tax purpose (note) | (741) | (1,517) | 0 |
Tax effect of R&D Credits | (2,311) | 0 | 0 |
Tax effect of tax losses not recognized | 10,277 | 7,027 | 360 |
Tax effect of foreign tax differential rates | (28,461) | (421) | (562) |
Income tax expense | $ 10 | $ 1 | $ 1 |
Income Tax Expenses - Summary_3
Income Tax Expenses - Summary of Income Tax Expense Income Reconciled to Loss Before Taxation as Per Consolidated Statements (Parenthetical) (Detail) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure Of Detailed Information About Income Tax [Line Items] | |
Percentage of income tax deduction in respect of qualifying research and development expenditures incurred | 75% |
US [Member] | Federal Income Tax Rate [Member] | |
Disclosure Of Detailed Information About Income Tax [Line Items] | |
Applicable tax rate | 21% |
Income Tax Expenses - Additiona
Income Tax Expenses - Additional Information (Detail) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure Of Detailed Information About Income Tax [Line Items] | |||
Tax expense (income) | $ 10,000 | $ 1,000 | $ 1,000 |
Accounting profit | $ (172,591,000) | $ (240,810,000) | $ (94,796,000) |
Apollomics Australia Pty Ltd [Member] | |||
Disclosure Of Detailed Information About Income Tax [Line Items] | |||
Applicable tax rate | 25% | 25% | 26% |
UNITED STATES | Federal Income Tax Rate [Member] | |||
Disclosure Of Detailed Information About Income Tax [Line Items] | |||
Applicable tax rate | 21% | ||
CHINA | |||
Disclosure Of Detailed Information About Income Tax [Line Items] | |||
Applicable tax rate | 25% | 25% | 25% |
HONG KONG | |||
Disclosure Of Detailed Information About Income Tax [Line Items] | |||
Applicable tax rate | 16.50% | ||
Tax expense (income) | $ 0 | $ 0 | $ 0 |
Accounting profit | $ 0 | $ 0 | $ 0 |
Loss for the Year - Summary of
Loss for the Year - Summary of Detailed Information about Loss After Charging Expenses (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Staff costs: | |||
Salaries and other allowances | $ 10,356 | $ 14,966 | $ 18,871 |
Retirement benefits scheme contributions | 499 | 662 | 749 |
Share-based payment expenses | 12,685 | 3,582 | 8,122 |
Total staff costs | 23,540 | 19,210 | 27,742 |
Depreciation of plant and equipment | 87 | 162 | 133 |
Depreciation of right-of-use assets | 587 | 593 | 528 |
Amortization of intangible assets | 20 | 20 | 20 |
Impairment loss of an intangible asset | 0 | 0 | 3,000 |
Other expense | $ 46,003 | $ 6,608 | $ 4,522 |
Dividends - Additional Informat
Dividends - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure Of Dividends [Abstract] | |||
Dividends Paid | $ 0 | $ 0 | $ 0 |
Loss Per Share - Disclosure of
Loss Per Share - Disclosure of Basic and Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | ||||
Mar. 29, 2023 | Mar. 28, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Earnings per share [line items] | |||||
Loss for the year attributable to owners of the Company for the purpose of calculating basic and diluted loss per share | $ (172,601) | $ (240,811) | $ (94,797) | ||
Weighted average number of ordinary shares used in calculating basic earnings per share | 404,186 | 74,411 | 28,528 | 28,107 | |
Weighted average number of ordinary shares used in calculating diluted earnings per share | 390,944 | 74,411 | 28,528 | 28,107 | |
Total basic earnings (loss) per share | $ (0.23) | $ (2.32) | $ (8.44) | $ (3.37) | |
Total diluted earnings (loss) per share | $ (0.62) | $ (2.32) | $ (8.44) | $ (3.37) |
Loss Per Share - Additional Inf
Loss Per Share - Additional Information (Detail) - $ / shares shares in Thousands | 12 Months Ended | ||||
Mar. 29, 2023 | Mar. 28, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Earnings per share [line items] | |||||
Weighted average number of common shares outstanding - Basic | 404,186 | 74,411 | 28,528 | 28,107 | |
Weighted average number of common shares outstanding - Diluted | 390,944 | 74,411 | 28,528 | 28,107 | |
Total basic earnings (loss) per share | $ (0.23) | $ (2.32) | $ (8.44) | $ (3.37) | |
Total diluted earnings (loss) per share | $ (0.62) | $ (2.32) | $ (8.44) | $ (3.37) |
Loss Per Share - Disclosure o_2
Loss Per Share - Disclosure of Detailed Information about Anti Dilutive Securities Excluded from Computation of Diluted Loss Per Share (Detail) - shares | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Series A1 Preferred Shares [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 132,057,583 | 132,057,583 | |
Series A2 Preferred Shares [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 73,371,157 | 73,371,157 | |
Series B Preferred Shares [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 297,352,949 | 297,352,949 | |
Series C Preferred Shares [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 256,449,944 | 256,449,944 | |
Exchange Ratio of 0.071679 [Member] | Series A1 Preferred Shares [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 9,465,754 | 9,465,754 | |
Exchange Ratio of 0.071679 [Member] | Series A2 Preferred Shares [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 5,259,170 | 5,259,170 | |
Exchange Ratio of 0.071679 [Member] | Series B Preferred Shares [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 21,313,959 | 21,313,959 | |
Exchange Ratio of 0.071679 [Member] | Series C Preferred Shares [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 18,382,073 | 18,382,073 | |
Unvested Restricted Shares [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 6,930,235 | 8,094,901 | |
Unvested Restricted Shares [Member] | Exchange Ratio of 0.071679 [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 496,752 | 580,234 | |
Share Options [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 12,132,460 | 135,979,705 | 155,059,183 |
Share Options [Member] | Exchange Ratio of 0.071679 [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 12,132,460 | 9,746,889 | 11,114,487 |
Apollomics Private Warrants [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 619,400 | ||
Apollomics Private Warrants [Member] | Exchange Ratio of 0.071679 [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 619,400 | ||
Apollomics Public Warrants [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 10,350,000 | ||
Apollomics Public Warrants [Member] | Exchange Ratio of 0.071679 [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 10,350,000 | ||
Penny Warrants [Member] | |||
Earnings per share [line items] | |||
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount | 57,500 |
Plant and Equipment - Summary o
Plant and Equipment - Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of detailed information about property, plant and equipment [line items] | |||
Beginning balance | $ 485 | ||
Provided for the year | (87) | $ (162) | $ (133) |
Ending balance | 161 | 485 | |
Leasehold Improvements [Member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Beginning balance | 21 | ||
Ending balance | 3 | 21 | |
Furniture and Other Equipment [Member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Beginning balance | 464 | ||
Ending balance | 158 | 464 | |
Gross carrying amount [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Beginning balance | 928 | 561 | |
Additions | 367 | ||
Disposals | (363) | ||
Ending balance | 565 | 928 | 561 |
Gross carrying amount [member] | Leasehold Improvements [Member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Beginning balance | 135 | 135 | |
Ending balance | 135 | 135 | 135 |
Gross carrying amount [member] | Furniture and Other Equipment [Member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Beginning balance | 793 | 426 | |
Additions | 367 | ||
Disposals | (363) | ||
Ending balance | 430 | 793 | 426 |
Accumulated depreciation and amortisation [member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Beginning balance | (443) | (281) | |
Accumulated depreciation removal for disposals | 75 | ||
Provided for the year | (36) | (162) | |
Ending balance | (404) | (443) | (281) |
Accumulated depreciation and amortisation [member] | Leasehold Improvements [Member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Beginning balance | (114) | (80) | |
Provided for the year | (18) | (34) | |
Ending balance | (132) | (114) | (80) |
Accumulated depreciation and amortisation [member] | Furniture and Other Equipment [Member] | |||
Disclosure of detailed information about property, plant and equipment [line items] | |||
Beginning balance | (329) | (201) | |
Accumulated depreciation removal for disposals | 75 | ||
Provided for the year | (18) | (128) | |
Ending balance | $ (272) | $ (329) | $ (201) |
Plant and Equipment - Additiona
Plant and Equipment - Additional Information (Detail) | 12 Months Ended |
Dec. 31, 2023 | |
Bottom of Range [Member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated useful lives | 3 years |
Top of Range [Member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated useful lives | 5 years |
Plant and Equipment - Summary_2
Plant and Equipment - Summary of Depreciation Rates of Property Plant and Equipment (Detail) | 12 Months Ended |
Dec. 31, 2023 | |
Leasehold Improvements [Member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate, property, plant and equipment | 20% |
Furniture and Other Equipment [Member] | Bottom of Range [Member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate, property, plant and equipment | 14% |
Furniture and Other Equipment [Member] | Top of Range [Member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Depreciation rate, property, plant and equipment | 33% |
Right-of-Use Assets - Summary o
Right-of-Use Assets - Summary of Quantitative Information about Right-of-Use Assets (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of quantitative information about right-of-use assets [line items] | |||
Beginning balance | $ 991 | ||
Provided for the year | 587 | $ 593 | $ 528 |
Ending balance | 425 | 991 | |
Offices [Member] | |||
Disclosure of quantitative information about right-of-use assets [line items] | |||
Beginning balance | 977 | ||
Ending balance | 414 | 977 | |
Plant and Equipment [Member] | |||
Disclosure of quantitative information about right-of-use assets [line items] | |||
Beginning balance | 14 | ||
Ending balance | 11 | 14 | |
Cost [Member] | |||
Disclosure of quantitative information about right-of-use assets [line items] | |||
Beginning balance | 2,924 | 2,429 | |
Additions | 12 | 548 | |
Derecognised upon end of lease term | (337) | (53) | |
Ending balance | 2,599 | 2,924 | |
Cost [Member] | Offices [Member] | |||
Disclosure of quantitative information about right-of-use assets [line items] | |||
Beginning balance | 2,865 | 2,367 | |
Additions | 538 | ||
Derecognised upon end of lease term | (291) | (40) | |
Ending balance | 2,574 | 2,865 | |
Cost [Member] | Plant and Equipment [Member] | |||
Disclosure of quantitative information about right-of-use assets [line items] | |||
Beginning balance | 59 | 62 | |
Additions | 12 | 10 | |
Derecognised upon end of lease term | (46) | (13) | |
Ending balance | 25 | 59 | |
Accumulated Depreciation [Member] | |||
Disclosure of quantitative information about right-of-use assets [line items] | |||
Beginning balance | (1,933) | (1,393) | |
Provided for the year | (587) | (593) | |
Derecognised upon end of lease term | 53 | ||
Derecognized upon end of lease term and foreign exchange effect | 346 | ||
Ending balance | (2,174) | (1,933) | (1,393) |
Accumulated Depreciation [Member] | Offices [Member] | |||
Disclosure of quantitative information about right-of-use assets [line items] | |||
Beginning balance | (1,888) | (1,349) | |
Provided for the year | (568) | (579) | |
Derecognised upon end of lease term | 40 | ||
Derecognized upon end of lease term and foreign exchange effect | 296 | ||
Ending balance | (2,160) | (1,888) | (1,349) |
Accumulated Depreciation [Member] | Plant and Equipment [Member] | |||
Disclosure of quantitative information about right-of-use assets [line items] | |||
Beginning balance | (45) | (44) | |
Provided for the year | (19) | (14) | |
Derecognised upon end of lease term | 13 | ||
Derecognized upon end of lease term and foreign exchange effect | 50 | ||
Ending balance | $ (14) | $ (45) | $ (44) |
Right-of-Use Assets - Summary_2
Right-of-Use Assets - Summary of Right-of-Use-Assets Depreciated Over Lease Term (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of quantitative information about right-of-use assets [abstract] | |||
Expense relating to short-term leases | $ 122 | $ 96 | $ 56 |
Total cash outflow for leases | $ 566 | $ 782 | $ 667 |
Right-Of-Use Assets - Additiona
Right-Of-Use Assets - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Disclosure of quantitative information about right-of-use assets [line items] | ||
Lease liabilities | $ 425 | $ 991 |
Right-of-use assets | $ 425 | $ 991 |
Bottom of Range [Member] | ||
Disclosure of quantitative information about right-of-use assets [line items] | ||
Lease term | 12 months | |
Top of Range [Member] | ||
Disclosure of quantitative information about right-of-use assets [line items] | ||
Lease term | 60 months |
Intangible Assets - Summary of
Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | ||
Disclosure of detailed information about intangible assets [line items] | ||||
Beginning Balance | $ 14,778 | $ 14,798 | ||
Charge for the year | 20 | 20 | $ 20 | |
Impairment loss recognized | 0 | 0 | 3,000 | |
Ending Balance | 14,757 | 14,778 | 14,798 | |
Cost [Member] | ||||
Disclosure of detailed information about intangible assets [line items] | ||||
Beginning Balance | 18,875 | 18,875 | 11,375 | |
Addition | 7,500 | 7,500 | 7,500 | |
Ending Balance | 18,875 | 18,875 | 18,875 | |
Amortisation and Impairment [Member] | ||||
Disclosure of detailed information about intangible assets [line items] | ||||
Beginning Balance | (4,097) | (4,077) | (1,057) | |
Charge for the year | (21) | (20) | (20) | |
Impairment loss recognized | (3,000) | |||
Ending Balance | (4,118) | (4,097) | (4,077) | |
Patent Rights (available for use) [Member] | ||||
Disclosure of detailed information about intangible assets [line items] | ||||
Beginning Balance | [1] | 278 | 298 | |
Ending Balance | [1] | 257 | 278 | 298 |
Patent Rights (available for use) [Member] | Cost [Member] | ||||
Disclosure of detailed information about intangible assets [line items] | ||||
Beginning Balance | [1] | 375 | 375 | 375 |
Ending Balance | [1] | 375 | 375 | 375 |
Patent Rights (available for use) [Member] | Amortisation and Impairment [Member] | ||||
Disclosure of detailed information about intangible assets [line items] | ||||
Beginning Balance | [1] | (97) | (77) | (57) |
Charge for the year | [1] | (21) | (20) | (20) |
Impairment loss recognized | [1] | 0 | ||
Ending Balance | [1] | (118) | (97) | (77) |
Patent Rights (not yet available for use) [Member] | ||||
Disclosure of detailed information about intangible assets [line items] | ||||
Beginning Balance | [2] | 14,500 | 14,500 | |
Ending Balance | [2] | 14,500 | 14,500 | 14,500 |
Patent Rights (not yet available for use) [Member] | Cost [Member] | ||||
Disclosure of detailed information about intangible assets [line items] | ||||
Beginning Balance | [2] | 18,500 | 18,500 | 11,000 |
Addition | [2] | 7,500 | 7,500 | 7,500 |
Ending Balance | [2] | 18,500 | 18,500 | 18,500 |
Patent Rights (not yet available for use) [Member] | Amortisation and Impairment [Member] | ||||
Disclosure of detailed information about intangible assets [line items] | ||||
Beginning Balance | [2] | (4,000) | (4,000) | (1,000) |
Charge for the year | [2] | 0 | 0 | 0 |
Impairment loss recognized | [2] | (3,000) | ||
Ending Balance | [2] | $ (4,000) | $ (4,000) | $ (4,000) |
[1] The patent rights grant the Group the right to use certain scientific data for research and manufacture of pipelines, namely APL-501, APL-502 and APL-509. These patent rights are not yet available for use by the Group as the Group is still undergoing pre-clinical study application or clinical trials on the relevant drugs in designated territories under the patent rights and has yet to obtain regulatory approval for the new drug to be launched to the market. The patent rights are tested for impairment annually and whenever there is an indication that they may be impaired. Amortization will commence when the patent rights are available for use (i.e. when they are ready for commercialization and have obtained the regulatory new drug application approval in the designated territories) by the Group. During the years ended December 31, 2021, 2022 and 2023, patent rights with carrying amount of $ 3,000 , nil , and nil were impaired, respectively. For these patent rights, as they were acquired for combination trial of an existing drug candidate, which was subsequently replaced by another formulation, or acquired for self-development that the Group cannot proceed further research due to the failure in providing drug supplies by the original vendor according to the agreement. Accordingly, the Group has fully impaired the patent rights with reference to their respective recoverable amounts determined on value in use calculations. |
Intangible Assets - Summary o_2
Intangible Assets - Summary of Intangible Assets (Parenthetical) (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of detailed information about intangible assets [line items] | |||
Impairment loss recognized | $ 0 | $ 0 | $ 3,000 |
Patent Rights [Member] | |||
Disclosure of detailed information about intangible assets [line items] | |||
Impairment loss recognized | $ 0 | $ 0 | $ 3,000 |
Intangible Assets - Additional
Intangible Assets - Additional Information (Detail) - Patent Rights [Member] | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Bottom of range [member] | |||
Disclosure of detailed information about intangible assets [line items] | |||
Useful lives of patent rights | 10 years | 10 years | 10 years |
Top of range [member] | |||
Disclosure of detailed information about intangible assets [line items] | |||
Useful lives of patent rights | 18 years | 18 years | 18 years |
Deferred Taxation - Disclosure
Deferred Taxation - Disclosure of Detailed Information about Unrecognized Tax Losses Explanatory (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax liability (asset) | $ 0 | $ 0 | $ 0 |
(Charge) credit to profit or loss | 0 | 0 | 0 |
Deferred tax liability (asset) | 0 | 0 | 0 |
Accelerated Tax Depreciation [Member] | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax liability (asset) | (51) | (32) | (46) |
(Charge) credit to profit or loss | 40 | (19) | 14 |
Deferred tax liability (asset) | (11) | (51) | (32) |
Accrual [Member] | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax liability (asset) | 51 | 32 | 46 |
(Charge) credit to profit or loss | (40) | 19 | (14) |
Deferred tax liability (asset) | $ 11 | $ 51 | $ 32 |
Deferred Taxation - Summary of
Deferred Taxation - Summary of Unrecognized Tax Losses Temporary Differences and Unused Credits will be Carried Forward and Expire in Years (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax losses | $ 97,607 | $ 62,866 |
Tax effected deductible temporary differences | 17,221 | 15,506 |
Total unused tax credits | 7,462 | |
2024 [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax losses | 2,319 | 2,364 |
2025 [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax losses | 4,973 | 4,634 |
2026 [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax losses | 10,144 | 7,025 |
2027 [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax losses | 9,176 | 15,757 |
2028 [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax losses | 9,571 | |
Indefinite [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax losses | 61,424 | 33,086 |
Tax effected deductible temporary differences | 17,221 | $ 15,506 |
2038 [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax credits | 62 | |
2039 [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax credits | 229 | |
2040 [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax credits | 1,320 | |
2041 [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax credits | 1,800 | |
2042 [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax credits | 2,589 | |
2043 [Member] | ||
Disclosure Unrecognized Tass Losses [Line Items] | ||
Total unused tax credits | $ 1,462 |
Deferred Taxation - Additional
Deferred Taxation - Additional Inforation (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Deferred tax assets and liabilities [abstract] | ||
Unused tax losses | $ 97,607 | $ 62,866 |
Temporary differences | 17,221 | $ 15,506 |
Unused tax credit | 7,462 | |
Uncertain tax treatment | $ 2,190 |
Deposits, Prepayments and Def_3
Deposits, Prepayments and Deferred Expenses - Disclosure of Detailed Information about Deposits Prepayments and Deferred Expenses Explanatory (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Disclosure of Deposits Prepayments and Deferred Expenses [Abstract] | ||
Other prepayments | $ 1,073 | $ 624 |
Prepaid taxes | 312 | |
Value-Added Tax recoverable | 466 | 547 |
Deposits | 7 | 5 |
Payment in advance to suppliers | 250 | |
Deposits, prepayments and deferred expenses | $ 2,108 | $ 1,176 |
Short Term Bank Loans - Additio
Short Term Bank Loans - Additional Information (Detail) $ in Thousands, ¥ in Millions | 6 Months Ended | 8 Months Ended | |||||
May 31, 2024 USD ($) | May 31, 2024 CNY (¥) | Jul. 31, 2024 USD ($) | Jul. 31, 2024 CNY (¥) | Dec. 31, 2023 USD ($) | Nov. 30, 2023 USD ($) | Nov. 30, 2023 CNY (¥) | |
Disclosure of detailed information about borrowings [line items] | |||||||
Short term bank loans | $ 4,236 | ||||||
Line Of Credit | |||||||
Disclosure of detailed information about borrowings [line items] | |||||||
Short term bank loans | $ 11,200 | ¥ 80 | |||||
Line Of Credit 1 | |||||||
Disclosure of detailed information about borrowings [line items] | |||||||
Short term bank loans | $ 7,000 | ¥ 50 | |||||
Drew down Amount | $ 2,800 | ¥ 20 | |||||
Interest Rate | 3.70% | 3.70% | |||||
Line Of Credit 2 | |||||||
Disclosure of detailed information about borrowings [line items] | |||||||
Short term bank loans | $ 4,200 | ¥ 30 | |||||
Drew down Amount | $ 1,400 | ¥ 10 | |||||
Interest Rate | 3.20% | 3.20% |
Time Deposits with Original M_2
Time Deposits with Original Maturity Over Three Months/Cash and Cash Equivalents - Additional Information (Detail) | Dec. 31, 2023 | Dec. 31, 2022 |
Bottom of Range [Member] | ||
Disclosure Of Time Deposits With Banks [Line Items] | ||
Time deposits, interest rate | 0.01% | 0.01% |
Top of Range [Member] | ||
Disclosure Of Time Deposits With Banks [Line Items] | ||
Time deposits, interest rate | 3.05% | 0.05% |
Fixed Interest Rate [Member] | ||
Disclosure Of Time Deposits With Banks [Line Items] | ||
Time deposits, interest rate | 3.70% |
Other Payables and Accruals - S
Other Payables and Accruals - Summary of Other Payables and Accruals (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Disclosure Of Other Payables And Accruals [Abstract] | ||
Payables in respect of research and development expenses | $ 4,471 | $ 5,435 |
Accrued salaries and bonuses | 2,166 | 2,475 |
Accrued other expenses | 1,025 | 1,662 |
Deposit received for a potential out-licensing drug patent (note) | 1,000 | 1,000 |
Other payables | 500 | 1,103 |
Total | $ 9,162 | $ 11,675 |
Other Payables And Accruals - A
Other Payables And Accruals - Additional Information (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Disclosure Of Other Payables And Accruals [Abstract] | ||
Current deposits from customers | $ 1,000 | $ 1,000 |
Financial Liabilities Arising_3
Financial Liabilities Arising from Unvested Restricted Shares - Summary of Financial Liabilities Arising From Unvested Restricted Shares (Detail) $ in Thousands | Dec. 31, 2022 USD ($) |
Chief Executive Officer [Member] | Financial Liabilities, Arising From Unvested Restricted Shares [Member] | Dr. Yu [Member] | |
Disclosure of financial liabilities [line items] | |
Current financial liabilities at amortised cost | $ 68 |
Lease Liabilities - Summary of
Lease Liabilities - Summary of Detailed Information About Contractual Maturities of Lease Liabilities (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Disclosure of Lease Liabilities [Line Items] | ||
Lease liabilities payable | $ 425 | $ 991 |
Less: Amount due for settlement within 12 months shown under current liabilities | (158) | (614) |
Amount due for settlement after 12 months shown under non-current liabilities | 267 | 377 |
Within one year [member] | ||
Disclosure of Lease Liabilities [Line Items] | ||
Lease liabilities payable | 158 | 614 |
More than one year, but not exceeding two years [member] | ||
Disclosure of Lease Liabilities [Line Items] | ||
Lease liabilities payable | 126 | 126 |
More than two years, but not exceeding five years [member] | ||
Disclosure of Lease Liabilities [Line Items] | ||
Lease liabilities payable | $ 141 | $ 251 |
Lease Liabilities - Additional
Lease Liabilities - Additional Information (Detail) | Dec. 31, 2023 | Dec. 31, 2022 |
Disclosure of Lease Liabilities [Line Items] | ||
Weighted average lessee's incremental borrowing rate | 4.85% | 5.38% |
Top of Range [Member] | ||
Disclosure of Lease Liabilities [Line Items] | ||
Weighted average lessee's incremental borrowing rate | 6% | 6% |
Bottom of Range [Member] | ||
Disclosure of Lease Liabilities [Line Items] | ||
Weighted average lessee's incremental borrowing rate | 4.75% | 4.75% |
Convertible Preferred Shares -
Convertible Preferred Shares - Disclosure of Preferred Shares Issued Pursuant to Subscription Agreement (Detail) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Mar. 29, 2023 | Dec. 31, 2023 | |
Series A One Preferred Stock [Member] | ||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||
Total number of Preferred Shares issue | 9,465,755 | 132,057,583 |
Subscription price total | $ 6,000 | $ 6,000 |
Series A One Preferred Stock [Member] | July 26, 2016 to July 28, 2016 [Member] | ||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||
Total number of Preferred Shares issue | 6,310,503 | 88,038,389 |
Subscription price per share | $ 0.6338 | $ 0.04543 |
Subscription price total | $ 4,000 | $ 4,000 |
Series A One Preferred Stock [Member] | January 31, 2019 [Member] | ||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||
Total number of Preferred Shares issue | 3,155,252 | 44,019,194 |
Subscription price per share | $ 0.6338 | $ 0.04543 |
Subscription price total | $ 2,000 | $ 2,000 |
Series A Two Preferred Stock [Member] | July 21, 2017 to July 25, 2017 [Member] | ||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||
Total number of Preferred Shares issue | 5,259,170 | 73,371,157 |
Subscription price per share | $ 0.713 | $ 0.05111 |
Subscription price total | $ 3,750 | $ 3,750 |
Series B Preferred Shares [Member] | ||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||
Total number of Preferred Shares issue | 21,313,959 | 297,352,949 |
Subscription price total | $ 99,000 | $ 99,000 |
Series B Preferred Shares [Member] | September 19, 2018 to December 27, 2018 [Member] | ||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||
Total number of Preferred Shares issue | 18,687,400 | 260,709,579 |
Subscription price per share | $ 4.6443 | $ 0.3329 |
Subscription price total | $ 86,800 | $ 86,800 |
Series B Preferred Shares [Member] | January 8, 2019 to March 25, 2019 [Member] | ||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||
Total number of Preferred Shares issue | 2,626,559 | 36,643,370 |
Subscription price per share | $ 4.6443 | $ 0.3329 |
Subscription price total | $ 12,200 | $ 12,200 |
Series C Preferred Shares [Member] | ||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||
Total number of Preferred Shares issue | 18,382,073 | 256,449,944 |
Subscription price total | $ 124,250 | $ 124,250 |
Series C Preferred Shares [Member] | September 10, 2020 to September 30, 2020 [Member] | ||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||
Total number of Preferred Shares issue | 10,156,372 | 141,692,465 |
Subscription price per share | $ 6.7593 | $ 0.4845 |
Subscription price total | $ 68,650 | $ 68,650 |
Series C Preferred Shares [Member] | October 5, 2020 to November 5, 2020 [Member] | ||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||
Total number of Preferred Shares issue | 8,225,701 | 114,757,479 |
Subscription price per share | $ 6.7593 | $ 0.4845 |
Subscription price total | $ 55,600 | $ 55,600 |
Convertible Preferred Shares _2
Convertible Preferred Shares - Disclosure of Movement in Preference Shares at End of Each Reporting Period (Detail) - Series C Preferred Shares [Member] - Preferred Shares [Member] - Level 3 Fair Value [Member] - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of Movement in Preference Shares at End of Each Reporting Period [Line Items] | |||
Beginning Balance | $ 511,861 | $ 322,215 | $ 284,791 |
Change in fair value | 76,424 | 189,646 | 37,424 |
Conversion of convertible preferred shares into post-closing ordinary shares | $ (588,285) | ||
Ending Balance | $ 511,861 | $ 322,215 |
Convertible Preferred Shares _3
Convertible Preferred Shares - Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares (Detail) - Series C Preferred Shares [Member] - Preferred Shares [Member] | Dec. 31, 2022 yr | Dec. 31, 2021 yr |
Time to Liquidate [Member] | ||
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items] | ||
Significant unobservable input, liabilities | 1.25 | 1.5 |
Risk-free rate [Member] | ||
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items] | ||
Significant unobservable input, liabilities | 4.65 | 0.56 |
Expected volatility (note) [Member] | ||
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items] | ||
Significant unobservable input, liabilities | 75 | 72.5 |
Dividend Yield [Member] | ||
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items] | ||
Significant unobservable input, liabilities | 0 | 0 |
Possibility Under IPO Scenario [Member] | ||
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items] | ||
Significant unobservable input, liabilities | 85 | 25 |
Possibility Under Liquidation Scenario [Member] | ||
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items] | ||
Significant unobservable input, liabilities | 15 | 75 |
Convertible Preferred Shares _4
Convertible Preferred Shares - Additional Information (Detail) | 4 Months Ended | 12 Months Ended | ||
Apr. 17, 2023 USD ($) | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Series A One Preferred Stock [Member] | ||||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||||
Dividend rate on preferred stock | 8% | |||
Dividend declared before the financial statements are authorized for issue but not recognized as distribution to owners | $ 0 | |||
Conversion ratio of preferred shares into equity | 1 | 1 | ||
Series A Two Preferred Stock [Member] | ||||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||||
Dividend rate on preferred stock | 8% | |||
Dividend declared before the financial statements are authorized for issue but not recognized as distribution to owners | 0 | |||
Conversion ratio of preferred shares into equity | 1 | 1 | ||
Series B Preferred Shares [Member] | ||||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||||
Dividend rate on preferred stock | 8% | |||
Dividend declared before the financial statements are authorized for issue but not recognized as distribution to owners | 0 | |||
Conversion ratio of preferred shares into equity | 1 | 1 | ||
Period within which the redemption feauture shall be restored from the date on which the issue is closed | 18 months | |||
Convertible preferred stock redemption price as a percentage of original issue price | 100% | |||
Interest rate on payable on redeemable amount of convertible preferred stock | 12% | |||
Convertible preferred stock liquidation preference percentage | 100% | |||
Interest rate payable on redeemable preferred stock | 12% | |||
Series C Preferred Shares [Member] | ||||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||||
Dividend rate on preferred stock | 8% | |||
Dividend declared before the financial statements are authorized for issue but not recognized as distribution to owners | $ 0 | |||
Conversion ratio of preferred shares into equity | 1 | 1 | ||
Period within which the redemption feauture shall be restored from the date on which the issue is closed | 18 months | |||
Convertible preferred stock redemption price as a percentage of original issue price | 100% | |||
Interest rate on payable on redeemable amount of convertible preferred stock | 12% | |||
Convertible preferred stock liquidation preference percentage | 100% | |||
Interest rate payable on redeemable preferred stock | 12% | |||
Series A1 And Series A Two Preferred Stock [Member] | ||||
Disclosure of Preferred Shares Issued Pursuant To Subscription Agreement [Line Items] | ||||
Convertible preferred stock liquidation preference percentage | 100% |
Share Capital_Treasury Shares -
Share Capital/Treasury Shares - Summary of Share Capital (Detail) - USD ($) | 12 Months Ended | ||||||||
Jan. 01, 2022 | Jan. 01, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | ||||
Disclosure of classes of share capital [line items] | |||||||||
Exercise of share options, Value | $ 85,000 | [1] | $ 391,000 | [2] | $ 140,000 | [3] | |||
Ordinary Shares [Member] | |||||||||
Disclosure of classes of share capital [line items] | |||||||||
Number of shares authorised | 444,343,488 | 444,343,488 | 444,343,488 | 444,343,488 | |||||
Value of shares authorized | 44 | 44 | 44 | 44 | |||||
Number of shares issued and fully paid | 386,741,005 | 401,804,327 | 393,252,140 | ||||||
Value of shares issued and fully paid | $ 39,000 | $ 41,000 | $ 40,000 | ||||||
Exercise of share options, Shares | 8,552,187 | 6,511,135 | |||||||
Par value per share | $ 0.0001 | $ 0.0001 | |||||||
Exercise of share options, Value | $ 1,000 | $ 1,000 | |||||||
Ordinary Shares [Member] | Business combinations [member] | |||||||||
Disclosure of classes of share capital [line items] | |||||||||
Number of shares authorised | 600,000,000 | ||||||||
Value of shares authorized | 3 | ||||||||
Number of shares issued and fully paid | 89,495,790 | 28,800,926 | 28,187,914 | 27,721,202 | |||||
Value of shares issued and fully paid | $ 9 | $ 3 | $ 3 | $ 3 | |||||
Exercise of share options, Shares | 62,443 | 613,012 | 466,712 | ||||||
Par value per share | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||
Business combination, net of redemptions | 3,312,715 | ||||||||
Post-Closing Apollomics Ordinary Shares [Member] | Business combinations [member] | |||||||||
Disclosure of classes of share capital [line items] | |||||||||
Par value per share | $ 0.0001 | ||||||||
Conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares | 54,420,956 | ||||||||
Value of conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares | $ 6 | ||||||||
Post-closing Apollomics Class B Ordinary Shares [Member] | Business combinations [member] | |||||||||
Disclosure of classes of share capital [line items] | |||||||||
Par value per share | $ 0.0001 | ||||||||
Post-closing Apollomics Class B Ordinary Shares issued to PIPE Investors, net of transaction costs | 230,000 | ||||||||
post-closing Apollomics Series A Preferred Shares [Member] | Business combinations [member] | |||||||||
Disclosure of classes of share capital [line items] | |||||||||
Par value per share | $ 0.0001 | ||||||||
Issuance of post-closing Apollomics Class A Ordinary Shares upon the conversion of post-closing Apollomics Series A Preferred Shares | 2,668,750 | ||||||||
[1] The total number of shares issued from the exercise of stock options consisted of the issuance of 435,833 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2023 to March 28, 2023. These Pre-Closing Apollomics Ordinary Shares were exchanged for 31,241 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. The total number of shares issued from the exercise of stock options consisted of the issuance of 31,202 Post-Closing Apollomics Ordinary Shares between March 29, 2023 to December 31, 2023, totaling 62,443 exercise of stock options for the year ended December 31, 2023. The total number of shares issued from the exercise of stock options consisted of the issuance of 8,552,187 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2022 to December 31, 2022. These Pre-Closing Apollomics Ordinary Shares were exchanged for 613,012 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. The total number of shares issued from the exercise of stock options consisted of the issuance of 6,511,135 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2021 to December 31, 2021. These Pre-Closing Apollomics Ordinary Shares were exchanged for 466,712 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. |
Share Capital_Treasury Shares_2
Share Capital/Treasury Shares - Summary of Share Capital (Parenthetical) (Detail) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of classes of share capital [line items] | |||
Proceeds from exercise of options | $ 85 | $ 392 | $ 141 |
Two Thousand and Sixteen Plan [Member] | |||
Disclosure of classes of share capital [line items] | |||
Stock issued during the period exercise of stock options shares | 62,443 | 8,552,187 | 6,511,135 |
Share based compensation by share based award share options excercised weighted average exercise price | $ 0.046 | $ 0.022 | |
Business Combination [Member] | Two Thousand and Sixteen Plan [Member] | |||
Disclosure of classes of share capital [line items] | |||
Stock issued during the period exercise of stock options shares | 613,013 | 466,712 | |
Number of shares issued and fully paid exchange ratio pursuant to business combination | 0.071679 | 0.071679 | |
Exercise Price One [Member] | Two Thousand and Sixteen Plan [Member] | |||
Disclosure of classes of share capital [line items] | |||
Stock issued during the period exercise of stock options shares | 38,893 | 498,958 | 6,004,989 |
Share based compensation by share based award share options excercised weighted average exercise price | $ 0.28 | $ 0.01 | $ 0.01 |
Exercise Price One [Member] | Business Combination [Member] | Two Thousand and Sixteen Plan [Member] | |||
Disclosure of classes of share capital [line items] | |||
Stock issued during the period exercise of stock options shares | 35,765 | 430,432 | |
Share based compensation by share based award share options excercised weighted average exercise price | $ 0.14 | $ 0.14 | |
Exercise Price Two [Member] | Two Thousand and Sixteen Plan [Member] | |||
Disclosure of classes of share capital [line items] | |||
Stock issued during the period exercise of stock options shares | 16,202 | 7,088,541 | 134,375 |
Share based compensation by share based award share options excercised weighted average exercise price | $ 2.93 | $ 0.02 | $ 0.02 |
Exercise Price Two [Member] | Business Combination [Member] | Two Thousand and Sixteen Plan [Member] | |||
Disclosure of classes of share capital [line items] | |||
Stock issued during the period exercise of stock options shares | 508,100 | 9,632 | |
Share based compensation by share based award share options excercised weighted average exercise price | $ 0.28 | $ 0.28 | |
Exercise Price Three [Member] | Two Thousand and Sixteen Plan [Member] | |||
Disclosure of classes of share capital [line items] | |||
Stock issued during the period exercise of stock options shares | 4,122 | 101,146 | 371,771 |
Share based compensation by share based award share options excercised weighted average exercise price | $ 3.63 | $ 0.21 | $ 0.21 |
Exercise Price Three [Member] | Business Combination [Member] | Two Thousand and Sixteen Plan [Member] | |||
Disclosure of classes of share capital [line items] | |||
Stock issued during the period exercise of stock options shares | 7,250 | 26,648 | |
Share based compensation by share based award share options excercised weighted average exercise price | $ 2.93 | $ 2.93 | |
Exercise Price Four [Member] | Two Thousand and Sixteen Plan [Member] | |||
Disclosure of classes of share capital [line items] | |||
Stock issued during the period exercise of stock options shares | 3,226 | 863,542 | |
Share based compensation by share based award share options excercised weighted average exercise price | $ 4.32 | $ 0.26 | |
Exercise Price Four [Member] | Business Combination [Member] | Two Thousand and Sixteen Plan [Member] | |||
Disclosure of classes of share capital [line items] | |||
Stock issued during the period exercise of stock options shares | 61,898 | ||
Share based compensation by share based award share options excercised weighted average exercise price | $ 3.63 |
Share Capital_Treasury Shares_3
Share Capital/Treasury Shares - Summary of Treasury Shares (Detail) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure Of Treasury Shares [Line Items] | |||
Number of treasury shares, Beginning | 6,930,235 | 14,086,748 | 26,365,915 |
Treasury shares value, Beginning | $ 68,000 | $ 1,647,000 | |
Restricted shares vested | (1,164,666) | (6,352,715) | |
Restricted shares vested, subscription price per share | $ 0.01 | $ 0.01 | |
Restricted shares vested, value | $ (21,000) | $ (64,000) | |
Early exercised share options vested | (6,930,235) | (5,991,847) | (5,926,452) |
Early exercised share options vested, subscription price per share | $ 0.26 | $ 0.26 | $ 0.26 |
Early exercised share options vested, value | $ (68) | $ (1,558,000) | $ (1,541,000) |
Number of treasury shares, Ending | 6,930,235 | 14,086,748 | |
Treasury shares value, Beginning | $ 68,000 | $ 1,647,000 | |
Maxpro Capital Acquisition Corp. [Member] | |||
Disclosure Of Treasury Shares [Line Items] | |||
Number of treasury shares, Beginning | 496,752 | 1,009,724 | 1,889,882 |
Treasury shares value, Beginning | $ 68,000 | $ 1,647,000 | $ 3,252,000 |
Restricted shares vested | (83,482) | (455,356) | |
Restricted shares vested, subscription price per share | $ 0.14 | $ 0.14 | |
Restricted shares vested, value | $ (21,000) | $ (64,000) | |
Early exercised share options vested | (496,752) | (429,490) | (424,802) |
Early exercised share options vested, subscription price per share | $ 3.63 | $ 3.63 | $ 3.63 |
Early exercised share options vested, value | $ (68,000) | $ (1,558,000) | $ (1,541,000) |
Number of treasury shares, Ending | 496,752 | 1,009,724 | |
Treasury shares value, Beginning | $ 68,000 | $ 1,647,000 |
Share Capital_Treasury Shares_4
Share Capital/Treasury Shares - Additional Information (Detail) | Feb. 09, 2023 |
Disclosure of classes of share capital [abstract] | |
Share exchange ratio | 0.071679 |
Share-Based Payment Transacti_3
Share-Based Payment Transactions - Additional Information (Detail) | 12 Months Ended | |||
Dec. 31, 2023 USD ($) yr shares $ / shares | Dec. 31, 2022 USD ($) shares yr $ / shares | Dec. 31, 2021 USD ($) shares yr $ / shares | Feb. 09, 2023 | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Share exchange ratio | 0.071679 | |||
Two Thousand and Sixteen Plan [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Share based compensation by share based number of shares authorized for issuance | 337,225,866 | 337,225,866 | ||
Share based compensation by share based award term of stock options | yr | 6.25 | 6.078 | 6.078 | |
Weighted average remaining contractual life of outstanding share options | 6 years 3 months | 7 years 4 months 24 days | 8 years 2 months 12 days | |
Weighted average fair value per share of share options granted | $ / shares | $ 7.13 | $ 0.2035 | $ 2.28 | |
Share based compensation by share based award number of options excercised during the period | 8,552,187 | 6,511,135 | ||
Two Thousand and Sixteen Plan [Member] | Restricted Share Awards [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Notice period threshold post termination of employment repurchase option | 60 days | |||
Allocated share based compensation | $ | $ 0 | $ 39,000 | $ 7,000 | |
Two Thousand and Sixteen Plan [Member] | Time Based Restricted Shares [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Share based compensation by share based vesting period | 48 months | |||
Share based compensation by share based award initial vesting percentage | 25% | |||
Share based compensation by share based award remaining vesting period | 36 months | |||
Two Thousand and Sixteen Plan [Member] | Time Based Restricted Shares [Member] | Bottom of range [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Weighted average exercise price, granted | $ / shares | $ 0.003 | |||
Two Thousand and Sixteen Plan [Member] | Time Based Restricted Shares [Member] | Top of range [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Weighted average exercise price, granted | $ / shares | $ 0.01 | |||
Two Thousand and Sixteen Plan [Member] | Milestone Based Restricted Shares [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Share based compensation by share based award equity instruments other than options vested during the period | 496,752 | 0 | 0 | |
Two Thousand and Sixteen Plan [Member] | Share Options [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Share based compensation by share based award term of stock options | yr | 10 | |||
Two Thousand and Sixteen Plan [Member] | Time Based Share Options [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Share based compensation by share based award vesting period minimum | 24 months | |||
Share based compensation by share based award vesting period Maximum | 48 months | |||
Share based compensation by share based award initial vesting percentage one | 50% | |||
Share based compensation by share based award initial vesting percentage two | 25% | |||
Share based compensation by share based award remaining vesting period minimum | 12 months | |||
Share based compensation by share based award remaning vesting period maximum | 36 months | |||
Two Thousand and Sixteen Plan [Member] | Time Based Share Options [Member] | Dr Yu [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Share based compensation by share based award number of options excercised during the period | 853,575 | 853,575 | 853,575 | |
Share based compensation by share based award unvested early exercised share options outstanding | 0 | 0 | 429,490 | |
Exchange Ratio of 0.071679 [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Weighted average fair value per share of share options granted | $ / shares | $ 0.2035 | $ 0.16337 | ||
Share exchange ratio | 0.071679 | |||
Share based compensation by share based award number of options excercised during the period | (62,443) | (613,012) | (466,712) | |
Two Thousand Sixteen and Two Thousand Twenty Three Plan [Member] | Share Options [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Allocated share based compensation | $ | $ 12,685 | $ 3,543 | $ 8,115 | |
Allocated share based compensation consulting fees | $ | $ 19 | $ 27 | $ 129 |
Share-Based Payment Transacti_4
Share-Based Payment Transactions - Summary of Group's Restricted Shares Movement (Detail) - Unvested Restricted Shares [Member] - shares | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Two Thousand and Sixteen Plan [Member] | |||
Disclosure Of Movement In Restricted Shares [Line Items] | |||
Outstanding at January 1 | 6,930,235 | 8,094,901 | 14,447,616 |
Vested | (6,930,235) | (1,164,666) | (6,352,715) |
Outstanding at December 31, | 0 | 6,930,235 | 8,094,901 |
Exchange Ratio of 0.071679 [Member] | |||
Disclosure Of Movement In Restricted Shares [Line Items] | |||
Outstanding at January 1 | 496,752 | 1,009,724 | 1,889,882 |
Vested | (496,752) | (512,972) | (880,158) |
Outstanding at December 31, | 0 | 496,752 | 1,009,724 |
Share-Based Payment Transacti_5
Share-Based Payment Transactions - Summary of Company's Share Options (Detail) $ in Thousands | 12 Months Ended | |||
Mar. 29, 2023 USD ($) | Dec. 31, 2023 shares $ / shares | Dec. 31, 2022 shares $ / shares | Dec. 31, 2021 shares $ / shares | |
Disclosure Of Movement In The Share Options [Line Items] | ||||
Number of Options, Granted | $ | 14,282 | |||
Two Thousand and Sixteen Plan [Member] | ||||
Disclosure Of Movement In The Share Options [Line Items] | ||||
Number of Options, Beginning | 135,979,705 | 155,059,183 | 151,133,235 | |
Number of Options, Granted | 11,500,000 | 39,715,000 | ||
Number of Options,Exercised | (8,552,187) | (6,511,135) | ||
Number of Options, Forfeited | (22,027,291) | (29,277,917) | ||
Number of Options, Ending | 135,979,705 | 155,059,183 | ||
Number of Option, Excercisable | 67,667,737 | 78,269,054 | ||
Weighted average exercise price, Beginning | $ / shares | $ 0.217 | $ 0.203 | $ 0.169 | |
Weighted average exercise price, Granted | $ / shares | 0.31 | 0.279 | ||
Weighted average exercise price, Exercised | $ / shares | 0.046 | 0.022 | ||
Weighted average exercise price, Forfeited | $ / shares | 0.232 | 0.169 | ||
Weighted average exercise price, Ending | $ / shares | $ 0.217 | $ 0.203 | ||
Exchange Ratio of 0.071679 [Member] | ||||
Disclosure Of Movement In The Share Options [Line Items] | ||||
Number of Options, Beginning | 9,746,889 | 11,114,486 | 10,833,079 | |
Number of Options, Granted | 3,048,310 | 824,309 | 2,846,731 | |
Number of Options,Exercised | 62,443 | 613,012 | 466,712 | |
Number of Options, Forfeited | 808,341 | 1,578,894 | 2,098,612 | |
Number of Options, Ending | 11,924,415 | 9,746,889 | 11,114,486 | |
Number of Option, Excercisable | 7,859,478 | 4,850,356 | 5,610,248 | |
Weighted average exercise price, Beginning | $ / shares | $ 3.027 | $ 2.832 | $ 2.358 | |
Weighted average exercise price, Granted | $ / shares | 9.927 | 4.325 | 3.892 | |
Weighted average exercise price, Exercised | $ / shares | 1.397 | 0.642 | 0.307 | |
Weighted average exercise price, Forfeited | $ / shares | 0.57 | 3.237 | 2.238 | |
Weighted average exercise price, Ending | $ / shares | $ 4.615 | $ 3.027 | $ 2.832 |
Share-Based Payment Transacti_6
Share-Based Payment Transaction - Summary of Share-Based Payment Transactions (Detail) - Two Thousand and Sixteen Plan [Member] | 12 Months Ended | ||
Dec. 31, 2023 yr $ / shares | Dec. 31, 2022 yr $ / shares | Dec. 31, 2021 yr $ / shares | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Exercise price of share options granted | $ 0.31 | ||
Exercise price as converted | $ 4.32 | ||
Expected volatility (note) | 72.50% | ||
Expected life | yr | 6.25 | 6.078 | 6.078 |
Risk-free rate | 3.67% | ||
Expected dividend yield | 0% | 0% | 0% |
Bottom of Range [Member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Grant date option fair value per share | $ 0.01 | $ 0.0933 | $ 0.143 |
Exercise price of share options granted | 0.07 | 0.26 | |
Grant date option fair value per share as converted | 0.14 | $ 1.302 | 1.995 |
Exercise price as converted | 0.94 | $ 3.63 | |
Expected volatility (note) | 75% | 75% | |
Risk-free rate | 1.35% | 0.51% | |
Top of Range [Member] | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Grant date option fair value per share | 0.511 | $ 0.1517 | $ 0.1544 |
Exercise price of share options granted | 0.72 | 0.31 | |
Grant date option fair value per share as converted | 7.127 | $ 2.116 | 2.154 |
Exercise price as converted | $ 10.01 | $ 4.32 | |
Expected volatility (note) | 77.50% | 80% | |
Risk-free rate | 3.98% | 1.09% |
Share-Based Payment Transacti_7
Share-Based Payment Transaction - Summary of Restricted stock (Details) - Two Thousand Twenty Three Plan [Member] - Restricted share units [member] | 12 Months Ended |
Dec. 31, 2023 shares $ / shares | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Outstanding at January 1 | 0 |
Granted | 207,945 |
Outstanding at December 31, | 207,945 |
Exercisable | 0 |
Weighted average exercise price at January 1 | $ / shares | $ 0 |
Weighted average exercise price, granted | $ / shares | 5.41 |
Weighted average exercise price December 31 | $ / shares | $ 5.41 |
Financial Instruments - Summary
Financial Instruments - Summary of Financial Assets and Financial Liabilities are Measured at Fair Value (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Disclosure of Detailed Information About Financial Assets and Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items] | ||
Financial Assets | $ 55,387 | $ 76,475 |
Warrant liabilities | 330 | |
Level 1 of fair value hierarchy [member] | Warrants [Member] | ||
Disclosure of Detailed Information About Financial Assets and Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items] | ||
Warrant liabilities | $ 330 | |
Description of valuation techniques used in fair value measurement, liabilities | Public warrants and private warrants are based on the valuation of the public price of APLMW which is directly observable market (level 1) while the penny warrants are based on the underlying share price of APLM, also a directly observable market (level 1) | |
Level 1 of fair value hierarchy [member] | Maxpro Capital Acquisition Corp [Member] | Public Warrants [Member] | ||
Disclosure of Detailed Information About Financial Assets and Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items] | ||
Warrant liabilities | $ 259 | |
Description of valuation techniques used in fair value measurement, liabilities | The public warrants are traded on the Nasdaq, the valuation is based on unadjusted quoted prices in active markets for identical assets or liabilities | |
Level 2 of Fair Value Hierarchy [Member] | Maxpro Capital Acquisition Corp [Member] | Private Warrants [Member] | ||
Disclosure of Detailed Information About Financial Assets and Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items] | ||
Warrant liabilities | $ 15 | |
Description of valuation techniques used in fair value measurement, liabilities | Private warrants are considered to be economically equivalent to the public warrants. As such, the valuation of the public warrants was used to value the private warrants | |
Level 3 of fair value hierarchy [member] | Pipe Subscription Agreement [Member] | Penny Warrants [member] | ||
Disclosure of Detailed Information About Financial Assets and Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items] | ||
Warrant liabilities | $ 56 | |
Description of valuation techniques used in fair value measurement, liabilities | Black-Scholes model - the key inputs are: underlying share price, expected life in years, risk-free rate, expected volatility, and exercise price | |
Convertible Preferred Shares [Member] | Level 3 of fair value hierarchy [member] | ||
Disclosure of Detailed Information About Financial Assets and Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items] | ||
Financial liabilities | 511,861 | |
Description of valuation techniques used in fair value measurement, liabilities | Black-Scholes model and OPM method - the key inputs are: time to liquidation, risk-free rate, expected volatility and possibilities for IPO/liquidation scenario | |
Description of inputs used in fair value measurement, liabilities | Possibilityfor IPOscenario (note) | |
Description of sensitivity of fair value measurement to changes in unobservable inputs, liabilities | The higher the possibility for IPO scenario, the higher the fair value, and vice versa | |
Convertible Preferred Shares [Mem,ber] | Level 3 of fair value hierarchy [member] | ||
Disclosure of Detailed Information About Financial Assets and Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items] | ||
Description of valuation techniques used in fair value measurement, liabilities | Black-Scholes model and OPM method — the key inputs are: time to liquidation, risk- free rate, expected volatility and possibilities for IPO/liquidation scenario | |
Description of inputs used in fair value measurement, liabilities | Possibility for IPO scenario (note) | |
Description of sensitivity of fair value measurement to changes in unobservable inputs, liabilities | The higher the possibility for IPO scenario, the higher the fair value, and vice versa | |
Money Market Fund [member] | Level 1 of fair value hierarchy [member] | ||
Disclosure of Detailed Information About Financial Assets and Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items] | ||
Financial Assets | $ 5,761 | $ 19,067 |
Description of valuation techniques used in fair value measurement, assets | Redemption value quoted by banks with reference to the expected return of the underlying assets |
Financial Instruments - Summa_2
Financial Instruments - Summary of Categories of Financial Instruments (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Financial assets | ||
Financial assets at FVTPL | $ 5,761 | $ 19,067 |
Amortized cost | 32,166 | 39,983 |
Financial liabilities | ||
Financial liability at FVTPL | 330 | 511,861 |
Amortized cost | $ 5,970 | $ 7,606 |
Financial Instruments - Summa_3
Financial Instruments - Summary of Assets and Liabilities Denominated in Foreign Currencies (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Disclosure of Detailed Information about Assets and Liabilities Denominated in Foreign Currencies [Line Items] | ||
Assets | $ 32,166 | $ 39,983 |
Foreign Currency Denominated Market Risk [Member] | ||
Disclosure of Detailed Information about Assets and Liabilities Denominated in Foreign Currencies [Line Items] | ||
Assets | 6,867 | 10,240 |
Liabilities | 6,214 | 2,659 |
Renminbi ("RMB") | Foreign Currency Denominated Market Risk [Member] | ||
Disclosure of Detailed Information about Assets and Liabilities Denominated in Foreign Currencies [Line Items] | ||
Assets | 6,071 | 8,940 |
Liabilities | 5,443 | 1,210 |
Australian Dollars ("AUD") [Member] | Foreign Currency Denominated Market Risk [Member] | ||
Disclosure of Detailed Information about Assets and Liabilities Denominated in Foreign Currencies [Line Items] | ||
Assets | 796 | 1,300 |
Liabilities | $ 771 | $ 1,449 |
Financial Instruments - Summa_4
Financial Instruments - Summary of Sensitivity Analysis of Foreign Exchange Rate (Detail) - Currency Risk [Member] - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
RMB [Member] | |||
Disclosure Of Detailed Information About Sensitivity Analysis of Foreign Exchange Rate [Line Items] | |||
Impact on loss for the year | $ 659 | $ 386 | $ 295 |
Australian Dollars ("AUD") [Member] | |||
Disclosure Of Detailed Information About Sensitivity Analysis of Foreign Exchange Rate [Line Items] | |||
Impact on loss for the year | $ 26 | $ (7) | $ 22 |
Financial Instruments - Summa_5
Financial Instruments - Summary of Internal Credit Risk Grading Assessment Comprises (Detail) - Financial Assets at Amortized Cost [Member] | 12 Months Ended |
Dec. 31, 2023 | |
Low Risk [Member] | |
Disclosure of internal credit grades [line items] | |
Description | The counterparty has a low risk of default and does not have any past-due amounts |
Financial assets at amortized cost | 12-month ECL |
Watch List [Member] | |
Disclosure of internal credit grades [line items] | |
Description | Debtor frequently repays after due dates but settles the amounts in full |
Financial assets at amortized cost | 12-month ECL |
Doubtful [Member] | |
Disclosure of internal credit grades [line items] | |
Description | There have been significant increases in credit risk since initial recognition through information developed internally or external resources |
Financial assets at amortized cost | Lifetime ECL- not credit-impaired |
Loss [Member] | |
Disclosure of internal credit grades [line items] | |
Description | There is evidence indicating the asset is credit-impaired |
Financial assets at amortized cost | Lifetime ECL- credit-impaired |
Write-off [Member] | |
Disclosure of internal credit grades [line items] | |
Description | There is evidence indicating that the debtor is in severe financial difficulty and the Group has no realistic prospect of recovery |
Financial assets at amortized cost | Amount is written off |
Financial Instruments - Summa_6
Financial Instruments - Summary of Credit Risk Exposure (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Disclosure of credit risk exposure [line items] | ||
Financial assets at amortised cost | $ 32,166 | $ 39,983 |
Financial assets | 32,166 | 39,983 |
12-month ECL [Member] | Low Risk [Member] | Deposits [Member] | ||
Disclosure of credit risk exposure [line items] | ||
Financial assets | 110 | 129 |
12-month ECL [Member] | A3 [Member] | Time deposits with maturity less than twelve months [Member] | ||
Disclosure of credit risk exposure [line items] | ||
Financial assets | 0 | 2,872 |
12-month ECL [Member] | A3 [Member] | Time deposits with maturity greater than twelve months [Member] | ||
Disclosure of credit risk exposure [line items] | ||
Financial assets | 0 | 4,307 |
12-month ECL [Member] | A3 to Aa2 [Member] | Cash and cash equivalents [Member] | ||
Disclosure of credit risk exposure [line items] | ||
Financial assets | $ 32,056 | $ 32,675 |
Financial Instruments - Summa_7
Financial Instruments - Summary Of Liquidity and Interest Risk (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2023 | |
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Convertible Preferred Shares, Weighted Average Interest Rate | 12% | |
Lease liabilities, Weighted Average Interest Rate | 5.38% | 4.85% |
Convertible Preferred Shares | $ 338,492 | |
Other payables | 7,538 | $ 5,970 |
Financial liabilities arising form unvested restricted shares | 68 | |
Total | 346,098 | 5,970 |
Lease liabilities | 1,111 | 495 |
Convertible Preferred Shares, Carrying Amount | 378,332 | |
Other payables, Carrying Amount | 7,538 | 5,970 |
Financial Liabilities arising from Unvested Restricted Shares, Carrying Amount | 68 | |
Total, Carrying Amount | 385,938 | 5,970 |
Lease liabilities | 991 | 425 |
On demand or less than 1 Month [member] | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Other payables | 7,538 | 5,970 |
Financial liabilities arising form unvested restricted shares | 68 | |
Total | 7,606 | 5,970 |
Lease liabilities | 49 | 44 |
1 to 3 Months [member] | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Lease liabilities | 268 | 31 |
3 Months to 1 year [member] | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Lease liabilities | 391 | 83 |
1 to 2 Year [member] | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Convertible Preferred Shares | 338,492 | |
Total | 338,492 | |
Lease liabilities | 143 | 216 |
Lease liabilities | 126 | 126 |
2 to 4 Years [member] | ||
Disclosure of maturity analysis for non-derivative financial liabilities [line items] | ||
Lease liabilities | $ 260 | $ 50 |
Financial Instruments - Additio
Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of detailed information about financial instruments [line items] | |||
Net Assets | $ 41,234 | $ (448,120) | |
Convertible Preferred Shares, Carrying Amount | 378,332 | ||
Financial assets at FVTPL | 5,761 | 19,067 | |
Level 3 of fair value hierarchy [member] | |||
Disclosure of detailed information about financial instruments [line items] | |||
Gains (losses) recognised in profit or loss excluding exchange differences, fair value measurement, liabilities | $ 76,430 | 189,646 | $ 37,424 |
Convertible Preferred Shares [Member] | IPO scenario [Member] | |||
Disclosure of detailed information about financial instruments [line items] | |||
Percentage of reasonably possible increase in unobservable input, liabilities | 10% | ||
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities | $ 41,969 | 22,166 | |
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities | 0 | 0 | |
Series A Preferred Shares [Member] | |||
Disclosure of detailed information about financial instruments [line items] | |||
Convertible Preferred Shares, Carrying Amount | $ 133,529 | 0 | |
Preferred shares [member] | IPO scenario [Member] | |||
Disclosure of detailed information about financial instruments [line items] | |||
Percentage of reasonably possible increase in unobservable input, liabilities | 10% | ||
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities | 42,900 | ||
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities | $ 42,000 | ||
Currency risk [member] | |||
Disclosure of detailed information about financial instruments [line items] | |||
Percentage of decrease in foreign exchange rate | 5% | ||
Percentage of decrease increase in Foreign Exchnage Rate | 5% | ||
Percentage of increase in foreign exchange rate | 5% |
Retirement Benefits Plan - Addi
Retirement Benefits Plan - Additional information (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Employee benefits [Abstract] | |||
Total cost charged to profit or loss | $ 499 | $ 662 | $ 749 |
Related Party Disclosures - Sum
Related Party Disclosures - Summary of Compensation of Key Management Personnel (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of Compensation of Key Management Personnel [Line Items] | |||
Short term benefits | $ 4,112 | $ 2,473 | $ 2,214 |
Retirement benefit scheme contributions | 21 | 12 | 12 |
Share-based payment | 9,419 | 1,820 | 6,131 |
Total key management personnel compensation | $ 13,552 | $ 4,305 | $ 8,357 |
Reconciliation of Liabilities_3
Reconciliation of Liabilities Arising from Financing Activities - Summary of Detailed Information about Reconciliation of Liabilities Arising from Financing Activities (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of reconciliation of liabilities arising from financing activities [line items] | |||
Beginning Balance | $ 512,852 | $ 323,895 | $ 286,813 |
Financing cash flows | (688) | (686) | (1,784) |
Fair value change | 76,424 | 189,646 | 37,424 |
New leases entered | 548 | 53 | |
Issue costs accrued | 0 | (644) | 1,306 |
Preferred shares converted to common stock | (588,285) | ||
Interest expense | 122 | 93 | 83 |
Ending Balance | 425 | 512,852 | 323,895 |
Convertible Preferred Shares [Member] | |||
Disclosure of reconciliation of liabilities arising from financing activities [line items] | |||
Beginning Balance | 511,861 | 322,215 | 284,791 |
Financing cash flows | 0 | 0 | 0 |
Fair value change | 76,424 | 189,646 | 37,424 |
New leases entered | 0 | 0 | |
Issue costs accrued | 0 | 0 | 0 |
Preferred shares converted to common stock | (588,285) | ||
Interest expense | 0 | 0 | 0 |
Ending Balance | 0 | 511,861 | 322,215 |
Lease liabilities [member] | |||
Disclosure of reconciliation of liabilities arising from financing activities [line items] | |||
Beginning Balance | 991 | 1,036 | 1,511 |
Financing cash flows | (688) | (686) | (611) |
Fair value change | 0 | 0 | 0 |
New leases entered | 548 | 53 | |
Issue costs accrued | 0 | 0 | 0 |
Preferred shares converted to common stock | 0 | ||
Interest expense | 122 | 93 | 83 |
Ending Balance | 425 | 991 | 1,036 |
Accrued Share Issue Costs [Member] | |||
Disclosure of reconciliation of liabilities arising from financing activities [line items] | |||
Beginning Balance | 0 | 644 | 511 |
Financing cash flows | 0 | 0 | (1,173) |
Fair value change | 0 | 0 | 0 |
New leases entered | 0 | 0 | |
Issue costs accrued | 0 | (644) | 1,306 |
Preferred shares converted to common stock | 0 | ||
Interest expense | 0 | 0 | 0 |
Ending Balance | $ 0 | $ 0 | $ 644 |
Major Non-Cash Transactions - A
Major Non-Cash Transactions - Additional Information (Detail) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Jan. 01, 2021 |
Disclosure of Major Non-Cash Transactions [Line Items] | ||||
Right-of-use assets | $ 425,000 | $ 991,000 | ||
Lease liabilities | 425,000 | 991,000 | ||
Treasury shares | 68,000 | $ 1,647,000 | $ 3,252,000 | |
Non Cash Transaction [Member] | ||||
Disclosure of Major Non-Cash Transactions [Line Items] | ||||
Right-of-use assets | 0 | 548,000 | 53,000 | |
Treasury Shares [Member] | Non Cash Transaction [Member] | ||||
Disclosure of Major Non-Cash Transactions [Line Items] | ||||
Treasury shares | $ 68,000 | $ 1,579,000 | $ 1,605,000 |
Restricted Net Assets - Additio
Restricted Net Assets - Additional information (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
China [Member] | ||
Disclosure In Entirety Of Restricted Assets [Line Items] | ||
Restricted net assets | $ 52,298 | $ 35,000 |
Schedule I - Condensed Statemen
Schedule I - Condensed Statement of Loss and Other Comprehensive Loss (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure of Condensed Profit or Loss and Other Comprehensive Income of Parent Company [Line Items] | |||
Other income | $ 1,217 | $ 1,447 | $ 1,054 |
Fair value change of financial assets at fair value through profit and loss ("FVTPL") | 821 | 323 | 2 |
Fair value change of financial liabilities at FVTPL | 1,597 | ||
Fair value change of convertible preferred shares | (76,430) | (189,646) | (37,424) |
Research and development expenses | (34,193) | (35,457) | (35,568) |
Administrative expenses | (20,641) | (9,947) | (15,291) |
Finance costs | (150) | (93) | (83) |
Other expense | (46,003) | (6,608) | (4,522) |
Loss before taxation | (172,591) | (240,810) | (94,796) |
Income tax expense | 10 | 1 | 1 |
Loss and total comprehensive loss for the year, attributable to owners of the Company | (172,601) | (240,811) | (94,797) |
Separate [Member] | |||
Disclosure of Condensed Profit or Loss and Other Comprehensive Income of Parent Company [Line Items] | |||
Other income | 49 | 112 | 42 |
Fair value change of financial assets at fair value through profit and loss ("FVTPL") | 821 | 323 | 2 |
Fair value change of financial liabilities at FVTPL | 1,597 | ||
Fair value change of convertible preferred shares | (76,430) | (189,646) | (37,424) |
Research and development expenses | (7,772) | (992) | (2,643) |
Administrative expenses | (13,215) | (1,982) | (4,494) |
Finance costs | (28) | ||
Other expense | (46,003) | (5,532) | (4,522) |
Share of loss in subsidiaries | (31,610) | (43,094) | (45,757) |
Loss before taxation | (172,591) | (240,811) | (94,796) |
Income tax expense | (10) | ||
Loss and total comprehensive loss for the year, attributable to owners of the Company | $ (172,601) | $ (240,811) | $ (94,796) |
Schedule I - Condensed Statem_2
Schedule I - Condensed Statements of Financial Position (Detail) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Jan. 01, 2021 | Dec. 31, 2020 |
Non-current assets | |||||
Intangible assets | $ 14,757 | $ 14,778 | $ 14,798 | ||
Total non-current assets | 15,462 | 20,685 | |||
Current assets | |||||
Deposits, prepayments and deferred expenses | 2,108 | 1,176 | |||
Financial assets at FVTPL | 5,761 | 19,067 | |||
Cash and cash equivalents | 32,056 | 32,675 | 46,740 | $ 130,645 | |
Total current assets | 39,925 | 55,790 | |||
Total assets | 55,387 | 76,475 | |||
Current liabilities | |||||
Other payables and accruals | 9,162 | 11,675 | |||
Financial liabilities arising from unvested restricted shares | 68 | ||||
Total current liabilities | 13,556 | 12,357 | |||
Net current assets | 26,369 | 43,433 | |||
Total assets less current liabilities | 41,831 | 64,118 | |||
Non-current liabilities | |||||
Convertible preferred shares | 511,861 | ||||
Warrant liabilities | 330 | ||||
Total non-current liabilities | 597 | 512,238 | |||
Net assets (liabilities) | 41,234 | (448,120) | |||
Equity | |||||
Treasury shares | (68) | (1,647) | $ (3,252) | ||
Reserves | 26,716 | 14,228 | |||
Accumulated losses | (646,965) | (474,600) | |||
Total equity (deficit) | 41,234 | (448,120) | (212,861) | (127,931) | |
Separate [Member] | |||||
Non-current assets | |||||
Intangible assets | 1,759 | 1,778 | |||
Amount due from subsidiaries | 70,103 | 70,560 | |||
Total non-current assets | 71,862 | 72,338 | |||
Current assets | |||||
Deposits, prepayments and deferred expenses | 630 | ||||
Financial assets at FVTPL | 5,761 | 19,067 | |||
Cash and cash equivalents | 2,330 | 6,001 | $ 32,861 | $ 73,621 | |
Total current assets | 8,721 | 25,068 | |||
Total assets | 80,583 | 97,406 | |||
Current liabilities | |||||
Other payables and accruals | 366 | 2,986 | |||
Financial liabilities arising from unvested restricted shares | 68 | ||||
Total current liabilities | 366 | 3,054 | |||
Net current assets | 8,355 | 22,014 | |||
Total assets less current liabilities | 80,217 | 94,352 | |||
Non-current liabilities | |||||
Convertible preferred shares | 511,861 | ||||
Warrant liabilities | 330 | ||||
Deficit in subsidiaries | 38,653 | 30,611 | |||
Total non-current liabilities | 38,983 | 542,472 | |||
Net assets (liabilities) | 41,234 | (448,120) | |||
Equity | |||||
Share capital | 9 | 41 | |||
Treasury shares | (68) | ||||
Share premium | 661,474 | 12,279 | |||
Reserves | 26,716 | 14,228 | |||
Accumulated losses | (646,965) | (474,600) | |||
Total equity (deficit) | $ 41,234 | $ (448,120) |
Schedule I - Condensed Statem_3
Schedule I - Condensed Statements of Cash Flows (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
OPERATING ACTIVITIES | |||
Loss before taxation | $ (172,591) | $ (240,810) | $ (94,796) |
Adjustments for: | |||
Interest income | (821) | (431) | (467) |
Amortization of intangible assets | 20 | 20 | 20 |
Fair value change of financial assets at FVTPL | (323) | (2) | |
Fair value change of financial liabilities at FVTPL | (1,597) | ||
IFRS 2 listing expense | 45,524 | ||
Share-based payment expenses | 12,685 | 3,582 | 8,122 |
Operating cash flows before movements in working capital | (39,632) | (49,368) | (45,955) |
(Increase)/decrease in deposits, prepayments and deferred expenses | (932) | 3,651 | (453) |
Increase/(decrease) in other payables and accruals | (2,635) | 2,837 | 3,096 |
NET CASH USED IN OPERATIONS | (43,199) | (42,880) | (43,312) |
Tax paid | (10) | (1) | |
NET CASH USED IN OPERATING ACTIVITIES | (43,209) | (42,824) | (43,312) |
INVESTING ACTIVITIES | |||
Interest received | 821 | 431 | 467 |
Purchase of intangible assets | (7,500) | ||
Proceeds from disposal of financial asset at FVTPL | 13,307 | 5,000 | |
NET CASH (USED IN) FROM INVESTING ACTIVITIES | 21,365 | 29,053 | (38,950) |
FINANCING ACTIVITIES | |||
Proceeds from issue of shares upon exercise of share options | 85 | 392 | 141 |
Accrued issuance costs paid | (1,173) | ||
NET CASH (USED IN) FROM FINANCING ACTIVITIES | 21,225 | (294) | (1,643) |
NET (DECREASE) IN CASH AND CASH EQUIVALENTS | (619) | (14,065) | (83,905) |
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD | 32,675 | 46,740 | 130,645 |
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD | 32,056 | 32,675 | 46,740 |
Separate [Member] | |||
OPERATING ACTIVITIES | |||
Loss before taxation | (172,591) | (240,811) | (94,796) |
Adjustments for: | |||
Share of loss in subsidiaries | 31,610 | 43,094 | 45,757 |
Interest income | (49) | (112) | (42) |
Amortization of intangible assets | 20 | 20 | 20 |
Fair value change of financial assets at FVTPL | (821) | (323) | (2) |
Fair value change of financial liabilities at FVTPL | (1,597) | ||
Fair value change of convertible preferred shares | 76,430 | 189,646 | 37,424 |
IFRS 2 listing expense | 45,524 | ||
Share-based payment expenses | 12,685 | 818 | 4,056 |
Portion of PIPE issuance costs allocated to PIPE warrants | 38 | ||
Non-cash adjustments to other expenses | 2,484 | (2,563) | |
Operating cash flows before movements in working capital | (6,267) | (10,231) | (7,583) |
(Increase)/decrease in deposits, prepayments and deferred expenses | 630 | 2,812 | 162 |
Increase/(decrease) in other payables and accruals | (2,620) | 859 | 1,119 |
NET CASH USED IN OPERATIONS | (9,517) | (6,560) | (6,302) |
Tax paid | (10) | ||
NET CASH USED IN OPERATING ACTIVITIES | (9,527) | (6,560) | (6,302) |
INVESTING ACTIVITIES | |||
Interest received | 49 | 112 | 42 |
Investment in subsidiaries | (8,042) | (25,926) | (27,150) |
Advance to subsidiaries | (2,013) | (4,818) | |
Repayment from subsidiaries | 457 | 2,135 | |
Purchase of intangible assets | (1,500) | ||
Proceeds from disposal of financial asset at FVTPL | 13,307 | 5,000 | |
NET CASH (USED IN) FROM INVESTING ACTIVITIES | 5,771 | (20,692) | (33,426) |
FINANCING ACTIVITIES | |||
Proceeds from issue of shares upon exercise of share options | 85 | 392 | 141 |
Accrued issuance costs paid | (1,173) | ||
NET CASH (USED IN) FROM FINANCING ACTIVITIES | 85 | 392 | (1,032) |
NET (DECREASE) IN CASH AND CASH EQUIVALENTS | (3,671) | (26,860) | (40,760) |
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD | 6,001 | 32,861 | 73,621 |
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD | $ 2,330 | $ 6,001 | $ 32,861 |
Schedule I - Additional Informa
Schedule I - Additional Information (Detail) | 12 Months Ended |
Dec. 31, 2023 | |
Disclosure of Additional Information Explanatory [Line Items] | |
Minimum percentage requirement | 25% |